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Abstract
The simple anion inorganic nitrite (NO2 ) has previously been considered a 
relatively inert nitric oxide (NO) metabolite. However, recent evidence shows that 
NO2' exhibits an enhanced vasodilator effect in hypoxia. It has been suggested that 
this effect is mediated by intra-vascular reduction of NO2’ to NO by deoxygenated- 
haemoglobin.
This thesis investigated the effects o f low-dose NO2' supplementation in man, 
in three different environments where the actions of NO2’ may be potentiated. Firstly, 
the effect of systemic sodium nitrite (NaN0 2 ) administration upon forearm and 
pulmonary haemodynamics were assessed in healthy volunteers in both hypoxia and 
normoxia; conditions created by a controlled environmental chamber. The study- 
infusion resulted in an approximate doubling o f plasma [NO2 ], with similar 
pharmacokinetics observed in both hypoxia and normoxia. Forearm vasodilation 
occurred in hypoxia but not normoxia. In addition a pulmonary vasodilator effect was 
present in hypoxia only, and was not dependent upon simultaneous elevation of 
plasma [NO2"].
The same dose of NaNC>2 was given to patients with proven inducible 
myocardial ischaemia in the second study: a double-blind placebo-controlled clinical 
trial. Objective markers o f myocardial ischaemia were measured by tissue velocity 
imaging performed during dobutamine stress echocardiography. The results showed 
that low-dose NaN0 2  acts as an anti-ischaemic agent; despite no vasodilator effect 
being present in normoxia.
A third set of experiments were performed to assess the potential role of 
NaN0 2  as an ischaemic conditioning agent in a forearm model of 
ischaemia/reperfusion injury. Here NaN0 2  was able to act as a pre-conditioning but 
not a post-conditioning agent.
Two key results subtend this thesis. Firstly, tissue levels o f NO2’ are more 
important than intra-vascular levels, as its hypoxia-enhanced actions appear to be 
modulated from this site. Secondly, NaNC>2 may find clinically relevance in the future 
as a targeted vasodilator, providing a therapeutic effect to tissues in need only.
Commonly used abbreviations
ACh acetylcholine
ANOVA analysis of variance
ATP adenosine tri-phosphate
AUC area under curve
BA basal anterior
BAS basal antero-septal
BI basal inferior
BL basal lateral
BP blood pressure
BPost basal posterior
BS basal septal
Ca2+ calcium ion
CAD coronary artery disease
cGMP cyclic guanosine monophosphate
Cl confidence interval
C 0 2 carbon dioxide
CWD continuous-wave Doppler
Cx circumflex (coronary artery)
deoxy-Hb deoxygenated haemoglobin
DM diabetes mellitus
DSE dobutamine stress echocardiogram
EDRF endothelium derived relaxing factor
eNOS endothelial nitric oxide synthase
ETC electron transport chain
FBF forearm blood flow
Fi0 2 fraction of inspired oxygen
FMD flow mediated dilatation
V
GTN glyceryl trinitrate
H+ hydrogen ion
Hb haemoglobin
HbNO Iron nitrosyl haemoglobin
HbSNO S-nitrosohaemoglobin
HR heart rate
iNOS inducible nitric oxide synthase
IPC ischaemic pre-conditioning
IPostC ischaemic post-conditioning
IR ischaemia/reperfusion
IVRT isovolumic relaxation time
K+ potassium ion
LAD left anterior descending (coronary artery)
L-NAME L-Nitro-Arginine Methyl Ester
L-NMMA N°-monomethyl-L-arginine
LVOT left ventricular outflow tract
Met-Hb methaemoglobin
MPT mitochondrial permeability transition pore
n 2 nitrogen
Na+ sodium ion
NADPH nicotinamide adenine dinucleotide phosph;
NaN0 2 sodium nitrite
nNOS neuronal nitric oxide synthase
NO nitric oxide
N 0 2' nitrite anion
n o 3' nitrate anion
NOA nitric oxide analyser
NOx plasma N 0 2‘ & plasma protein bound NO
o 2 oxygen
Oz- superoxide
OBC ozone based chemiluminescence
onoct peroxynitrite
oxy-Hb oxygenated haemoglobin
PAP pulmonary arterial pressure
PASP pulmonary arterial systolic pressure
PAT pulmonary acceleration time
PSV peak systolic velocity
PWD pulsed-wave Doppler
RCA right coronary artery
RIPC remote ischaemic pre-conditioning
ROS reactive oxygen species
RSNO protein nitrosothiol species
SaC>2 oxygen saturation
SCD sickle cell disease
SD standard deviation
SEM standard error of the mean
sGC soluble guanylate cyclase
SGP strain gauge plethysmography
SNO nitrosothiol species
TR tricuspid regurgitation
VTI velocity time integral
XO xanthine oxidase
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C h a p t e r  1 G e n e r a l  I n t r o d u c t i o n
Chapter 1: General Introduction
1.1. The endothelium & nitric oxide
The discovery that the endothelium was more than simply an inert layer of 
cells lining the inner surface of blood vessels marked a paradigm shift in the field of 
vascular biology. In his seminal paper in 1980 Furchgott demonstrated, using isolated 
strips of rabbit aorta, that a transferable factor (which he coined Endothelium Derived 
Relaxing Factor - EDRF) was released from the endothelium in response to the 
administration of the known vasodilator acetylcholine (ACh)1. That this process was 
endothelium dependent was demonstrated by mechanical removal of the endothelium, 
which resulted in loss of the ACh effect. Subsequently it was realised that EDRF was 
in fact the already known exogenous vasodilator nitric oxide (NO) ’ . The mechanism 
of action by which NO elicits vasodilation is outlined in the next section and 
summarised in Figure 1-1 (below).
Bradyfcinin
AeeJyietnoiifte
: ■
Cycle GMP
Shea» stiess
Smooth musde
Endothafium
Figure 1-1: The vasodilator mechanism o f action o f NO. Adapted from  Moncada et 
al4.
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1,2. The vasodilator mechanism of action of NO
NO is produced by endothelial cells in response to an increase in the radial
shear stress placed upon them, or as a result of exposure to different autacoids (e.g.
2 +
bradykinin or ACh). These stimulating forces increase intracellular calcium (Ca ) 
levels which in turn activates the NO producing enzyme endothelial nitric oxide 
synthase (eNOS). Next eNOS catalyses the synthesis of NO and L-citrulline from the 
reaction between the amino acid L-arginine, oxygen (O2) and nicotinamide adenine 
dinucleotide phosphate (NADPH)4. L-arginine is a non-essential amino acid. 
However, the bodies requirement for NO production is so great and the endogenous 
production o f L-arginine comes at such a high energy cost that some is required to be 
ingested in the diet in order to remain healthy5. NO produced by eNOS next diffuses 
into vascular smooth muscle cells where it reacts with the enzyme soluble guanylate 
cyclase (sGC) which in turn forms cyclic guanosine monophosphate (cGMP) from 
guanosine-5'-triphosphate (GTP). cGMP then activates different protein kinases 
which in turn leads to smooth muscle cell relaxation.
A basal tone o f NO production is present in man. This is demonstrated by the 
increase in blood pressure observed following the administration of N^-Monomethyl- 
L-Arginine (L-NMMA), a competitive NOS inhibitor6. However, the changes seen 
are modest. This is due to a compensatory increase in other endothelial derived 
vasodilator mechanisms to ensure that adequate tissue perfusion is maintained. These 
alternative vasodilators include prostacyclin, which is produced via the arachadonic
7  o
acid pathway and endothelium derived hyperpolarising factor .
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1.3. The alternative biological actions of NO
The realisation that NO was a cellular signalling molecule provided an 
alternative angle from which many puzzling discoveries previously reported in the 
bio-medical literature could be reviewed afresh. It soon became apparent that NO is 
capable o f a myriad o f different actions throughout the body. Its effects can be 
broadly divided into three groups, each category being associated with one o f the 
three different sub-types o f NOS enzyme.
1.3.1. Vascular
As well as producing smooth muscle cell relaxation, as described in section 
1.2 (page 2), NO has other distinct functions upon the circulation. It is an antiplatelet 
agent9, reducing both platelet adhesion and aggregability. NO is also capable of 
controlling mitochondrial O2 consumption by inhibiting the enzyme cytochrome c- 
oxidase (complex 4) on the electron transport chain (ETC) 10 (see section 1.6.1.; page 
40). The inhibitory action of NO upon mitochondria was known several years before 
the biological significance o f NO was discovered. This is because the diatomic 
structure o f NO closely resembles that o f O2 and it was therefore used as a 
competitive inhibitor in early studies o f mitochondrial function11.
In summary, the different effects o f NO within the vasculature and 
surrounding tissue act in concert to ensure the adequate local delivery o f O2 . Blood 
flow is promoted through antiplatelet and vasodilator activity. NO also facilitates the 
distribution o f O2 throughout tissue by decreasing O2 utilisation at mitochondria 
proximal to blood vessels and thus promoting O2 diffusion to more remote tissue12.
However, the presence o f NO is not just intricate to acute O2 delivery to 
tissue; it also ensures an adequate supply o f blood in the long term via an angiogenic
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effect. This property is well demonstrated in the treatment of broncho-pulmonary 
dysplasia o f the premature newborn13. Broncho-pulmonary dysplasia is characterised 
by a lack of pulmonary alveolar and arterial development, resulting in a pruned 
appearance to the pulmonary arterial vascular tree on angiography as the normal 
structural complexity of the lung is lost14. Inhaled NO therapy helps to protect against 
the development o f this condition through the promotion of local angiogenesis.
1.3.2. Nervous system
It was first identified that NO was a neurotransmitter in the intestine; as L- 
NMMA inhibited the effect o f NANC (non-adrenergic non-cholinergic) nerve 
stimulation15. Neuronal NOS (nNOS) was subsequently isolated as the discrete source 
of NO released from these nerves16. It has since been recognised that NO plays a key 
role in the modulation of neural tissue function throughout the central and peripheral
17 18nervous system . It has an expected influence upon cerebral blood flow but also is 
important in the long term potentiation of nerves; a critical component in the process
1Q 7 0  71of memory development ’ and social-behaviour learning .
It has recently been suggested, in a study using a selective nNOS inhibitor, 
that the basal tone of NO in blood vessels is released by nNOS from vessel associated 
nerves rather than from eNOS22.
1.3.3. Inflammation
Whilst both eNOS and nNOS are Ca2+ dependent constituent enzymes a third 
type of NOS, inducible Nitric Oxide Synthase (iNOS), is Ca2+ independent and only 
expressed in response to inflammatory agent stimulation (e.g. pro-inflammatory 
cytokines or bacterial membrane lipopolysaccharide). Consequently this type of NOS 
does not produce pulsed bursts o f NO but more a sustained high-level release after a
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period o f cellular up-regulation23. Production o f NO in this manner forms part of the 
body’s host defence mechanism.
1.3.3.1. NO as a host defence agent
The role of NO as a cytotoxic agent was suggested by two experimental 
observations. Firstly nitrite (NO2 ) and nitrate (NO3 ), both metabolites o f NO (see 
section 1.4.1; page 10) were found in the urine of mice that had a concomitant 
bacterial infection24. Secondly, it was discovered that macrophages require a supply 
of L-arginine in order to destroy tumour cells25. In the second study it was also noted 
that tumour cells were not killed when exposed to NO2 ' alone. As a result it was 
suggested that a ‘reactive nitrogen intermediary ’ was responsible for the 
immunological effect of macrophages; an agent which was subsequently recognised 
as iNOS originating NO26.
Macrophages are able to utilise the cytotoxic effect of NO by first enveloping 
their target. Next NO is released into the enclosed space created around the pathogen. 
NO then diffuses inside the pathogen and disrupts their iron-containing enzymes; a 
critical component o f cellular respiration4. Importantly, this process relies upon the 
concomitant production of superoxide (O2 ) by the macrophage and therefore the 
cytotoxic action of NO may require the additional step o f conversion to peroxynitrite
77(ONOO’) first (see section 1.4.1.3, page 13) . Evidence supporting this mechanism of
action can be found in an electro-paramagnetic resonance spectroscopy image
28reported in 1983; which displays NO bound to a ferrous component of c. botulinum . 
The cytotoxic nature of NO displayed in this paper explains the rationale behind the 
common manufacturing practice of adding sodium nitrite (NaN0 2 ) to cured meat in 
order to reduce the incidence o f c. botulinum food poisoning.
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I.3.3.2. NO and septic shock
As the body mounts a response to an infection its rate o f NO manufacture is in 
balance between sufficient production to exhibit an antibacterial effect and an 
overproduction which will result in systemic vasodilation. If the latter situation occurs
OQit is called septic shock . Unsurprisingly, there has been substantial interest in the use 
of NOS inhibitors in septic shock. However, the result of a large scale randomised 
controlled trial where L-NMMA was given to patients in septic shock was
*1 A
disappointing . The increased mortality rates observed in the study arm of this trial 
were attributed to the inability o f L-NMMA to isolate the effects of down-regulation 
of NO production to one specific body compartment31. Therefore, despite beneficial 
haemodynamic effects being observed, organ dysfunction was amplified. The use of 
iNOS selective inhibitors may be able to overcome these problems, although the 
results of animal studies have been unconvincing32. The disappointing outcomes from 
these trials could have perhaps been predicted from the inconclusive results of 
numerous previous studies o f steroid use in sepsis33; as one of the actions of 
glucocorticoids therapy is to temper iNOS upregulation34.
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1.3.4. Summary of the biological actions of NO
The varied effects o f NO arise from its unique biochemistry and are 
summarised in Figure 1-2 (below). It is a small gaseous molecule which easily 
diffuses to neighbouring tissue and can readily react with a number of different 
targets; due to the unpaired electron it possesses, (hence NO is often written as NO ). 
Consequently, NO is highly unstable and as a discrete molecule in biological systems 
difficult to identify. Therefore it is often the metabolites of NO which are detected in 
the circulation, as shadows o f previous NO production.
homeostasis
iNOS
Central &
Vascular
Antiplatelet
Vasodilatation
Mitochondrial regulation
Host * Macrophage function 
defence . Septic shock
peripheral 
nervous system
Neurotransmitter 
Memory development
Figure 1-2: Summary of the different actions of NO throughout the body.
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1.4. The metabolism of NO in blood
In 1916 HH Mitchell, an American physician, noted that a greater 
concentration o f NO3* was excreted in the urine than could be accounted for by diet 
alone35. This was the first suggestion that the body endogenously produced NO3' as 
what would subsequently be discovered to be the major vascular metabolite of NO 
production.
It is not possible for NO to be stored in the endothelium and therefore all NO 
produced from eNOS immediately diffuses away from its source. Some of this NO is 
responsible for the end organ effects outlined in section 1.3 (page 3), however a 
significant proportion enters the vessel lumen where it readily reacts with a variety o f 
the different constituents found in blood. Three main groups of reactions occur: that 
with either dissolved plasma O2 to form NO2’ or to a lesser extent O2’ to form ONOO'; 
erythrocyte metabolism to form methaemoglobin (Met-Hb) & NO3' if  oxygenated 
haemoglobin (oxy-Hb) is present or HbNO if  deoxygenated haemoglobin (deoxy-Hb) 
is present; and nitrosylation o f thiol-groups on certain proteins to form RSNO species, 
(see Figure 1-3; page 9). These products o f blood metabolism of NO will each be 
discussed in turn in the next section.
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Hb(Fe3+)
(met-Hb) 
\
ONOO
>
> Deoxy-Hb 
Hb(Fe2+)NO  
HbSNO
RSNO
>> + ..
Figure 1-3: Summary diagram o f the products o f blood metabolism o f NO. The 
reactions o f NO within both an oxygenated and a deoxygenated erythrocyte are 
illustrated, together with the reaction products o f NO with O2, O f and plasma 
proteins.
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1.4.1. Oxidative metabolites of NO
1.4.1.1. Inorganic nitrite (NO2 )
o ^ o
Figure 1-4: The chemical structure of N02~. An electron is shared between the two 
oxygen molecules and the nitrogen molecule (dashed line) resulting in anion 
formation. In turn a nitrite-salt will be formed when N02' binds to a positive ion (e.g. 
sodium nitrite, NaN02).
The foremost reaction of NO in plasma is with lA O2 to form the anion 
inorganic NO2’. The NO2' created then forms a salt, predominantly with sodium 
(Na+), to give NaN0 2 . NO2' is a biochemically stable molecule in normoxic plasma 
and further oxidation o f NO2’ to NO3’ is not favoured without the catalytic effect of 
Hb36.
NO2’ itself is a vasodilator . However this effect is relatively weak when 
compared to specific NO donor agents such as organic nitrates, e.g. glyceryl trinitrate 
(GTN)38.
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I.4.I.2. Inorganic nitrate (NO3 )
o11
Figure 1-5: The chemical structure of inorganic N03'. An electron is shared between 
the three oxygen molecules and the nitrogen molecule (dashed line) resulting in 
anion formation. Therefore, in turn, a nitrate salt will be formed when N03' binds to a 
positive ion (e.g. sodium nitrate, NaN03).
TQThe principle reaction o f NO in blood is with oxy-Hb to form the anion 
inorganic NO3' and met-Hb. The M V  formed is subsequently removed from the 
erythrocyte into plasma and then excreted by the kidneys.
NO3’ is a highly stable molecule which has no intrinsic vasodilator properties. 
However, when ingested orally N 0 3 * can be converted into NO2’; a process which can 
result in a measurable vasodilator effect40 (see section 1.4.5; page 20).
I.4.I.2.I. NO passage into the erythrocyte
There is no consensus opinion o f the precise mechanism by which NO enters 
the erythrocyte to participate in the reaction outlined above. NO gas can freely diffuse 
across the bilayer phospholipid structure of the erythrocyte membrane. However the 
presence o f an erythrocyte free zone adjacent to the endothelium41, a state favoured by 
laminar blood flow, will divert free NO as it leaves the endothelium towards the non- 
erythrocytic metabolic routes outlined in this section. It is therefore more probable 
that the majority of NO3' substrate enters the erythrocyte in the form of NO2’ 42. 
However, unlike other cellular membranes which allow a free flux of small ions43
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(including NO2 ), the erythrocyte membrane has a high cholesterol composition that 
renders it relatively impermeable to small ion transit44, (see Figure 1-6, below). 
Consequently, erythrocyte membrane ion transport is controlled by specific channels; 
anion exchange principally occurring via anion exchange channel 1 (AE1). The 
primary function of this channel is to allow a smooth flux of bicarbonate (HCO3') 
across the erythrocyte membrane to aid circulatory carbon dioxide (CO2) transport 
and pH buffering. AE1 therefore forms a critical component of erythrocyte function. 
However, it is not specific to HCO3’ and the structurally similar NO2 ' can also be 
ported by it, albeit at a slower rate than NO2’ is transported into other compartments 
of the body42.
Figure 1-6: The transit o f N 02 across d ifferent cellular membranes. Left panel = a 
standard bilayer phospholipid membrane. The flu id ity  inherent to this structure 
allows fo r  relatively free ion transit (N02 illustrated). Right panel = the erythrocyte 
membrane contains a much greater proportion o f cholesterol. Correspondingly, anion 
transit is only possible through the specific ion exchange proteins (AE1 illustrated).
In summary, NO produced by the endothelium that enters the circulation is 
predominantly metabolised to NO3' in a process which requires Hb. NO2' is a 
potential intermediate of this process, which is formed by the reaction of NO and O2 
in plasma before entering the erythrocyte.
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1.4.1.3. Peroxynitrite (ONOO )
/ O -
o
Figure 1-7: The chemical structure of peroxynitrite
Peroxynitrite (ONOO') is the product of the reaction between NO and 
superoxide (O2’)45, a form of reactive oxygen species (ROS). This reaction does not 
require an enzymatic catalyst. It occurs at a near diffusion-limited rate whenever the 
two substrates are produced in proximity to one another; a situation which arises 
when the body is placed under any pro-inflammatory stimulus. In the instance of an 
acute bacterial infection this is beneficial (see section 1.3.3.1; page 5). However, 
certain chronic diseases are characterised by a constant exposure to a low grade 
inflammatory stimulus and in these situations the production of ONOO' can be 
detrimental (see section 1.4.1.3.2; page 14).
I.4.I.3.I. Superoxide (O2 )
There are three main in-vivo sources o f O2 '. The majority arises as a product 
of white blood cell NADPH oxidase activity, an important part of the host defence 
mechanism (see section 1.3.3.1; page 5). In addition, O2 ' is produced when 
incomplete reduction of O2 takes place along the mitochondrial ETC. This event is 
known as mitochondrial uncoupling or ‘electron leakage’ and is enhanced by an 
ischaemic environment (see section 1.6.1.2; page 41). Thirdly, O2' is generated when 
an activated NOS enzyme lacks either the substrate L-arginine or the essential co­
factor tetrahydrobiopterin; the latter situation is often referred to as ‘NOS 
uncoupling’46. Indeed the presence of O2' will deplete tetrahydrobiopterin, thus
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uncoupling NOS and forming a positive feedback cycle which will exaggerate its own 
production.
O2’ will react with and damage any protein or other biological structure which 
it comes into contact with. To counter this, the enzyme super-oxide dismutase (SOD) 
is present throughout the body to rapidly remove O2' as soon as it is formed. 
However, the rate-constant for the reaction of NO with O2’ is greater than that o f O2’ 
with SOD, thus permitting ONOO* formation47.
I.4.I.3.2. The biological significance of ONOO
Unlike NO, ONOO’ has little role as a signalling molecule. It is a strong 
oxidant48 and through its production the body is able to convert NO from an integral 
component of vascular homeostasis to part o f the immune system. However, 
pathologies which chronically up-regulate these processes and favour NO metabolism 
to ONOO* will detrimentally deter NO from its more usual biological functions. This 
occurs, for example, in hyperlipidaemia, metabolic syndrome, diabetes mellitus (DM) 
and rheumatoid arthritis49. This specific pathological feature o f these diseases is often 
referred to as ‘endothelial dysfunction’. Significantly there is a strong correlation 
between endothelial dysfunction, as measured by physiological ‘stressing’ of the 
endothelium, and cardiovascular mortality50.
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1.4.2. T h io l bound NO m etabolites
O
II
Figure 1-8: The chemical structure of an S-nitrosylated protein. The 7?' represents the 
body of the protein chain and the 'S' the thiol group which binds to NO.
Sulfhydryl groups (-SH, also known as thiol-groups) are frequently found in 
proteins and play a key role in the post-translational modification of their quaternary 
structure. This is due to the ability of the labile S-H bond to react with a number of 
different substrates, and in doing so alter the conformational state of the protein. This 
process acts as a molecular regulator of protein function, as the resulting shape of the 
protein either enhances or inhibits the intended action51. One such substrate is NO, the 
reaction with this molecule resulting in a semi-stable group of compounds called 
mtrosothiol (SNO) species . In plasma, protein thiol bound NO groups are called 
RSNO groups; the R relating to the associated protein structure on which the thiol- 
group is found.
The most abundant source of RSNO in plasma is albumin bound SNO52. In- 
vitro experiments show that RSNOs exhibit a NO-type effect upon platelets and 
vascular smooth muscle, but are more stable than NO gas53. When assessed in 
equimolar concentrations they are a more potent vasodilator than NO2’38.
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1,4.3. Intra-erythrocyte NO metabolites
NO will enter the erythrocyte as either NO gas or NO2’ and is then primarily 
metabolised to NO3’ by oxy-Hb (see section 1.4.1.2; page 11). Although there are 
reports of a 2 : 1  intraiextra erythrocyte gradient54, other groups report that a 
much smaller amount of NO2’ is found inside the erythrocyte55. Furthermore, the 
complex structure of Hb and how this alters with variation in O2 result in additional 
metabolites of NO forming within the erythrocyte.
I.4.3.I. The molecular structure of Hb
The most common type of Hb in adults is HbA; a tetrameric molecule 
consisting o f four subunits56. Each subunit contains a large globular protein chain 
called a globin (two of both a and (3 types) which is tightly associated with a haem 
group. The haem group consists of an iron molecule held in position by a porphyrin 
ring. This iron molecule is capable of reversibly binding O2 (or other diatomic gases, 
e.g. carbon dioxide (CO2) or NO) when it is in a ferrous (Fe2+) configuration. In this 
state an electron is temporarily donated to the bond. However, if  the bound diatomic 
gas extracts itself from the haem group in an oxidised state (i.e. by absorbing this 
electron into its own structure) then the iron molecule is altered to a Fe3+ state. This 
redox arrangement of haemoglobin is known as methaemoglobin (met-Hb). Hb(Fe3+) 
is not capable of binding O2 . Consequently the erythrocyte contains an enzyme, called 
methaemoglobin reductase57, which reactivates Hb by reducing Hb(Fe3+) back to 
Hb(Fe ). O2 transport by Fib in itself does not result in the formation of met-Hb.
Page | 16
C h a p t e r  1 G e n e r a l  I n t r o d u c t i o n
1.4.3.2. The allosteric regulation of Hb structure
The four globin molecules of Hb adopt a different allosteric structure as they 
switch from an oxygenated (relaxed or R state structure) to a deoxygenated form 
(tense or T state structure). Hb therefore adopts a different conformational structure as 
each of these four globin groups either gains or looses an O2 molecule. This in turn 
results in the sigmoid-shaped binding curve of Hb for O2 and the regulation of O2 
delivery to tissue.
1.4.3.3, Hb bound NO
HbNO
HbSNO
Figure 1-9: Diagram o f the fo u r globin units o f Hb (red (a) and blue (6)) and their fo u r 
associated haem units (green rings held w ithin each globin unit). NO w ill attach at 
each haem binding site to fo rm  HbNO and in addition can bind to a free th io l site on 
each 6-globin unit to fo rm  HbSNO. Adapted fro m  www.mcat45.com.
NO will react with Hb at any available empty haem-binding site to form
24* 58Hb(Fe )NO . This reaction is favoured more with the T state configuration of 
deoxy-Hb. Hb can also bind NO on a thiol site of the J3-globin subunit at the p-93
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cysteine codon; to form HbSNO59. This occurs when HbNO is re-oxygenated, as the 
presence of O2 displaces NO from the haem-binding site to the P-93 cysteine position. 
This reaction is therefore favoured when Hb is in the R state60. Crucially, when this
^ I
reaction occurs the haem group retains the Fe configuration and therefore remains 
able to bind O2 . Figure 1-9 (page 17) is a figure illustrating these two forms of Hb 
bound NO.
1.4.4. The relative distribution of blood NO metabolites
In summary, NO produced at the endothelium is highly reactive and rapidly 
forms a variety of secondary molecules. Some of these products result in signal 
transduction and the biological effects of NO. Others occur within the vasculature; the 
predominant reaction being NO3' formation by oxy-Hb. Figure 1-10 (below) displays 
the distribution of the different metabolites of NO typically found in venous blood.
1 t i l !  1  
: ! I  :
E3SRSNO
C U  HbSNO ■ ■  HbNO
Other NO metabolites
Figure 1-10: The relative distribution o f NO metabolites in venous blood. Data taken 
from  chapter 3 o f this thesis.
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1.4.4.1. NO metabolite distribution as a function of Hb-02 
saturation
A decrease in Hb- 0 2  saturation will cause a decrease in plasma [NO2 ] and an 
increase in [HbNO]55, a correlation shown in Figure 1-11 (below). This observation, 
that the local concentration of O2 is responsible for the different apportionment of NO 
metabolites in blood, has been the focus of a large body of research which will be 
discussed in the next section. The drive behind this work has been the central tenet 
that the biochemical shifts observed with a decrease in O2 are responsible for the 
physiological changes of hypoxia.
* HbNO 
A Plasma [N02 ]
25 50 75 100
Haemoglobin saturation ( % )
Figure 1-11: The relationship between HbNO and plasma N02' levels with altering Hb
saturation. Adapted from Rogers et al55.
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1.4.5. Dietary N0 3 ‘ as a source of plasma NO2'
30% of plasma [NO2’] is obtained from the diet, with the balance arising from 
intravascular metabolism of NO produced by the endothelium61. The major dietary 
sources o f plasma [NO2’] are foods rich in NO3"/ M V , e.g. vegetables and red meat62. 
After ingestion, commensal bacteria in the upper gastro-intestinal tract reduce NO3' to 
NO2*, which is then further reduced to NO by the acidic environment o f the stomach. 
NO gas is then absorbed into the circulation, where it is oxidized to NO2 ’ in plasma .
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1.5. The physiological importance of blood NO metabolites
1.5.1. The endocrine properties of NO
The reaction of NO with pure Hb occurs at a near diffusion-limited rate (107 
m.s'1)64. Therefore, and despite the presence o f the erythrocyte-membrane which 
retards the diffusion of NO to Hb, the half life of NO in blood is very short (<2ms) 
and in normoxic tissue it has been estimated to be only marginally longer at 
approximately 0.1s65. Correspondingly NO itself has a limited diffusion distance over 
which it is capable of exhibiting an effect66; a finding which concurs with the 
observation that NOS enzymes are intricately regulated at a local level and are highly 
compartmentalised23. This led to the field of NO research asserting that the 
metabolism of NO in blood was a one-way process. In addition it was stated that NO 
had a sphere o f influence that was strictly limited to the area immediately adjacent to 
where it was produced .
This opinion was challenged when a detailed analysis of the physiological 
effects of inhaled NO gas (at higher doses of 80 parts per million) was performed. 
Cannon showed that during administration of inhaled NO the expected 
vasoconstriction that would result from regional L-NMMA infusion into the forearm 
was prevented . The concentrations o f several blood NO metabolites were raised m 
this experiment, suggesting that one or more o f these could be a stable intermediate 
by which blood was capable of transporting a NO-type effect to a site remote to its 
production or administration. This observation led to the formation of two different 
theories; each an attempt to explain the biochemistry responsible for the endocrine 
properties of NO. These theories will be critiqued in turn in the following sections.
Page | 21
C h a p t e r  1 G e n e r a !  i n t r o d u c t i o n
1.5.2. HbSNO as a modulator of endocrine NO function
1.5.2.1. Theory
Stamler demonstrated in 1992 that plasma protein-nitrosothiols vasodilate 
isolated rings of aorta and inhibit platelets53. The same author also reported, using 
photolysis-chemiluminescence to measure SNO levels, that the concentration of 
HbSNO was greater in arteries (311 ± 55nM) than in veins (32 ± 14nM)60. These 
observations prompted the formation of the following theory o f how HbSNO is 
involved in the regulation of blood vessel tone69.
Hb(Fe2+)NO, is formed in the venous circulation as the product o f the reaction 
between NO and deoxy-Hb (i.e. Hb in the T state). Upon reaching the lungs this 
molecule of ferrous bound NO is transferred to the p93-cys residue o f Hb as the 
haem-binding site becomes occupied by O2 and the allosteric conformation of Hb 
switches to the R state. HbSNO has a less avid binding capacity for NO than ferrous 
bound NO and, in addition, the thiol bond of HbSNO is stronger in the R state than 
the T state. These two biochemical features combine to promote the release of NO 
from HbSNO as the erythrocyte subsequently arrives in the peripheral vasculature. 
Consequently local (‘hypoxic’) vasodilatation occurs70. This theory is summarised in 
Figure 1-12 (page 23).
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Figure 1-12: The Stamler model o f HbSNO delivery o f NO to the hypoxic peripheral 
vasculature. Adapted from  McMahon et a I69
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I.5.2.2. Criticisms of the HbSNO theory
The HbSNO model as a means to explain the endocrine properties of NO is 
intuitively appealing. It offers a simplistic and elegant means by which both 
biochemical and physical forces are balanced as the environment switches from high 
to low O2 . However, many groups have queried its validity.
71Joshi questioned the biochemical relevance of the supporting experiments 
performed by Stamler and colleagues. In the original work performed by Gow72 it was 
reported that HbSNO was produced when NO was mixed with Hb. Joshi repeated this 
experiment but, rather than giving a large bolus of pure NO, instead used an 
equivalent concentration of an NO-donor agent (MAHMA-NO) to provide a slow and 
steady supply of NO. Under these revised conditions, claimed by the authors to be a 
closer mimic of physiology, NO3' was formed to a far greater extent than HbSNO.
Gladwin reported that HbSNO is highly unstable when in the intracellular 
environment of the erythrocyte73, as opposed to the more stable purified conditions 
used by Stamler in his original supportive work. In a separate paper74 Gladwin also 
failed to replicate the gradient o f HbSNO between artery (45 ± 14nM) and vein (63 ± 
13nM) previously reported by Stamler60. However, a different analytical technique 
was used in this experiment to detect HbSNO (i.e. tri-iodide chemiluminescence).
Theoretical concerns o f the HbSNO theory have also been raised. Schechter 
suggested that the levels of HbSNO measured in vivo (i.e. less than 70nM) were too 
low to justify the status of HbSNO as an important agent of vascular reactivity75. The 
quantitative nature of this observation has been disputed due to the methodological 
differences between groups in how HbSNO is measured76. However, irrespective of 
this point it was countered by Stamler that the absolute level of NO signal produced 
by a compound when it is measured does not equate to the associated bioactivity of
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that molecule77. Indeed, Stamler also commented that NO gas is present at just 
picomolar concentrations in tissue but is still an important vasodilator.
Lastly, studies have been performed using mice where an alanine molecule has 
been substituted for the cysteine group at the (393 position of Hb78. Hb from these 
mice is therefore unable to form HbSNO. Upon testing (393-cys knockout mouse 
erythrocytes in an isolated vessel preparation it was found that they exhibited a 
similar hypoxia-dependent vasodilator effect to erythrocytes containing wild type Hb. 
It is important to clarify that whilst this negative data is significant it does not 
discount the HbSNO theory altogether. Merely it confirms that in the absence of 
HbSNO the erythrocyte contains alternative vasodilator mechanisms which can 
assume equal importance.
In summary, the inability of the proponents of the HbSNO theory to perform 
any in-vivo experiments, other than simple observational studies, has rendered it 
difficult for this theory to be convincingly confirmed or refuted. Consequently much 
of the supporting work has been in the form of laboratory experiments which have 
been criticised for the methods used and the conclusions drawn from their results.
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1.5.3. N02 & deoxy-Hb as modulators of endocrine NO function
1.5.3.1. Theory
NO2' is the second most abundant metabolite of NO in blood (after NO3 ') and 
is therefore theoretically appealing as the major intra-vascular source of bioactive NO. 
In a human forearm experiment, performed by Gladwin in 2000, a negative gradient 
of plasma [NO2’] from artery (540 ± 74nM) to vein (466 ± 79nM) was reported74. In 
addition, it had previously shown by another group that a positive gradient of [HbNO] 
between artery (536 ± 99nM) and vein (894 ± 126nM) exists60. In the same paper 
Gladwin also reported that the cross-vascular gradient of plasma [NO2"] was more 
pronounced in the presence of (maximal) exercise and L-NMMA; interventions which 
both act to decrease venous O2 levels. Therefore it was suggested that consumption of 
NO2*, to form bioactive NO, was occurring with the transit of blood from artery to 
vein, in response to a decrease in O2 level. Although no mechanism was investigated 
in this observational study, it was proposed that NO2 ' was being reduced to NO across 
the vascular bed and as a result contributing to arterial tone.
1.5.3.1.1. Deoxy-Hb as a N02 reductase
The observations detailed above are consistent with the reaction kinetics of 
NO2* and deoxy-Hb first described by Doyle in 198158:
N 02 + H+ + HbFe2+(deoxy) -> HbFe3+ + OH + NO (-> HbFe2+-NO)
Equation 1-1: N02' reacts with deoxy-Hb to give met-Hb and NO, this NO is 
subsequently captured by an adjacent free haem group to produce HbNO.
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However, this simplified equation does not explain the complexity of the 
different reactions between NO2 ' and Hb which occur at different O2 levels. The 
bimolecular rate-constant of NO2’ with R state (oxy-)Hb is ten-times greater than with 
T state (deoxy-)Hb79, but the T state conformation of Hb offers a greater number of 
unoccupied haem-groups for binding NO2'. Furthermore, a study by Cosby (and 
Gladwin) showed that, using isolated rings of aorta, the vasodilator effect of NO2’ in
OA
the presence of erythrocytes is enhanced when O2 levels are reduced . However, this 
result was not replicated when the same experiment was repeated by a different 
group81. Cosby also reported that this NCV-erythrocyte dependent vasodilatation 
initially occurred at an O2 tension of 50 mmHg, which was calculated to correspond 
to a Hb saturation of approximately 50%. These findings led Gladwin to suggest that 
the most efficient conformational state o f Hb to allow NO2’ reduction to NO was at an 
O2 saturation of 50%82.
As a result of these observations Gladwin proposed that NO2" reduction to NO 
occurs as the environment becomes increasingly hypoxic, and that this process takes 
place within the erythrocyte. Deoxy-Hb was identified as the reductase responsible for 
this reaction, with a maximal reaction rate occurring at 50% O2 saturation, (see Figure 
1-13; page 28). Furthermore, it was contended that this process was responsible for 
both the maintenance of normal blood vessel tone and the phenomenon of hypoxic 
vasodilation83.
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Figure 1-13: Schematic diagram o f the deoxy-Hb theory o f N02 reduction during 
transit from  artery to vein. Adapted from  Gladwin et a I83.
I.5.3.2. Criticisms of the deoxy-Hb/NOz* reductase theory
As with the HbSNO theory, there have been many criticisms of the deoxy-Hb 
theory of NO2" reduction as the means to explain the endocrine properties of NO.
The principle concern raised by several groups is the lack of an obvious 
mechanism by which the NO produced either extracts itself from Hb (which will bind 
it more avidly the lower O2 levels become) or once it has extracted itself is able to 
leave the erythrocyte72. The formation of an intermediate molecule has been 
suggested as a means of bridging this conceptual gap54. However no clear
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intermediate has been identified and the inclusion of this concept adds an 
unsatisfactory extra layer of complexity to the theory.
Secondly, other groups have reported that whilst a change in oxygenation will 
result in a re-apportionment of NO within the vasculature no overall consumption of 
NO metabolites is present over a single arterial to venous transit cycle55.
Thirdly, the vasodilator activity of NCV is enhanced by hypoxia in an isolated 
vessel model; an environment which is erythrocyte independent . Indeed, there are 
several haem-containing enzymes found within the blood vessel wall and associated 
tissue, which are all capable of NO2’ reductase activity. Xanthine oxidase (XO) is one 
such enzyme which has been shown to have an enhanced capacity as a NO2’ reductase 
in hypoxia85. Simple acid disproportionation of NO2" will also result in NO 
formation86, although it should be acknowledged that this mechanism is more 
appropriate to an ischaemic environment rather than a purely hypoxic one.
In summary, the deoxy-Hb/N0 2 ’ reductase theory has received a number of 
criticisms relating to the conceptual gaps it contains and inconsistencies which have 
been exposed when it has been explored in different models. However, one of the 
enduring strengths of this theory has been the ability of others to continually support 
or challenge it by the performance o f studies which involve the administration of 
NO2’ to humans.
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1.5.4. Previous human studies of exogenous NO2 administration
There have been five previous studies where the effects o f intravenous NO2" 
administration upon humans have been examined. These are addressed individually 
below and are summarised in Table 1-1 and Table 1-2 (pages 35 & 36).
1.5.4.1. Lauer et al
In 2001, before the publication o f the deoxy-Hb/NCV reductase theory, Lauer 
reported an experiment where a brachial artery infusion o f NaNC>2 was given to three 
healthy human subjects87. No difference in forearm blood flow (FBF) was observed in 
this study despite a one hundred-fold increase in plasma [NO2 ] to >130pM. In their 
discussion the authors discounted the notion that NO2’ possessed any significant 
vasodilator action. Instead they proposed that it was simply a marker o f regional NO 
production by the endothelium.
1.5.4.2. Cosby et al
The very small sample size used by Lauer together with the negative result 
prompted Cosby to perform a similar study in 200380. An infusion of NaN0 2  was 
given into the brachial artery o f healthy human subjects at doses ascribed to be either 
pharmacological (i.e. associated with an increase in ipsilateral venous plasma [NO2 ] 
from 200nM at baseline to 221jxM at peak) or physiological (i.e. an increase from 
200nM to 2.56pM). FBF was measured using strain gauge plethysmography (SGP) in 
the ipsilateral arm to that infused and found to increase in both groups by 175% and 
25% respectively. It was further observed that during exercise (which was associated 
with a reduction in venous O2 levels) there was an additional increase in FBF and 
decrease in venous plasma [NO2’]. This study forms an important part o f the
supporting evidence that underpins the deoxy-Hb/NCV reductase theory.
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1.5.4.3. Dejam et al
In 2007 Dejam conducted a series o f experiments to explore in-vivo the 
potential mechanisms responsible for NO2 ' associated vasodilation88. The influence o f  
NaNC>2 (delivered via the brachial artery) upon FBF was measured in healthy human 
subjects. Co-administration o f either allopurinol (to block XO) or ascorbic acid (to 
promote acid disproportionation) accompanied the NO2 ' infusion. Neither o f these 
additional agents had a significant effect upon NO2’ bioactivity. In addition, a dose 
escalation regime o f  NO2 * was infused and the subsequent decay profiles o f both 
venous [HbNO] and plasma [NO2*] were recorded. The profiles o f these two NO 
metabolites followed both each other and the simultaneously recorded profile of 
ipsilateral FBF. This observational evidence was used by the authors in support o f the 
deoxy-Hb/nitrite reductase theory.
1.5.4.4. Maher et al
In 2008, after this thesis was started, Maher performed an experiment 
examining the physiological effects o f NO2 ' infusion upon the human forearm89. 
Forearm venous volume was measured in addition to FBF. It was reported that veins 
respond to NO2’ at a lower dose than arteries do in normoxia. As an additional 
experiment subjects inhaled a hypoxic gas mixture to reduce their capillary O2 
saturation level from 97% to 83-88%. Equivalent quantities o f NO2’ infused in this 
environment had an enhanced effect upon FBF than when they had been delivered 
under normoxia conditions. In addition, an isolated vessel model was used to confirm 
the relative sensitivity o f veins to NO2’, when compared to arteries. This model also 
emphasized an observation reported by other groups81, 84 that hypoxia-mediated
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changes in vascular sensitivity to NO2* can occur in an erythrocyte-independent 
environment.
1.5.4.5. Mack et al
This phase 1 clinical trial was designed to investigate the physiological effects 
and safety o f a similar infusion regime o f NaNC>2 given intra-arterially to either 
homozygous sickle cell disease (SCD) patients or healthy volunteers90. The control 
group data was taken from the Cosby study, performed 5 years earlier80. Mack 
reported that venous plasma [NO2 ] levels measured in the patient group were lower 
than that recorded in matched controls, despite a slightly greater concentration o f  
NaNC>2 having been infused. Unfortunately the O2 saturation levels o f the two groups 
were not reported. Unsurprisingly, the lower concentration o f plasma NO2’ achieved 
in the patient group corresponded with a less pronounced change in ipsilateral FBF 
compared to the controls. The authors suggested that this was due to a decrease in 
NO2 * bioavailability in sickle cell disease patients. It was also proposed that this 
observation could explain the mechanism behind some o f the vascular complications 
o f sickle cell disease.
1.5.4.6. Criticisms of the above studies
Many criticisms can be made o f the conclusions derived from these in-vivo 
studies investigating the effects o f NO2 ' supplementation upon vascular function.
Firstly, although Cosby asserted that the infusion o f NaNC>2 given in their 
study was ‘physiological’ it resulted in a ten-fold increase in plasma [NO2’]. The 
authors claimed that this level was still close to the normal range o f human plasma 
[N 0 2‘]. Whilst it should be acknowledged that any infusion is by definition 
pharmacological and therefore the point at which an infusion becomes
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‘pharmacological’ as opposed to ‘physiological’ is a somewhat nebulous concept; 
there is clearly a need to investigate the effect o f NO2* supplementation at lower doses 
to those previously employed. An infusion o f NaNC>2 which results in a measurable 
physiological effect at the lowest concentration o f plasma [NO2 ] possible would be 
optimal.
A general criticism o f the previous studies performed is that high doses of  
NaNC>2 have tended to be used. This will have had the effect o f swamping some o f the 
pathways o f NO metabolism and in the process potentially missing subtle 
physiological and biochemical changes. This defect is well illustrated by Dejam, 
where a dose escalation regime o f NaN 0 2  is used to calculate the pharmacokinetic 
properties o f NO2’. The standard pharmacological method in this situation would be to 
use a single infusion dose o f NaN0 2  and to observe the decay profile following its 
cessation.
Secondly, most o f the previous investigations have been confined to a single 
vascular bed; the forearm. By limiting observations in this manner the differential 
effect o f  NaNC>2 upon other vascular compartments could have been missed along 
with important mechanistic insights. In particular the pulmonary vasculature 
frequently behaves differently to the systemic circulation and as such would provide a 
potentially insightful environment in which to examine the effects o f NaN0 2 .
Thirdly, Maher produced hypoxia through the use o f an inhaled I0 W-O2 
mixture delivered via a face mask for approximately 30 minutes. Exposure to hypoxia 
alone will result in systemic vasodilation which does not plateau until after more than 
two hours o f continuous exposure91. It is therefore important to allow an adequate 
hypoxia equilibration period when performing studies in hypoxia, to ensure that a
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steady baseline is present on which the effects o f the study intervention can be 
measured.
Lastly, all bar one o f the previous studies performed have been in healthy 
volunteers. Whilst these studies are vital to ensure the safety and efficacy o f NO2' 
there is an urgent need to explore the effect o f NaNC>2 in patient groups. In particular 
the effect o f NaNC>2 upon patients with cardiovascular disease requires further 
investigation as this group is the most likely to benefit from NCV-based therapies in 
the future.
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Table 1-1: Previous studies of N02 administration to man (part 1).
Author Year Number & type of subjects
Physiological
measure
NaN02 delivery 
regime
Results Conclusions drawn
Lauer 
et a l 87 2001 3 (healthy subjects)
SGP
measurement o f  
FBF
Brachial artery infusion: 
•  0.01 - 36pmol/min
•  Peak venous plasma [N 0 2‘] >130pM.
•  No change in FBF noted at any dose.
•  N 0 2' possesses no intrinsic 
vasodilator properties.
Cosby 
et a l 80 2003 18 (healthy subjects)
SGP
measurement o f  
FBF
Brachial artery infusion:
•  36(imol/min 
(5 min)
•  400nmol/min 
(5 min)
•  Peak venous plasma [N 0 2 ] = 
221.82|iM.
175% increase in ipsilateral FBF & 
systemic BP I 7mmHg.
[HbNO] increase observed. Associated 
with both N aN 02 infusion & 
decreasing S a02.
• Peak venous plasma [N 0 2 ] = 2.56|iiM. 
28% increase in ipsilateral FBF.
•  N 0 2‘ has vasodilator properties 
at both ‘pharm acological’ &  
‘physiological ’ doses; due to its 
conversion to NO.
•  The mechanism o f N 0 2‘ 
reduction to NO is catalysed by 
deoxy-Hb.
Dejam  
et a l 88 2007
•  Part A = 10 
(healthy subjects)
• Part B = 15 
(healthy subjects)
SGP
measurement o f  
FBF
Brachial artery infusion:
•  Part A:
7, 14, 28 ,55 , 110 
pmol/min (5 min/dose)
• Part B:
0.07, 0.14, 0.35, 1.4,
3.5, 7, 14, 28 pmol/min 
(5 min/dose)
+/- co-infusion:
- saline (n=5)
- oxypurinol (n=5)
- ascorbic acid (n=5)
•  Ipsilateral & contralateral increase in 
FBF with each dose given. Venous 
profile o f [HbNO] and plasma [N 0 2 ] 
identical.
•  Co-administered agents increased FBF 
across all doses o f N aN 02 but not 
significantly at any individual dose.
• FBF increased with the lowest dose 
infusion (i.e. 0.07pmol/min), which 
was associated with an estimated 
venous plasma [N 0 2 ] o f 350nmol.
•  N 0 2' is a regional and systemic 
vasodilator
• N 0 2' infusion is associated with 
an increase in [HbNO]; 
suggesting that deoxy-Hb is the 
responsible reductase for its 
vascular function.
•  Co-infusion with an inhibitor of  
XO (oxypurinol) or a promoter 
o f acidic disproportionation o f  
N 0 2' (ascorbic acid) does not 
affect N 0 2' potency.
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Table 1-2: Previous studies o f NO2 administration to man (part 2).
Author Year Number & type of 
subjects
Physiological
measure
NaN02 delivery 
regime
Results Conclusions drawn
Maher 
e t a l 89 2008
•  Part A  = 26 
(healthy subjects)
•  Part B = 14 
(healthy subjects)
SGP
measurement o f  
FBF
Radionuclide 
measurement o f  
FVV
Brachial artery infusion:
•  Part A
0.04, 0.1,0 .314, 0.748, 
3.14, 7.84 pmol/min 
(30 min/dose)
•  Part B:
Repeat study in hypoxia 
(S a02 = 83-88%) with: 
0.314pmol/min (n=7) & 
7.48|imol/min (n=7)
•  FBF increased at the 3.14 pmol/min 
dose and above only, in normoxia 
(venous plasma [N 0 2'] = 35pM)
F W  increased at 0.748 pmol/min 
dose and above in normoxia (venous 
plasma [N 0 2‘] = lOpM)
•  F W  similar in hypoxia to normoxia. 
FBF increased at 0.314pmol/min dose 
and above in hypoxia (venous plasma 
[N 0 2‘] = 5|xM).
•  Veins are more responsive than 
arteries to N aN 02.
•  Hypoxic arteries exhibit a 
greater vasodilator response to 
N aN 02 than normoxic arteries. 
The response o f veins is 
unaffected by hypoxia.
Mack 
et a l 90 2008
•  14
(homozygous SCD 
patients)
•  Control group 
taken from study 
by Cosby et af°.
SGP
measurement o f  
FBF
Brachial artery infusion: 
•  0.4, 4, 40 pmol/min 
(8 min each dose)
•  Ipsilateral venous plasma [N 0 2 ] & 
FBF increased in response to each 
dose o f N aN 02 infused.
• The venous plasma [N 0 2 ] levels 
achieved were lower in the SCD group 
compared to the control group. 
Consequently the SCD-FBF response 
to N aN 02 was decreased compared to 
the control group.
•  N aN 02 produces regional 
vasodilatation in patients with 
SCD.
• N aN 02 does not exhibit any 
signs o f toxicity at the doses 
administered.
• The bioavailability o f N aN 02 is 
lower in patients with SCD 
compared to control subjects.
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1.5.5. NO2 ' administration to the hypoxia pulmonary vasculature
The effect o f exogenous NO2’ administration upon the pulmonary vasculature 
has not previously been assessed in man. However, three studies have been performed 
in animals.
Hunter92 induced pulmonary hypertension in anaesthetised newborn lambs and 
treated them with nebulized NO2’. Two groups were assessed with invasive 
haemodynamic monitoring. The first group received a thirty minute exposure to an 
inhaled hypoxic gas mixture (FiC>2 1 2 %), maintaining their SaC>2 at 55%. Pulmonary 
arterial pressure increased from 21 to 34mmHg and was subsequently reduced by the 
administration o f nebulized NO2’ (a 6 mM dose was given over twenty minutes) to 
25mmHg; a fall o f 60%. This effect was associated with an increase in [HbNO] and 
exhaled NO. In the second group a greater degree o f pulmonary hypertension was 
induced by a thromboxane-analog (24 to 51mmHg) and then reduced to 44mmHg by 
the same regime o f nebulized NO2 '. Exhaled NO levels increased in this group but 
interestingly [HbNO] levels did not change.
The second group showed a similar absolute reduction in pulmonary arterial 
pressure to the first. However, due to the enhanced degree o f vasoconstriction present 
initially only a 25% reduction in pulmonary arterial pressure occurred. The authors 
capitalised on this baseline discrepancy to propose that NO2' is a more potent 
vasodilator in hypoxia and that this increased efficacy is due to its reduction by 
deoxy-Hb, inferred by the presence o f HbNO.
Following this publication, Casey93 employed a rat model to assess whether 
NO2' exhibits enhanced potency as a pulmonary vasodilator in hypoxia. He showed 
that in rats treated with a thromboxane-analog, to achieve a pulmonary pressure of 
30mmHg, iv NaN0 2  reduced pulmonary arterial pressure by 8 mmHg whilst either a
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hypoxic gas mixture (F1O2 10%) or room air was inhaled. This suggested that hypoxia 
was not the responsible mechanism behind the enhanced vasodilator activity o f NO2' 
in hypoxia-driven pulmonary hypertension. However a very short period o f  exposure 
to hypoxia was used; long enough to reduce SaC>2 levels but perhaps not long enough 
to affect other physiological & biochemical changes o f hypoxia.
In addition Casey demonstrated that the pulmonary vasodilator action o f NO2’ 
could be partly attenuated by the addition o f allopurinol, in the normoxic, 
thromboxane-analog model o f pulmonary hypertension. This suggests that, in 
normoxia, deoxy-Hb is not a significant reducer o f  NO2’ to NO; as would be expected.
Lastly Diaz-Junior94 examined the effect o f NO2* in a canine model o f acute 
pulmonary embolism. He showed that low-dose NO2' (achieving plasma levels of 
approximately 500nM) reduced indices o f pulmonary vascular resistance in this 
model o f pulmonary hypertension. However, it should be noted that this pathological 
model o f acute pulmonary embolism will have resulted in both local hypoxia and 
ischaemia; both environmental modifications capable o f enhancing the vasodilator 
effect o f NO 2’.
In summary these three studies have demonstrated that NO2’ is a pulmonary 
vasodilator in animals whose effect is enhanced when a greater degree o f pulmonary 
vasoconstriction is present; this may be due to hypoxia alone or in combination with 
other factors. It is uncertain whether deoxygenated Hb is an important catalyst to this 
process.
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1.5.6. Summary of the two theories of endocrine NO function
Each o f the two theories outlined in section 1.5.2 (page 22) and section 1.5.3 
(page 26) propose that the erythrocyte plays a key role in the regulation o f vascular 
tone and delivery o f O2 to tissue. However, the theories differ in that each one 
attributes this effect to an alternative intravascular metabolite o f NO. Crucially, one 
theory chooses a more potent but less abundant mediator (i.e. HbSNO) compared to 
the other theory (i.e. NO2'). It is important to emphasize that donation o f NO by any 
vehicle will increase the pool o f circulating NO metabolites, as the reactions outlined 
in this chapter experience a shift in their kinetic equilibrium. Consequently, the 
addition o f NO2’ to blood will result in an increase in HbSNO levels and vice-versa, 
regardless o f physiological function per-se95. It has therefore proved extremely 
difficult to definitively prove or disprove either theory, as by their very essence they 
are interconnected.
Advances in the field o f NO metabolite research have therefore been curtailed 
by the complexity inherent to the system being examined. Many o f the issues raised 
are technical relating to the analytical tools being employed, but also it may equally 
hold true that the whole system is too demanding to allow a systems biologist 
approach96. As a result o f this impasse the literature has shifted focus in recent years 
away from attempts to explain baseline physiology to the pharmacological effect o f 
NO donation in other, pathological, models. A major area o f interest has been the 
effect that NO2’ has upon ischaemia/reperfusion (IR) injury. This will be discussed in 
the next section.
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1.6. The role of NO2 ' in ischaemia/reperfusion (1R) injury
One aspect o f NO metabolite research in which advances have been 
forthcoming is that o f IR injury and the mitigating effect which NO and certain NO 
metabolites have upon this process97. This represents an important facet o f NO 
bioactivity, one which combines a number o f the different biological effects o f NO. 
Central to an understanding o f the role o f NO in the pathophysiological process o f IR 
injury is the structure and function o f the mitochondrion. This will be detailed in the 
next section.
1.6.1. IR injury background: the mitochondrion
Mitochondria are membrane enclosed organelles found within virtually all 
human cells. They are responsible for aerobic respiration and are consequently present 
at different densities in different cell types dependent upon the local tissue energy 
requirement .
1.6.1.1. Mitochondrion structure
Each mitochondrion comprises o f four separate compartments or layers which 
are shown in Figure 1-14 (page 41). Outermost is the outer membrane, a semi-porous 
structure which allows relatively free diffusion o f most small particles (i.e. < 5000 
Daltons). Inside this is found the intermembrane space (IMS). This space contains a 
similar concentration o f simple ions and small molecules to the cytosol surrounding 
the mitochondria, but also has a number o f specific proteins at higher concentration 
which are intrinsically involved in mitochondrial respiratory function. The inner 
mitochondrial membrane is beneath the IMS and separates this from the matrix, 
which is found at the centre o f the mitochondrion. Unlike the outer membrane the 
inner membrane is a highly impermeable structure; thus creating a barrier between the
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IMS and the matrix. Within the inner membrane are a number of specific ion channels 
which span it’s structure and operate in unison to effect the aerobic production of 
energy by the mitochondria; these are collectively known as the electron transport 
chain (ETC). In order to enhance ETC function the inner membrane has numerous 
folds to maximise the surface area available between the IMS and the matrix; these 
are known as cristae.
Inner
m em brane
Outer
m em brane
Matrix
In termembrane
sp a c e
Figure 1-14: The structure o f a m itochondrion. Adopted fro m  www.cartage.org
1.6.1.2. Mitochondrion function: the electron transport chain
At the core of the ETC are four transmembrane proteins which span the inner 
mitochondrial membrane. These are called complexes I, II, III & IV and work in 
series to transport electrons provided by the citric acid cycle (part of the Krebb’s 
cycle) to O2 and H+ to make H20 . The process of this shuttling of electrons causes H+ 
ions to be preferentially stored in the IMS; resulting in a pH gradient between the IMS 
and the matrix which is then used to drive the production of adenosine tri-phosphate
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(ATP) by a transmembrane ATPase (also known as complex 5). Figure 1-15 (below) 
is a schematic diagram of the ETC.
For the purpose of this chapter it is important to emphasize three key features 
of the ETC. Firstly complex 4 (also known as cytochrome-c) is an integral link of the 
ETC but is not membrane bound, instead being mobile within the IMS. Secondly, in 
addition to being able to bind O2 cytochrome-c can also bind NO. When this occurs 
the ETC is halted and thus mitochondrion respiration inhibited. Thirdly, complexes I 
& III are capable o f ‘electron leakage’ under certain conditions. This results in the 
acceptance of an extra electron by O2 , producing O2’ (a form of ROS; see section 
1.4.1.3.1, page 13).
Outer membrane
;ATP
Synthase
NADH
f  Citric V  
k acid 1
Matrix
S uccinateFumarate
Inner membrane
f Intermembrane space 
f f i l f f i W p W
Figure 1-15: Schematic diagram o f the electron transport chain (ETC). Adapted from : 
www.comm ons, wikimedia.org.
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1.6,2. The pathophysiology of IR Injury
The relief o f an acute coronary arterial occlusion was discovered to reduce the 
degree o f associated myocardial necrosis by Gink in 1972". However the author 
noted that a degree o f damage persisted despite a re-canalized artery. In 1985 
Braunwald100 recognised that this damage was due to a deleterious effect inherent to 
the early reperfusion phase following ischaemia, a process which became known as 
IR injury. He suggested, amongst other mechanisms, a key role for ROS generated by 
damaged mitochondria in the mediation o f this damage. Whilst the currently accepted 
mechanisms responsible for IR injury are more complex, this insightful observation o f  
the pivotal role that mitochondria play in its development remains at the centre o f  
several explanatory theories.
1.6.2.1. The biochemical cascade of I/R injury
The energy depleted state o f ischaemia causes a rise in cytosolic Ca2+ via a 
decrease in ATP-membrane pump activity101 (see Figure 1-16; page 44). A 
subsequent redistribution o f ions in response to osmotic forces results in the 
mitochondrial matrix becoming overloaded with Ca2+. At reperfusion this leads to the 
formation o f a large indiscriminate conductance megachannel across the 
mitochondrial membranes called the mitochondrial permeability transition pore 
(MPT)102. The exact constituents o f the MPT are unknown, though it is thought that 
several proteins organise at the meeting point o f the outer and inner mitochondrial 
membranes in order to produce it. It is perhaps easier to view the MPT not as a 
specific protein channel which is turned on at reperfusion, but more a transient state 
which is favoured during the development o f IR injury and characterised by 
disruption o f the usually highly stable mitochondrial membranes. It is probable that 
the MPT has evolved as part o f the apoptotic process; whereby a cell sacrifices itself
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when it has been damaged in order that efficient harmony o f the remaining tissue 
continues103.
In response to the presence of the MPT, swelling of the mitochondria and leakage 
of proteins from within it (including cytochrome-c) follows. Consequently the ETC 
becomes uncoupled and this leads to an abundance of ROS generation. This in turn 
has a positive feedback effect on the MPT to increase its permeability and a viscous 
cycle ensues. As a result of this disruption to the energetic powerhouse o f the heart 
myocardial stunning (due to contractile apparatus dysfunction), cellular necrosis and 
apoptosis all ensue103.
lactate
I: Air
glyco lysis
Upon reperfusion
Stunning _ . . N ecrosis3 A poptosis
Figure 1-16: Diagram o f ischaemia/ion balance. The anaerobic metabolism o f 
ischaemia leads to an increase in in tracellu lar lactate and reduction in pH. The cell 
attem pts to remove these H+ ions via the Na+/H + exchange channel, which in turn 
exacerbates ATP demand via the Na+/lC  port. This results in an increase in 
in trace llu lar [Ca2+]  which consequently enters the m itochondria. Once a norm al pH is 
resumed during reperfusion the MPT channel is activated by the increased levels o f 
m itochondria l [Ca2+]. Adapted fro m  M urphy et a!103.
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1.6.3. The phenomenon of ischaemic conditioning
In 1986 Murry demonstrated that exposure o f a myocardial tissue bed to four 
cycles o f 5 min o f ischaemia and 5 min o f  reperfusion immediately prior to a 
subsequent sustained ischaemic insult protected against IR injury104. This 
phenomenon was termed ischaemic pre-conditioning (IPC).
IPC confers two windows o f protection upon the recipient. The first, known as 
the classic or early window, has an effect which lasts for 3-4 hours. The second, 
known as the delayed or late window, is not present until 24 hours after the IPC 
stimulus and lasts for between 24 & 48 hours105. In addition it is possible in-vivo to 
provide a similar beneficial window upon ischaemic tissue as with early phase IPC 
through the application o f short bursts o f ischaemia in the immediate phase after 
reperfusion. This phenomenon is known as ischaemic post-conditioning (IPostC)106.
1.6.3.1. The mechanisms responsible for ischaemic conditioning
IPC & IPostC exhibit their effect via a series o f complex biochemical 
pathways which, although recognised, are incompletely understood. Importantly the 
common end point is inhibition o f the formation o f the MPT, by a reduction in 
mitochondrial ATP depletion and Ca2+ uptake107.
The process o f IPC begins by activation o f the pro-survival kinases o f the 
Reperfusion Injury Salvage Kinase (RISK) pathway108. This cascade has both a direct 
effect upon mitochondria and results in eNOS expression o f NO; which in turn leads 
to sGC/protein kinase activation (as outlined previously in section 1.2; page 2). This 
causes activation o f mitochondrial K a t p  channels which act to limit ATP depletion 
and mitochondrial calcium uptake109. A summary diagram o f the cellular pathways 
involved in ischaemic conditioning is in Figure 1-17; page 47. Importantly, the
process o f IPostC follows a similar, though less diverse pathway to IPC.
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In animal models o f IR injury it has been shown that the beneficial effects o f  
IPC can be mimicked by interventions to promote different stages o f this pathway. 
The RISK pathway is activated by insulin110 and atorvastatin111. Agents which limit
^ i  ^ • 119
intracellular Ca accumulation during ischaemia such as Ca channel blockers or 
Na+/H+ exchange inhibitors113 are also effective. Furthermore drugs which reduce the 
sensitivity o f the MPT to Ca2+ (e.g. cyclosporine) 97 have been shown to reduce 
subsequent IR injury. Finally, given the key roles that eNOS and NO have in the 
pathway o f IPC it is not surprising their modulation has an influence upon IR injury. 
Exogenous administration o f NO prior to ischaemia is capable o f mimicking the 
benefits o f early phase IPC. However, blockade o f eNOS with L-NAME does not 
abolish the effects o f IPC105. These two observations suggest that endogenous eNOS 
derived NO is a part of, but not integral to, the metabolic mediation o f IPC. However, 
inhibition o f either eNOS114 or sGC115 will block the beneficial effects o f IPostC, 
suggesting an integral role o f NO in this process.
The effect o f different forms o f NO donation upon IR injury will be discussed 
in the next section.
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Figure 1-17: Cellular pathways involved in the process o f IPC (le ft hand pathway) and 
IPostC (righ t hand pathway). Adapted fro m  M urphy et a!103.
1.6.4. The specific role of NO in ischaemic conditioning
A variety of different means of NO supplementation have been shown in 
rodent heart models to be capable of mimicking early phase IPC; these include 
exogenous NO donation by GSNO116 and sodium nitroprusside117 as well as agents 
which enhance endogenous NO release, e.g. bradykinin118.
A number of different mechanisms by which NO supplementation is capable 
of reducing the effects of IR injury have been proposed, (see Figure 1-18; page 48). 
Firstly, sGC dependent activation of protein kinases reduces MPT opening directly as 
outlined in the previous section. In addition, the presence of NO will result in S- 
nitrosylation of key intracellular proteins. For instance, the mitochondrial membrane
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L-type Ca2+ channel can be S-nitrosylated by NO119; with an associated reduction in 
its function. Also complex I of the ETC, which is responsible for ‘electron leakage’ 
and an abundance o f ROS formation during reperfusion, can be inhibited by S- 
nitrosylation120.
eNOS
SNO
1 1 
L-type Ca2* Complex 1 
channel \
i Ca2*
NO donor 
agent
sGC
\
cGMP
PKG/C
Figure 1-18: The pathways by which NO may act to reduce IR injury. Adapted from  
M urphy e t a!103.
In summary NO is capable of reducing the damage caused by IR injury via a 
number of different cellular pathways. It is, however, essential for there to be 
sufficient NO present within the mitochondria at the time of reperfusion to produce 
these benefits; an observation supported by the existence of mitochondrial NOS121. 
eNOS derived NO may not alone be sufficient to achieve high enough levels of NO 
during early phase IPC; an observation supported by the presence of a threshold effect 
to the stimuli which provide IPC122. However exogenous NO donation is capable of 
providing sufficient substrate to exhibit an IPC-type effect. In addition significant 
amounts of NO may potentially be made from NO2’ during ischaemia, as a low pH 
environment favours enzymes which convert NO2’ to NO as well as direct acid 
disproportionation of NO2’.
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1.6.5. The evidence for NO2 ' as an ischaemic conditioning agent 
NO2" reduction to NO is favoured in an ischaemic environment. Zwier 
demonstrated that this phenomenon was attributable to non-enzymatic acidic 
disproportionation o f NO2’ 123. However tissue-based haem enzymes, such as 
myoglobin124 and XO108, have also been implicated as a potential mechanism.
Webb demonstrated in 2004, using a Langendorff model, that NCV 
administered pre-ischaemia was capable o f reducing myocardial infarction (MI) size. 
This effect was abolished by the co-administration o f CPTIO (a NO scavenger) and 
was also associated with increased XO activity125. High (mM) concentrations o f NO2 ' 
were used in this model, but a protective effect o f  NO2 ' upon liver IR injury has been 
reported with an increase in plasma [NCV] o f just +2 0 0 nM126.
It has also been proposed in animal models that NO2’ could act as a post­
conditioning agent. Gonzalez used a canine model o f a two hour simulated MI to 
demonstrate that NO2’ administered during the last sixty minutes or five minutes of  
ischaemia reduced subsequent infarct size110.
In summary it has been established in both in-vitro and animal in-vivo models 
that NO2 ' is capable o f acting as an IPC and an IPostC agent. It is currently unknown 
whether NO2" will be able to confer a similar degree o f benefit in humans. This form 
o f study urgently needs to be performed in order to ascertain whether a large multi­
centre study o f the effect o f NO2’ upon acute MI would be feasible.
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1.7. The key Ideas contained within this chapter
1. NO has a myriad of effects across the various systems of the body. Two 
important actions are vasodilation and ischaemic conditioning.
2. Metabolism of NO in blood is predominantly to NO3', an inert product. 
However a number of other NO metabolites are present in blood, each 
possessing different degrees of vascular activity.
3. N 02‘ is the second most abundant NO metabolite in blood. As a small 
anion NOz* rapidly equilibrates across all fluid spaces (apart from the 
erythrocyte).
4. N 02' is a weak vasodilator in normoxia. However, its vasoactivity is 
enhanced in a hypoxic environment. In addition N 02‘ can act as an 
ischaemic conditioning agent.
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1.8. Aims of this thesis
Overall this thesis has been designed to investigate the effects o f NO2’ 
supplementation in man, delivered via systemic NaN0 2  infusion. There are two key 
features which pervade each set o f experiments performed that make this body o f  
work novel. Firstly, the dose o f NaN0 2  should be as low as possible to observe a 
physiological effect; and secondly environmental modifications known to enhance the 
effects o f NO2’ (i.e. hypoxia and ischaemia) will be used in tandem with NaNC^ 
administration. There are three specific aims to this thesis.
1. To examine in hypoxia and normoxia the vasodilator effects o f a low-dose 
NaNC>2 infusion upon the systemic and pulmonary vasculature in healthy 
human subjects.
2 . To examine whether a low-dose NaNC>2 infusion, given to patients with 
established coronary artery disease, reduces objective markers o f inducible 
myocardial ischaemia during a dobutamine stress echocardiogram.
3. To examine whether NaNC>2 is an ischaemic conditioning agent in healthy 
human subjects in a forearm model o f IR injury.
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Chapter 2: General Methodology
2.1. Controlled environment chamber
A controlled environmental chamber (Design Environmental Ltd, Ebbw Vale, 
UK) was used at the University of Glamorgan, Pontypridd, UK. This was a room able to 
accommodate comfortably both the subject and the investigator, measuring approximately 
6 m x 5m x 4m. The temperature, humidity and Fi0 2  inside the chamber could be adjusted 
and maintained for several hours. A nitrogen (N2) rich hypoxic gas mixture was delivered 
to the room at a high flow rate to create a normobaric/hypoxic environment. Due to this 
continuous gas exchange CO2 levels did not alter from those found in normoxia. Figure 
2 - 1 , below, is an illustration of the chamber.
Figure 2-1: Outside (left) and inside (right) the controlled environment chamber.
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2.2. Subject recruitment
All studies performed were approved by the South East Wales Regional Ethical 
Committee -  Panel D and each subject gave informed consent prior to participation.
2.2.1. Healthy volunteers
For chapters 3 & 5 healthy volunteers were recruited from the local staff and 
student population o f the Universities o f Cardiff & Glamorgan. Exclusion criteria were: 
hypertension, hypercholesterolaemia, DM, a family history o f premature coronary artery 
disease, being a current smoker and taking regular prescription medication.
Additional criteria were used for studies in chapter 3. Firstly, an echocardiogram 
was performed prior to inclusion to ensure a structurally normal heart. Secondly, only 
men were recruited as women have cyclical variability in basal NO metabolite levels127 
and pulmonary arterial vasoreactivity128 which could have interfered with study 
interpretation.
2.2.2. Coronary artery disease patients
Patients with proven angina, documented by a positive exercise tolerance test and 
the presence o f significant coronary artery disease (CAD) at coronary angiography, were 
invited to participate in the study in chapter 4. Exclusion criteria were the presence o f  
unstable symptoms requiring urgent treatment or angina upon minimal exertion. The latter 
was defined as a positive exercise tolerance test at early stage two or sooner o f a standard 
Bruce protocol. Subjects were required to stop all anti-anginal medication for 48 hours 
prior to each study.
2.3. Forearm blood flow (FBF)
Non-invasive measurement o f changes in forearm blood flow (FBF) was performed 
using forearm plethysmography. Initially, two different techniques were considered to
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ascertain the best measure for this thesis. Common to both methods was a 
plethysmographic means by which arterial inflow to the forearm vascular bed was 
isolated and measured; expanded on in the next paragraph.
The non-dominant arm was held in a fixed position with the subject sitting and the 
arm at the level of the right atrium. A wrist cuff was attached to the same arm and inflated 
to a pressure 50 mmHg above arterial systolic pressure to exclude hand circulation. A cuff 
was then placed around the upper arm and a rapid cuff inflator (EC-20, Hokanson) used to 
inflate it to 50mmHg for seven seconds to exclude venous outflow from the arm. Two 
methods were used to measure the increase in forearm volume resulting from temporary 
inflation of the proximal cuff; these are illustrated in Figure 2-2 (below).
Arm cuff 
(50mmHg)
Strain Gauge Plethysmography
Wrist cuff 
(~ 200mmHg)
IRS plethysmography
Figure 2-2: Setup o f the tw o d ifferent techniques used to measure forearm  (arterial) 
blood flo w . SGP records a relative increase in the diam eter o f the forearm  (y-axis) over 
tim e (x-axis). NIRS-plethysmography demonstrates an increase in the deoxy-Hb (blue 
line) oxy-Hb (red line) and total-Hb (green line) signals (y-axis) over time (x-axis).
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2.3.1. Near Infrared spectroscopy (NIRS) plethysmography
Light in the near infrared range (wavelength: 700 -  l , 0 0 0 nm) penetrates through 
skin and soft tissue but is absorbed by Hb. Specifically, light emitted at either 780nm or 
830nm will be absorbed by oxy-Hb or deoxy-Hb respectively129. Near Infra-Red 
Spectroscopy (NIRS) plethysmography utilises this phenomenon to provide a measure of 
the change in the concentration o f Hb over time130.
A continuous-wave near-infrared spectrophotometer (OXYMON, University o f  
Nijmegen, Nijmegen, The Netherlands), consisting o f an emitted and a receiving probe, 
was placed on the subject’s skin. The first probe irradiated the local tissue bed with laser 
beams at the above discrete wavelengths. An adjacent probe detected the residual light 
signal present following its passage through the intervening tissue. Both probes were 
separated by just a few cm and fixed to the forearm by tape. An attached personal 
computer converted the absorption difference between the two probes into a relative 
concentration o f oxy-Hb and deoxy-Hb, which was combined to give the relative 
concentration o f total-Hb. The increase in total-Hb concentration that occurred during 
inflation o f the proximal forearm cuff was then used to calculate the percentage change in 
total-Hb concentration per minute (i.e. % change [total-Hb]/min).
2.3.2. Strain gauge plethysmography (SGP)
A mercury-filled silastic strain gauge (EC-6 , Hokanson; Bellevue Washington, 
USA) was attached to the widest part o f the forearm and connected to the 
plethysmography reading device. The change in forearm diameter measured by the strain 
gauge was transmitted via a Powerlab/4SP system (ADInstruments) and recorded on a 
personal computer using the software package Chart (ADInstruments). The percentage 
change in FBF was expressed as mL per lOOmL o f forearm tissue per minute (i.e. 
m l/1 0 0 ml/min)13'.
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2.3.3. Comparison between the above two measures of FBF
A temperature controlled clinical research laboratory at the Wales Heart Research 
Institute, Cardiff University, was used for a study o f four healthy subjects. Each 
underwent repeated single-measure assessment o f FBF performed using both NIRS- 
plethysmography and SGP. Figure 2-3 (page 56) contains two graphs illustrating the 
correlation between the readings taken using each technique.
Agreement was better with SGP (Pearson r 0.81; p=0.02) compared to NIRS 
plethysmography (Pearson r 0.29; p=0.49). Therefore it was decided that SGP would be 
the preferred method for the assessment o f FBF used in this thesis. Furthermore, when 
SGP was used in this thesis, FBF was taken as the average o f five consecutive readings 
with analysis being performed by an interpreter who was blinded to the study performed.
NIRS plethysmography SGP
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Figure 2-3: Correlation between two consecutive readings of FBF taken using either NIRS 
plethysmography (left) or SGP (right). The red line in each graph is the mean linear 
regression line of the values plotted.
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2.4. Pulmonary arterial pressure
A commercially available echocardiography system (GE-Vingmed System 5; 
General Electric, Fairfield, Connecticut, USA) with a 2.5 MHz phased array transducer 
was used to obtain cross-sectional images, blood pool Doppler profiles, and tissue 
Doppler images, with the subject in a left lateral decubitus position. Loops, recorded 
during passive held expiration, were stored digitally for post-processing using an Echopac 
workstation. Three different validated surrogate markers o f pulmonary arterial pressure 
were used.
2.4.1. Pulmonary acceleration time
Pulmonary arterial flow was sampled using pulsed-wave Doppler (PWD) between 
the cusps o f the pulmonary valve. The pulmonary acceleration time (PAT) was measured 
as the time (in ms) between the onset and the peak velocity o f pulmonary arterial 
forwards flow132. As all readings were taken with a HR <100 bpm PAT was not 
normalized for the pulmonary ejection time133. Figure 2-4 (page 58) contains an example 
PWD trace used in the measurement o f the PAT.
2.4.2. Iso-volumic relaxation time
In the normal heart, early diastolic pressure in the right ventricle is lower than 
right atrial pressure and the tricuspid valve opens as systole ends. A normal right ventricle 
therefore experiences no isovolumic relaxation time (IVRT) period whereas this develops 
when afterload is increased, for example in pulmonary hypertension134. The IVRT was 
measured from pulsed tissue Doppler traces o f lateral tricuspid annular velocity recorded 
in an apical four chamber view. Figure 2-4 (page 58) contains an example PWD trace 
used in the measurement o f the IVRT period.
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2.4.3. Tricuspid regurgitation velocity
The systolic pressure gradient between the right ventricle and the right atrium in 
mmHg was calculated from the peak velocity of tricuspid regurgitation (TR) using the 
modified Bernoulli equation135. The TR jet was captured in the apical four chamber 
window and measured using continuous-wave Doppler (CWD). Right atrial pressure was 
estimated from the change in diameter of the inferior vena cava during respiration and 
added to the right ventricular systolic pressure to give the pulmonary arterial systolic 
pressure (PASP)136. Figure 2-4, below, contains an example CWD trace used in the 
measurement of this parameter.
Pulmonary 
acceleration time
Isovolumic 
relaxation tim e  
period
Tricuspid
regurgitation
velocity
Figure 2-4: Annotated examples o f the three echo indices o f pulm onary arteria l pressure 
measured.
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2.5. Cardiac output
Cardiac output was calculated using echocardiography and haemodynamic 
variables. PWD at the left ventricular outflow tract (LVOT) was used to measure the 
velocity time integral of the LVOT (VTI (lvot)); also known as the left ventricular stroke 
distance, (see Figure 2-5, below). The mean of three traces was used. This value, together 
with the LVOT diameter (in cm) obtained from a parasternal long-axis window and the 
heart rate (HR), was used to calculate cardiac output (see Equation 2-1, below)137. The 
assumption was made that the LVOT is of circular cross section.
((Vi x LVOT diameter)2 x n ) x VTI(Lvot) x  heart rate) / 1000 = cardiac output (L/min) 
Equation 2-1: The calculation o f cardiac output.
Figure 2-5: Example PWD trace use in the measurement o f the VTI(lvot)- The righ t hand 
side cardiac cycle has been annotated to illustra te  the envelope o f forw ards blood f lo w  
through the LVOT used in the calculation o f the VTI(LVot)-
C h a p t e r  2 G e n e r a l  M e t h o d o l o g y
2.6. Basic haemodynamic & blood measurements
Peripheral blood pressure was measured with the subject reclined using a cuff 
placed around the non-dominant upper arm which was attached to an Omron 705CP 
automated blood pressure monitor (Omron Corporation, Kyoto, Japan). Capillary oxygen 
saturation (Sa0 2 ) was measured using a Nellcor N-200 pulse oximeter (Covidien-Nellcor, 
Boulder, Colorado, USA). Venous blood pH & [O2 ] were measured using a RapidLab 248 
blood gas analyzer (Siemens Healthcare Diagnostics, Deerfield, Illinois, USA).
2.7. Statistical analyses
Statistical analysis o f data was performed using the software package GraphPad 
Prism 4.0 (La Jolla, California, USA). The individual tests performed are identified 
within the text o f each results chapter.
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2.8. Blood NO metabolite measurement
Figure 2-6, below, is a summary diagram of the methods employed in the 
measurement of blood NO metabolites. All chemical were purchased from Sigma (Poole, 
UK) unless stated otherwise in the text.
W hole blood
J L
plasma
+ RSNO Total
+ acidified
RSNO sulphanilamide
(1:10) \
3000G /  5min
erythrocyte
u
Total
M ixS
Mix H
HbNO + HbSNO + N 0 2 
HbNO +  HbSNO 
HbNO
plasma
[RSNO] [NOz l
erythrocyte 
[HbNO] [NOz ] [HbSNO]
Figure 2-6: Flow diagram o f the processes used in the separation and analysis o f blood to 
calculate the constituent NO metabolites . The concentrations o f individual NO 
metabolites are deduced fro m  the results o f d iffe rent pre-treatm ents perform ed on 
plasma or erythrocyte samples.
2.8.1. Blood preparation
Venous samples were injected into 4ml EDTA collection tubes (Greiner Bio-One, 
Frickenhausen, Germany) and immediately centrifuged (3000G for 5 minutes at 4°C). 
The plasma and erythrocyte fractions were separated (the intervening buffy coat was 
discarded), snap frozen in liquid nitrogen and stored at minus 80°C. All samples were 
analysed within seven days of collection. Immediately prior to analysis aliquots were 
rapidly thawed by placement in a warm water bath (set at 37°C) for three minutes.
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2.8.2. Ozone-based chemiluminescence
Ozone-based chemiluminescence (OBC) was used to detect NO liberated from 
samples by chemical reagent cleavage96; Figure 2-7, below, is a diagram of its 
components. A chemical reagent (explained in detail in the next three sections) was 
placed into a glass purge vessel. This vessel was held in a water bath which was kept at a 
fixed temperature (50°C unless stated otherwise) by a thermostatically controlled hot 
plate. A constant flow of inert gas (N2) was bubbled through the reagent to collect NO gas 
liberated by the assay. The purge vessel was connected to a trap of 25ml sodium 
hydroxide (NaOH), which removed any acid vapours. The trap was then connected to the 
NO analyser (NOA) (NOA280i, Sievers, Boulder, USA). The reaction of NO with ozone 
(O3) is associated with the production of a photon (hv). The NOA enables this reaction to 
occur in a controlled environment and then, via a photo-multiplier tube (PMT), converts 
this luminescent energy into a potential difference. The output produced by the NOA in 
response to a supply of NO gas is therefore measured in mV.
PMT1M NaOH Trap
W ater Jacket
Heated Stirrer
Reagents
Gas Outlet
Purge Vessel
Rubber Septum  Injection Port
Gas Inlet
NO+ 0-
Signal (mV)
N0,+ 0 ,  + hv
Inert Carrier Gas
At Controlled 
Flow Rate-100- 
200 crrF/min
E.g. N;
Figure 2-7: Diagram of OBC setup for the measurement of blood NO metabolites.
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2.8.3. Sample pre-treatment
Table 2-1, below, contains a summary o f the different pre-treatments performed 
on a sample prior to its injection into the OBC system.
Sam ple R eagent P re-trea tm en t
NO m etabolite(s) 
m easured
Plasma
Acidified
tri-iodide
solution
Nil
NOx
(N 02‘ & protein bound 
NO)
270|il plasm a sam ple + 30pl 5% 
acidified sulphanilam ide solution
Protein bound NO
Acidified
VCI3
Nil N 03' & NOx
Erythrocyte
Modified
acidified
tri-iodide
solution
nil
HbNO, HbSNO &
erythrocyte-associated
N 02‘
200pl erythrocyte sam ple + 800pl 
dilute acidified sulphanilam ide 
solution (= M ix  S)
HbNO & HbSNO
270pl Mix S + 30pl H g C I2 (= M ix  H) HbNO
Table 2-1: Sum m ary o f  the pre -trea tm ents perfo rm ed  on and m etabo lites measured in 
both  p lasm a and erythrocyte  samples.
2.8.3.I. Plasma NOx
An acidified tri-iodide solution was mixed on the day o f analysis. This reagent has 
previously been validated as an efficient reductive agent that provides a good signal for 
the measurement o f  blood NO metabolites138. To prepare the solution 70ml o f glacial 
acetic acid was mixed with 650mg iodine (I2) crystals. To this lg  o f potassium iodide 
(KI), dissolved in 20ml HPLC (high performance liquid chromatography) grade water, 
was added139. 5ml o f tri-iodide reagent, together with 30pl antifoam 204, was placed into 
the purge vessel. A fresh purge vessel o f tri-iodide reagent was prepared for the analysis
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o f each sample. 2 0 0 pl o f freshly thawed plasma was injected into the side port of the 
purge vessel, to generate a plasma total signal (comprising NO2’ and protein bound NO 
groups). This group is also known as plasma NOx.
270pl o f the same plasma sample was then added to 30pl of 5% acidified 
sulphanilamide solution (500mg sulphanilamide dissolved in 10ml 1M hydrochloric 
(HC1) acid) and incubated in the dark for fifteen minutes. Acidified sulphanilamide reacts 
with NO2' to create a highly stable compound from which NO cannot be cleaved by tri­
iodide reagent. 2 0 0 pl o f this solution was then injected into the purge vessel to provide a 
protein bound NO signal. The concentration calculated from this signal was then 
subtracted from the plasma [NOx] concentration to give the plasma [NO2’] concentration.
2.8.3.2. Erythrocyte associated NO
The original tri-iodide solution was modified by the addition o f potassium
1 1
hexacyanoferrate (K^Fe (CN)6) immediately prior to sample analysis, (1:10 to tri­
iodide). This agent prevents auto-capture o f liberated NO by Hb whilst in the assay140. 
8 ml modified tri-iodide reagent, together with 30pl antifoam 204, was placed into a purge 
vessel. 2 0 0 pl o f freshly thawed erythrocyte sample was injected into the purge vessel to 
generate an erythrocyte-total signal (HbNO, HbSNO and erythrocyte-associated NO2 ).
2 0 0 pl o f the same erythrocyte sample was then added to 800pl of dilute acidified 
sulphanilamide solution (1:10 dilution with HPLC grade water) to remove erythrocyte- 
associated NO2’. This solution was known as ‘mix S’. 270pl o f mix S was then added to 
30pl o f mercuric chloride (H gC y to give ‘mix H’. Both mix S & mix H were incubated 
in the dark for fifteen minutes. Incubation o f the erythrocyte sample with HgC^ removed 
thiol bound NO from Hb; and the resulting free NO is then stabilised by the dilute 
acidified sulphanilamide present. 200pl o f mix S was injected into a fresh purge vessel o f 
modified tri-iodide reagent, to provide a Hb-bound NO signal (HbNO & HbSNO). 200pi
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o f mix H was then injected to give a HbNO signal. The calculated [HbNO] concentration 
was subtracted from the [Hb-bound NO] concentration to give the [HbSNO] 
concentration. To calculate the erythrocyte-associated [NO2’] concentration the [Hb- 
bound NO] concentration was subtracted from the erythrocyte-total concentration.
2.8„3.3. Plasma NO3 '
Acidified vanadium III chloride (VCI3) was used as the chemical reagent in the 
measurement o f plasma N 0 3 * by OBC141. VCI3 is a powerful reducing species, more 
potent than tri-iodide, and when used at higher temperatures (85°C) is able to liberate NO 
from all plasma sources, including NO3'. A 50mM reagent solution was prepared by the 
addition o f 0.785g VCI3 (dissolved in 20ml HPLC grade water) to 80ml 1M HC1 acid. 
30ml o f acidified VCI3 was added to a larger-sized purge vessel. A Liebig condenser was 
connected between the purge vessel and the NaOH trap but otherwise the setup was 
unaltered from that previously stated. 2 0 pl o f freshly thawed plasma was injected into the 
purge vessel to generate a plasma NO3 ' & NOx signal. From this concentration the plasma 
[NOx] concentration was subtracted to give the plasma [NO3 '] concentration.
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2.9. Interpretation of data produced by the NOA
The software package Origin 7.0 (OriginLab Corps, Massachusetts, USA) was 
used to analyse the signal output o f the NOA. This signal (in mV) was plotted vs time (in 
seconds) to give a raw trace and then a fifty-point adjacent averaging algorithm was used 
to smooth this trace. The peak analysis package for Origin was then used to calculate the 
area under curve (AUC) o f each peak (mV.s) which was converted to a concentration o f  
NO using a standard curve, expanded on in the next section. Figure 2-8, below, illustrates 
this analytical process.
2 5 -
<O
Z
0 1000500
25 -
< 1 6 -
1 0 -
200 i00 12000
Tim* (*) Time (s)
Figure 2-8: Analysis of NOA output using Origin 7.0. The left graph contains the raw 
output and the right graph the smoothed data. The first peak in each represents a 
plasma-total injection (i.e. plasma NOx) and the second, smaller, peak a plasma + 
sulphanilamide injection (i.e. plasma protein bound NO).
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2.10. Calibration of OBC
A 200pl standard curve, using freshly prepared standards o f either NaNCh or 
NaN0 3 , was performed each day for each separate chemical reagent used. The AUC 
measured from increasing concentration o f known standards was plotted and linear 
regression analysis o f this data provided a multiplication factor by which an NOA reading 
(in mV.s) could be converted into a concentration (in nmol/1). Figure 2-9, below, is an 
example standard plot.
Our laboratory has previously reported a co-efficient o f variability o f 7% & 10% 
respectively for intra-assay and inter-assay repeated analysis o f blood NO metabolite
14 2measurement
I/)
2000-
y = 2.67x 
R2 = 0.998
CL
1000-
200 400
NaNOz concentration (nmoi/i)
600 800 1000
Figure 2-9: Example of a standard curve plot of the NOA output measured against
increasing concentrations of NaN02 analysed using tri-iodide reagent based OBC In this 
case the NOA output o f subsequent samples would need to be divided by 2.67 to be 
interpreted as a concentration of N02~.
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2.11. Assessment of endothelial function: Flow mediated dilatation
Endothelial function was assessed by flow mediated dilatation (FMD) o f the 
brachial artery in the non-dominant arm143. Subjects were reclined horizontally on a bed 
in a temperature-controlled dedicated clinical research room at the Wales Heart Research 
Institute, Cardiff University. A B-mode scan in the longitudinal axis o f the brachial artery 
at a point 5-10cm above the antecubital fossa was obtained using a high-resolution 
vascular ultrasound machine; Aloka ProSound SSD-5500 (Aloka, Tokyo, Japan). 
Electrocardiogram (ECG)-gated end-diastolic images were acquired in this window every 
three seconds for offline analysis. A l-2cm segment o f artery was highlighted for 
processing using the automated edge detection software package Brachial Analyser fo r  
Research 5 (Medical Imaging Applications LLC, Coralville, Iowa, USA). This gave a 
profile o f the diameter o f the brachial artery for each image taken during the protocol. In 
addition PWD blood flow velocity at the centre o f the brachial artery was recorded 
continuously and analysed using the same software.
Arterial flow was manipulated by means o f a blood pressure cuff placed around 
the forearm immediately below the antecubital fossa. After one minute o f baseline 
recording the cuff was inflated to 200mmHg using a rapid cuff inflator. The cuff 
remained inflated for five minutes and was then released, resulting in a period o f reactive 
hyperaemia during which time the brachial arterial diameter increased. This change in 
diameter was recorded for five minutes. Each FMD protocol therefore lasted eleven 
minutes and was recorded by a total o f 220 images. Figure 2-10 (page 69) is a summary 
illustration o f this method.
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Figure 2-10: FMD analysis. Clockwise from top left. 1. Picture of the setup for brachial 
arterial FMD analysis. 2. Ultrasound imaging of the brachial artery (top = longitudinal 
image of the artery with the region for analysis highlighted, bottom = PWD flow  velocity 
trace from the centre of the artery). 3. Brachial arterial diameter profile during the FMD 
protocol. Note the steady baseline in the first minute (images 0-20), followed by an 
increase in arterial diameter after cuff deflation a t six minutes (image 120).
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2.11.1. Analysis of FMD images
The baseline diameter o f the brachial artery was the mean o f the first twenty 
images recorded. Peak arterial diameter was the mean o f the three largest diameters 
obtained following cuff deflation. FMD was expressed as the percentage increase in 
arterial diameter at peak compared to baseline.
The brachial arterial PWD flow velocity o f a single cardiac cycle was measured 
on each image. A baseline value was the mean o f three cardiac cycles recorded in the first 
minute o f  the protocol. Peak flow velocity was the greatest reading recorded during the 
first ten images after cuff deflation. The flow stimulus responsible for each FMD response 
was calculated as the percentage increase that the peak flow velocity was compared to the 
baseline velocity.
2.12. Forearm IR injury protocol
Transient endothelial dysfunction was produced in the non-dominant forearm by 
means o f  a period o f IR injury144. A blood pressure cuff was placed around the upper arm 
and inflated to 200mmHg using a rapid cuff inflator. The cuff remained inflated for 
twenty minutes. At this time the cuff was deflated and a twenty minute reperfusion period 
followed. Quantification o f the degree o f endothelial dysfunction produced by this 
stimulus was calculated by repeated ipsilateral FMD analyses, performed both before and 
after IR injury. The difference between these FMD measurements represented the degree 
o f endothelial injury resulting from exposure to the IR stimulus. Figure 2-11 (page 71) is 
a schematic diagram o f this protocol.
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Figure 2-11: Forearm IR injury protocol. The transient endothelial dysfunction that results 
from twenty minutes of arm ischaemia followed by twenty minutes of reperfusion is 
quantified by FMD measurements taken a t the start and end of the protocol.
2.13. Dobutamine stress echocardiography
A standard dobutamine stress echocardiogram (DSE) protocol combined with 
myocardial velocity imaging was used to assess functional reserve in subjects with proven 
ischaemia and CAD145. Dobutamine was infused into a peripheral arm vein. An escalating 
dose regime of 0, 5, 10, 20, 30 & 40pg/kg/min was delivered in three minute stages.
Images were obtained by the same method as stated in section 2.4 (page 57); with 
the exception of the use of a GE System 7 machine. Each subject was rested for thirty 
minutes prior to the recording of baseline images. At this (and each subsequent) stage the 
apical 4 chamber, apical 2 chamber and apical long axis windows were recorded together 
with a PWD trace taken with the cursor placed within the left ventricle at the junction of 
the mitral inflow and aortic outflow regions (in order that aortic valve closure and mitral 
valve opening could be timed). Figure 2-12 (page 72) contains examples of the four echo 
images taken at each stage of the protocol. Three cardiac cycles were recorded for each 
window. The depth and width of each image was optimised to ensure that the frame rate 
recorded was >120 frames per second.
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Dobutamine stress 
echocardiogram 
windows
Figure 2-12: Example images taken a t each stage of the DSE protocol. Clockwise from top 
left: 1. Apical 4 chamber window. 2. Apical 2 chamber window. 3. PWD trace taken a t the 
junction between mitral inflow and aortic outflow. 4: Apical long axis window.
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2.13.1. Myocardial velocity imaging parameters
A six segment basal wall model was used to assess the longitudinal peak systolic 
velocity (PSV) of myocardium in all regions of the left ventricle145. This comprised of the 
basal septal (BS) and basal lateral (BL) walls in the apical 4 chamber window, the basal 
anterior (BA) and basal inferior (BI) walls in the apical 2 chamber window and the basal 
antero-septal (BAS) and basal posterior (BPost) walls in the apical long axis window. The 
myocardial velocity profile of each basal wall was assessed at a site that was above the 
mitral annulus throughout the whole cardiac cycle, (see Figure 2-13; below). The PSV 
was measured as the maximum systolic velocity outside of the left ventricular isovolumic 
contraction time period. The PSV is always positive when measured in apical windows.
v(cm/s) -8.43
24/03/2009 10A3N 
T1:53:54
Freq.: 1.7MHJE/3.4 
FPS: 154 1/1*4 1 
Depth 11.0.</m 
Gain: 3 adEr 
Scale I^OTkFte
Figure 2-13: Example profile of the velocity of the left ventricular basal lateral wall. The 
far right cardiac cycle has been annotated to illustrate PSV measurement
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2.14. Isolated vessel preparation
New Zealand White rabbits (male, 2-2.5 kg, 6 - 8  weeks old) were terminally 
anaesthetised with intravenous pentobarbitone (150mg/kg). The abdominal aorta and the 
main pulmonary artery (just proximal to its bifurcation) were dissected and prepared into 
2mm wide rings. These were mounted using hooks facing opposing directions and 
attached to a force transducer. Mounted rings were placed into 8 ml individual organ 
chamber bioactivity assays maintained at 37°C by surrounding warm water, (Figure 2-14, 
page 75). Each ring was bathed in 5mls o f Krebs solution and perfused with 95% O2 . 
After thirty minutes equilibration time a basal tension o f 2g was set. Three successive 
constriction / relaxation cycles were performed using lfiM phenylephrine (PE) and 10pM 
ACh. The bath was emptied and washed out four times over a thirty minute period 
between each cycle.
After the rings had been prepared as outlined above they were again constricted 
using lpM  PE. NaNC>2 was added to the bath once peak tension had been achieved. 
Matched control rings did not receiving any additional agents. The resulting relaxed 
tensions at twenty minutes were measured. Each bath was then washed four times as 
described earlier.
In order to create hypoxic conditions the perfusing gas was changed from 95% 
oxygen to a mixture o f 9 5 %N2/5 % CO2 . Given that each organ chamber was exposed at 
its surface to room air this resulted in an effective local tissue environment o f 1 % O2 . 
After a 10 minute equilibration period constriction was again performed but this time 
using 3pM PE. The increased dose was necessary in order to achieve the same
OQ
quantitative level o f constriction as that gained during normoxia . lOpM NaNC>2 was 
added to each bath and the tension at twenty minutes recorded. This dose o f NaNC>2 was
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chosen as it has previously been shown in this model to be the lowest dose that results in 
an appreciable dilator effect89.
The relaxation response o f each vessel to NaNC>2 was expressed as a percentage of 
the maximal tension achieved, averaged between each pair o f rings and corrected for the 
corresponding control ring pair.
FORCE TRANSDUCER
PERFUSION GAS
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BLOODVESSEL RING
KREBS BUFFER @37‘C
Figure 2-14: Diagram of the setup of the organ chamber bioassay study.
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Chapter 3: Nitrite and Hypoxia
3.1. Introduction
3.1.1. The physiological effect of hypoxia upon the cardiovascular 
system
In man, exposure to acute hypoxia results in systemic vasodilation and 
pulmonary vasoconstriction146. These physiological changes work in tandem to ensure 
that O2 delivery to tissue remains as efficient as possible. An increase in cardiac 
output and systemic vasodilatation augment the cycling o f oxygenated blood around 
the body. In addition, regions o f the pulmonary vasculature will constrict to shunt 
blood away from hypoventilated lung segments. This is an appropriate response if  
there is regional hypoxia, for example in the case o f a lobar pneumonia. However, 
when hypoxia is global (e.g. when FiC>2 is decreased) then the entire pulmonary 
vascular tree will constrict and the workload o f the right ventricle will increase.
The above physiological changes occur over a period o f hours. Dorrington 
reported, in six healthy individuals, the pulmonary and systemic cardiovascular 
responses during eight hours exposure to isocapnic hypoxia (FiC>2 1 2 %)91. After two 
hours o f hypoxia more than 70% o f the total eight hour reduction in systemic vascular 
resistance had occurred (see Figure 3-1, Panel B; page 77). Furthermore, the rate o f  
change in systemic vascular resistance decreased markedly after this time-point; a 
plateau having already been reached. In addition, cardiac output increased as a 
function o f HR alone with stroke volume remaining unchanged. This increase in 
cardiac output compensated for the decrease in systemic vascular resistance, resulting 
in systemic blood pressure remaining constant (see Figure 3-1, Panel A; page 77).
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Changes in the pulmonary circulation followed a similar profile, with approximately 
80% o f the total eight hour augmentation o f pulmonary vascular resistance having 
occurred after two hours o f exposure to hypoxia (see Figure 3-1, Panel C; below).
H Y P O X IA
H Y P O X IA HYPOXIA
T i m r ( h )
Figure 3-1: The cardiovascular effects of eight hours exposure to hypoxia (Fi02 12%). 
Panel A; systemic blood pressure, cardiac output, HR and left ventricular stroke 
volume. Panel B; systemic vascular resistance. Panel C; pulmonary vascular resistance 
Adapted from Dorrington e t a!91.
Page | 77
C h a p t e r  3 N i t r i t e  a n d  H y p o x i a
3.1.2. Aims of this chapter
The present study was designed to test the physiological effects that a modest 
elevation in plasma [NO2 *] would have upon the systemic and pulmonary vasculature 
when tested in either hypoxia or normoxia. Healthy volunteers were investigated 
during stable hypoxia in an environmental chamber and during normoxic conditions 
breathing room air. An iv infusion o f a low-dose o f NaNC>2 or 0.9% saline was given.
Due to the intensive nature o f data collection required during this study it was 
performed in partnership with another British Heart Foundation PhD Fellow, Andrew 
Pinder. I acquired and analysed all o f the physiological measurements and the plasma 
NOx samples. Andrew analysed the erythrocyte component of each blood sample. In 
addition, Janis Weeks (Medical Microbiology, Cardiff University) performed the 
analysis o f plasma NO3 ' levels.
3.1.3. Original hypotheses
1. NaN02 will vasodilate the systemic vasculature preferentially in hypoxia 
compared to normoxia and this effect will be associated with a change 
in blood NO metabolite levels.
2. NaN02 will vasodilate the pulmonary vasculature preferentially in 
hypoxia compared to normoxia.
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3.2. Study design (specific protocols)
The criteria used to recruit healthy volunteers for the studies performed in this 
chapter are outlined in section 2.2.1 (page 53). Subjects were asked to refrain from 
alcohol, caffeine and foods with a high NCV/NCb" content for twelve hours before 
each study. Each had a light breakfast before and then fasted for the duration o f the 
study. Three studies were conducted, one as the index intervention (hypoxia/NO2 )  
and two as control studies (hypoxia/saline, normoxia/NO2 ).
3.2.1. Protocol 1: Hypoxia/NCh*
In twelve subjects, “baseline” (i.e. protocol time = 0 min) investigations were 
completed during normoxia, and then the FiC>2 in the environmental chamber was 
reduced from 21% to 12% over a one hour period. It was maintained at 12% for two 
more hours, so that subjects experienced a total o f three hours o f hypoxia (known as 
the hypoxia-equilibration period) before the “pre-infusion” (i.e. protocol time = 
180min) measurements were obtained. An iv infusion o f NaNC>2 was then given, into 
the dominant arm, at lml/min (lpmol/min) for thirty minutes before '‘peak” (i.e. 
protocol time = 210 min) measurements were taken. The study infusion was given 
single-blind so that the study physician was aware o f when NaNC>2 was being infused 
for safety reasons. Subjects remained in the hypoxic chamber for a further one hour 
after the infusion was completed, before a final “one hour” (i.e. protocol time = 270 
min) set o f measurements were made.
In addition to the four key stages outlined above, where all physiological and 
biochemical measurements were performed, further blood and FBF measures were 
taken at additional times during the protocol as outlined in Figure 3-2 (page 80); a 
schematic diagram o f both protocols 1 & 2 .
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Figure 3-2: Diagram of the experimental design of protocol 1 (hypoxia/NOf) & 
protocol 2 (hypoxia/saline).
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3.2.2. Protocol 2: Hypoxia/saline
Six different subjects underwent a control study in the hypoxic chamber. This 
group followed an identical protocol to that outlined previously in section 3.2.1 (page 
79), but a single-blinded infusion o f 0.9% saline (lml/min for thirty minutes) was 
given instead o f NaNC>2 .
3.2.3. Protocol 3: Normoxia/N02
Six o f the twelve subjects whom had participated in protocol 1 (hypoxia/NOf) 
underwent this control study, which was performed in room air (FiC>2 2 1 %). 
Consequently no hypoxia-equilibration period was included, and only a short period 
o f rest was required before the “pre-infusion ” (protocol time -  0 min) measures were 
taken. Thereafter, the study was identical to that o f protocol 1; with “peak” (protocol 
time = SO min) and “one hour” (protocol time = 90 min) measurements being taken. 
The same infusion regime o f NaNC>2 was used as in protocol 1 . Figure 3-3 (below) is a 
diagram o f this protocol.
FiO,
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Protocol
time
Infusion
"pre-
infusion'
W ashout
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t i  t  i t i t  t  i t
t i  t  : t i  t i t
"peak"
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one
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Figure 3-3: Diagram of the experimental design o f protocol 3 (normoxia/NOf)-
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3.3. Results
The interpretation o f the biochemical and physiological variables recorded is 
concentrated upon certain key time points within each protocol. In protocols 1 & 2 
these are: “baseline” ( 0  min), “pre-infusion” (180min), “peak infusion” ( 2 1 0  min) 
and “one hour” (270min). In protocol 3 these are “pre-infusion ” (0 min), “peak” (30 
min) and “one hour” (90 min). For each variable, where appropriate, the effects o f 
hypoxia are dealt with separately to the effects o f the infusion. All continuous data is 
reported as mean ± SEM.
Within group comparisons have been carried out using a repeated-measures 
ANOVA test with Newman-Keuls post-test. Between-groups comparisons, at the 
same protocol time-point, have been performed using an unpaired t-test.
3.3.1. Demographics
Summary demographics o f the participants in this study are outlined below in 
Table 3-1. The left ventricular ejection fraction was calculated by the biplane 
Simpson’s method.
Demographic
Number 18
Age (years) 24.2 ± 1.0
Weight (kg) 78.6 ± 2.2
Body Mass Index 24.3 ± 0.6
Left Ventricular Ejection Fraction (%) 65.0 ± 1.0
Table 3-1: Summary demographics of the subjects who participated in the studies 
reported in Chapter 3.
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3.3.2. The environmental chamber & subject oxygenation
Figure 3-4 (page 84) contains four graphs which detail the chamber’s ambient 
environment and the subject’s capillary Sa0 2  during the two studies where the 
controlled environmental chamber was used (i.e. hypoxia/NOi and hypoxia/saline 
protocols).
The FiC>2 had reached 1 2 % by one hour into each hypoxia study and remained 
constant following this. The temperature during the hypoxia/NOi protocol was 
slightly greater than during the hypoxia/saline protocol at each point (e.g. “peak” 
hypoxia/NOi = 22.3°C ± 0.4 vs. “peak” hypoxia/saline = 2 1 .0 °C ± 0.3; p = <0.05). 
However the temperature remained constant within each protocol for their duration.
Capillary SaC>2 decreased by a similar degree during the hypoxia-equilibration 
period o f both hypoxia protocols (i.e. hypoxia/NOi: “baseline” = 97.7 ± 0 .2 % vs 
“pre-infusion” = 82.0 ± 2.4 %, p<0.01. hypoxia/saline: “baseline” = 97.8 ± 0.4% vs 
“pre-infusion” = 85.7 ± 1.2 %, p<0.01) and did not change thereafter for the 
remainder o f either protocol. There was no difference in the degree o f hypoxia 
achieved between these two groups.
In summary, by 180 minutes into each study both hypoxia protocols had 
achieved a steady state in terms o f room temperature and subject oxygenation.
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3.3.3. Basic haemodynamic variables
Figure 3-5 (below) shows the HR and BP profiles recorded during each o f the 
three protocols performed.
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Figure 3-5: HR (left column) and systolic/diastolic BP (right column) during the three 
protocols: hypoxia/NOf (panel A), hypoxia/saline (panel B) and normoxia/NOf 
(panel C). * p<0.05.
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In both hypoxia protocols HR increased as a result o f the hypoxia- 
equilibration period (combined data, "baseline ” = 63 ± 3 bpm vs “pre-infusion ” = 11 
± 2  bpm, p<0 .0 1 ), and thereafter it did not alter significantly during either protocol. 
This increase in HR resulted in the increase in cardiac output observed during the 
hypoxia-equilibration period (see section 3.3.7 page 97). HR decreased during the 
normoxia/NOi protocol, a difference occurring between “pre-infusion ” = 74.2 ± 4.6 
bpm and “peak” = 62.5 ± 3.8 bpm (p<0.05).
Blood pressure did not alter as a result o f the hypoxia-equilibration period. In 
addition blood pressure did not change throughout the hypoxia/saline or the 
normoxia/NOi protocol. However, systolic BP did increase in the hypoxia/NOi 
protocol { “pre-infusion ” = 122 ± 2mmHg vs “peak” 128 ± 3 mmHg; p<0.05).
In summary the effect o f hypoxia upon HR and BP are as would be expected 
from the literature91. In particular, a steady state had been achieved by the end o f the 
hypoxia-equilibration period on which the effects o f the subsequent infusion could be 
assessed.
3.3.4. Plasma NO metabolites
Figure 3-6 (page 87) contains summary profiles o f the three plasma metabolites 
o f NO recorded during each protocol. No difference was seen across any protocol in 
[RSNO] or [NO3'] levels. Changes were observed in plasma [NO2’] levels which are 
expanded on further in the next section.
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Figure 3-6: Plasma [N O /]  ( le ft column), p lasm a [RSNO] (m iddle colum n) and plasm a [NO 3 ]  (r igh t colum n) p ro files during the: hypo x ia / N 0 2 
p ro toco l (panel A), hypoxia/saline p ro toco l (panel B) and  n o rm o x ia /N O f p ro toco l (panel C). *  p<0.05.
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3.3.4.I. The effect of acute hypoxia upon plasma [NO2  ]
Plasma [NO2’] increased during the first thirty minutes o f the hypoxia- 
equilibration period in all eighteen subjects whom underwent a hypoxia study 
(combined data, “baseline ” = 189.0 ±11.3 nmol/1 vs. “protocol time 30 min ” = 226.2 
± 1 3 .8  nmol, p<0.05). However, in the same subjects no difference in plasma [NO2 '] 
was present (again compared to “baseline”) after the hypoxia-equilibration period 
had been completed (combined data, “pre-infusion ” = 199.4 ± 12.4 nmol/1; p>0.05).
“Pre-infusion” plasma [NO2’] levels were similar between the two hypoxia 
groups and both o f these concentrations were greater than the “pre-infusion ” plasma 
[N 02‘] measured in the normoxia group (hypoxia/NOi = 191.0 ± 12.3 nmol/1, 
hypoxia/saline = 216.0 ± 28.6 nmol/1, normoxia/NOi = 125.5 ± 14.8 nmol/1; p<0.05). 
A difference was also present between the plasma [NO2’] sample taken in room air in 
the hypoxia/NOi study and the normoxia/NOi study in the six subjects who 
underwent both o f  these protocols (i.e. hypoxia/NOi “baseline” = 177.0 ± 12.4 
nmol/1 & normoxia/NOi “pre-infusion ” -  125.5 ± 14.8 nmol/1; p<0.05).
These combined results demonstrate a difference in plasma [NO2 ] when 
samples were taken in hypoxia compared to normoxia. However, the nature o f these 
results means that it is difficult to ascribe this difference to an isolated effect o f 
hypoxia alone. In particular it should be emphasized that plasma NO metabolites have 
a large dietary component61 and therefore significant day to day variability will be 
present in their levels. This point is illustrated in the previous paragraph by the 
difference in starting plasma [NO2 ] values in the same six subjects who were studied 
on different days in different protocols.
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In addition, it should be acknowledged that although plasma [NO2 ] varied from 
day to day in this study it did not alter over the relatively short investigation period of 
the, control, hypoxia/saline study (i.e. 270 minutes). In particular, it did not alter over 
the 90 minute infusion-investigation period o f the study {hypoxia/saline “pre­
infusion ” = 216.0 ± 28.6 nmol/1 vs “one hour ” 244.2 ± 27.1 nmol/1; p = ns).
3.3.4.2. The pharmacokinetics of NaN02
The pharmacokinetic profiles o f plasma [NO2 ] were similar in both the 
hypoxia/NOi and normoxia/NOi protocols (see Figure 3-7; page 90).
There was no difference in the infusion-associated increase in plasma [NO2 ] 
concentration (“peak” minus “pre-infusion” concentration) observed in the 
hypoxia/NOi and normoxia/NOi protocols (+205.5 ± 20.9 nmol/1 vs. +206.3 ± 36.7 
nmol/1; p>0.05). The half lives for decay o f plasma [NO2’] after stopping the infusion 
were also similar (in hypoxia 21.7 ± 3.0 min, and in normoxia 21.3 ± 3.4 min). In both 
groups plasma [NO2 ] had returned to a level similar to the corresponding pre-infusion 
concentration by one hour after cessation o f the NaNC>2 infusion.
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3.3.5. Erythrocyte NO metabolites
Figure 3-8 (page 93) is a series o f graphs detailing the profiles o f the three 
erythrocyte metabolites o f NO recorded during each study. No difference was seen 
across any protocol in erythrocyte-associated [NO2"] and [HbSNO] levels. Changes 
were observed in [HbNO] levels which are expanded on in the next section.
3.3.5.I. The effect of acute hypoxia exposure upon [HhNO]
During the first thirty minutes o f the hypoxia-equilibration period [HbNO] did 
not alter in either hypoxia protocol (combined data: “baseline” = 53.7 ± 7.9 nmol vs 
"protocol time 30 min” = 45.8 ± 6.0 nmol, p>0.05). This finding is dissimilar to 
plasma [M V ], which increased over the same time period. However, in the same 18 
subjects there was an increase in [HbNO] as a result o f the whole hypoxia- 
equilibration period (combined data: "baseline” = 53.7 ± 7.9 nmol vs "pre-infusion” 
= 98.4 ± 14.8 nmol; p<0.05). Accordingly, a difference in "pre-infusion” [HbNO] 
levels between the combined hypoxia groups and the normoxia group was also 
present (normoxia/NOi "pre-infusion” = 28.9 ± 12.4 nmol; p<0.05).
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3.3.5.2. The response of [HbNO] to the NaN02 infusion
[HbNO] increased as a result o f the infusion o f NaN0 2  in hypoxia 
(ihypoxia/NOi: “pre-infusion ” = 106.0 ± 19.1 nmol vs “peak” = 237.6 ± 58.4 nmol; 
p<0.01). However, the increased [HbNO] level had returned to a level similar to “pre- 
infusion ” by fifteen minutes after the infusion had finished ( “protocol time 225 min ” 
= 101.8 ± 12.4 nmol, p>0.05).
During the normoxia/NOi protocol [HbNO] increased as a result o f the infusion 
o f NaN0 2  { “pre-infusion” = 28.9 ± 12.4 nmol, “peak” = 90.9 ± 13.2 nmol; p<0.05). 
The [HbNO] concentration was then slower to reduce than in the hypoxia/NOi 
protocol, reaching a level similar to “pre-infusion ” only one hour after the infusion 
had stopped ( “owe hour” = 64.1 ± 15.3nmol).
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Figure 3-8: [HbNO] (left column), erythrocyte-associated [N02] (middle column) and [HbSNO] (right column) profiles during the: hypoxia/N02 
protocol (panel A), hypoxia/saline protocol (panel B) and norm oxia/N02' protocol (panel C). * p<0.05.
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3.3.6. Forearm blood flow
Figure 3-9 (page 95) contains three graphs detailing the profiles o f FBF recorded 
during each protocol. FBF did not alter as a result o f the hypoxia-equilibration period 
in either o f the two hypoxia protocols (combined data: “baseline” = 2 . 1 0  ± 
0.12ml/100ml/min vs “pre-infusion” = 2.24 ± O.lOml/lOOml/min, p >0.05). Indeed, 
FBF remained unchanged throughout the hypoxia/saline protocol; demonstrating that 
the experimental design provided a steady baseline on which the infusion o f NaNC>2 
could be assessed.
FBF increase during the NaNC>2 infusion in the hypoxia/NOi group { “pre- 
infusion” = 2.15 ± 0.13 ml/lOOml/min vs “peak” = 2.77 ± 0.17 ml/lOOml/min; 
p<0.05). This increase in FBF had reduced by thirty minutes after the infusion had 
finished to a value similar to that measured “pre-infusion” { “protocol time 240” = 
2.61 ± 0.24 ml/lOOml/min; p>0.05). FBF did not change throughout the 
normoxia/NOi protocol.
3.3.6.I. Changes in FBF compared to key NO metabolites
The profile o f change in FBF in the hypoxia/NOi group was o f a similar pattern 
to plasma [NO2*] but not [HbNO], see Figure 3-10 (page 96). Further analysis o f the 
data, detailed in Figure 3-11 (page 96), demonstrated that a significant correlation 
between plasma [NO2"] and FBF was present in the hypoxia/NOi group (Pearson r = 
0.31, p<0.01). No similar correlation was present in the normoxia/NOi group, or 
between FBF and [HbNO] in either group (Pearson r values shown for comparison on 
the relevant graphs within the same figure).
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Figure 3-10: The profile o f plasma [N 02'J, [HbNO] and FBF during the hypoxia/N02 
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protocol.
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3.3.7. Pulmonary arterial pressure (PAP)
The profiles o f the echocardiographic surrogate markers o f pulmonary arterial 
pressure (PAP) throughout the three protocols are reported in Table 3-2, (page 100).
3.3.7.I. The effect of acute hypoxia exposure upon PAP
Figure 3-12, (page 98) contains typical examples o f the echocardiographic 
images recorded to measure the three surrogate markers o f PAP both before and after 
the hypoxia-equilibration period. All three markers significantly altered as a result of 
this three-hour hypoxia exposure.
The estimated PASP almost doubled in response to the hypoxia-equilibration 
period in the two hypoxia protocols (combined data: “baseline” = 20 ± 1 mmHg vs 
“pre-infusion” = 39 ± 2 mmHg, p<0.01). The diameter of the inferior vena cava and 
its respiratory variation did not change significantly throughout all studies, and so the 
estimated right atrial pressure was constant at 5 mmHg. A significant shortening of 
the PAT occurred (combined data: “baseline” = 157 ± 4 ms vs “pre-infusion” =113  
± 3 ms, p<0.01) and the IVRT o f the right ventricle lengthened (combined data: 
“baseline” = 7 ± 6  ms vs “pre-infusion” = 96 ± 8  ms, p<0.01). There were no 
significant differences between the hypoxia/NOi and hypoxia/saline groups in all 
three indices recorded at either “baseline ” or “pre-infusion ”.
Subsequent to the hypoxia-equilibration period both the estimated PASP and the 
PAT did not alter for the remainder o f the hypoxia/saline protocol. However, the 
IVRT did continue to increase at the “peak” and “one hour” time-points o f this 
control protocol (see Table 3-2; page 100).
Page | 97
C h a p t e r  3 N i t r i t e  a n d  H y p o x i a
IVRT
Figure 3-12: Example, annotated, echocardiographic images recorded to measure the 
three surrogate markers of PAP, acquired a t "baseline" (top row) or "pre-infusion" 
(bottom row).
3.3.7.2. The effects of NaNCh upon the hypoxic pulmonary 
vasculature
In the hypoxia/NOi group the infusion of NaNC>2 reduced the estimated PASP 
by 16%. Furthermore, although plasma [NO2’] had returned to normal by one hour 
after the infusion had stopped, estimated PASP remained significantly reduced 
compared to “pre-infusion ”, see Figure 3-13 (page 99).
Similar changes were observed in the two alternative echo indices recorded. The 
PAT was prolonged at peak infusion by 12% compared to pre-infusion, an effect 
which was also present one hour later. The duration of the IVRT was attenuated by
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NaNC>2 both at the end of the infusion (by 17%) and one hour later. All three echo 
surrogates o f pulmonary arterial pressure were unchanged throughout the 
normoxia/NOi protocol.
Between group analysis confirmed an effect of NaNC>2 at peak (p<0 . 0 1  for all 
three indices). The persistent vasodilator effect of NaN0 2  at one hour was shown by 
changes in IVRT (p<0.01); the effect upon PAT tended to significance (p=0.07) while 
the changes in PASP were not analyzed between groups due to a low prevalence of a 
TR jet in the hypoxia/saline group. See marked comparisons and legend in Table 3-2 
(page 1 0 0 ) for details.
Hypoxia/salineHypoxia/NO 2 Normoxia/N02
Figure 3-13: Estimated PASP during the infusion of either NaN02 or saline in each of 
the three protocols performed. * p<0.01. Only statistically significant comparisons 
are shown.
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* s* i C i i t  <3 c i i i C i  y p  d  X I 01
Baseline
Pre­
in fus ion
Peak
p va lue vs 
pre -in fus ion
One h o u r
p  value vs 
pre -in fus ion
N
PASP (mmHg)
h yp o x ia /N O i 20 ± 1 38 ± 2 32 ± 2 - i  * <0.01 33 ± 2 <0.01 1
hypoxia/saline 20 ± 4 38 ± 7 39 ± 6 J  ns 37 ± 6 ns 3
n o rm o x ia /N O i n/a 24 ± 2 24 ± 1 ns 24 ± 1 ns 5
PAT (ms)
h ypo x ia /N O i 153 ± 5 111 ± 3 124 ± 3 - i  * <0.05 121 ± 4 —] j. <0.05 12
hypoxia/saline 164 ± 3 116 ± 6 114 ± 6 —1 ns 113 ± 6 J  ns 6
n o rm o x ia /N O i n/a 166 ± 7 162 ± 8 ns 161 ± 4 ns 6
IVRT (ms)
h ypo x ia /N O i 8 ± 8 105 ± 11 87 ± 9 1  „ <0.01 95 ± 9  --i * <0.05 11
hypoxia/saline 5 ± 5 79 ± 1 0 91 ± 1 3 J  <0.05 103 ± 12 -J  <0.01 6
n o rm o x ia /N O i n/a 0 0 n/a 0 n/a 6
Table 3-2: Echo surrogate m arkers o f  pu lm onary a rte r ia l pressure during each protocol. A dd itiona l s ta tis tica l comparisons between the  
h y p o x ia /N O i and hypoxia/saline groups are m arked in the "peak" and "one h o u r" columns. This analysis compares the delta  between "pre­
in fus ion " and "peak" ("p re -in fus ion" minus "peak") o r "p re -in fus ion" and "one h ou r" ("p re-in fus ion" m inus "one hour").
* p < 0 .0 1 ,f p = 0.07. N = num ber o f  subjects.
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3.3.8. Cardiac output
Table 3-3 (page 102) summarises the profile o f cardiac output (together with its 
constituent components o f stroke distance (i.e. VTI(lvot)) and HR) during each 
protocol. Cardiac output increased by 25% in response to the hypoxia-equilibration 
period in all subjects whom underwent a hypoxia protocol (combined data: 
"baseline" = 4.53 ± 0.23 1/min vs “pre-infusion" 5.61 ± 0.26 1/min, p<0.01). This 
was due to an increase in HR, see Section 3.3.3 (page 85).
In the hypoxia/NOi group cardiac output decreased by an average o f 8 % when 
the study-infusion was infused. This was the result o f a small reduction in both HR 
and stroke distance. Of the two variables stroke distance tended towards significance 
(p = 0.07), consistent with reduced preload secondary to NaN0 2  induced venodilation.
The increase in cardiac output related to hypoxia was unaltered by the infusion 
o f saline. When NaN0 2  was infused during normoxia, no changes were observed in 
HR, VTI(lvot) or cardiac output.
3.3.9. Analysis of variance of physiological measures
Thirty paired readings, chosen at random, o f the five physiological variables 
used in this chapter were used to determine intra-observer reproducibility. The results 
o f these analyses are shown in Figure 3-14 (page 103) and Table 3-4, (page 104). The 
coefficient o f variation was calculated as the ratio o f the standard deviation o f the 
differences (i.e. measurement 1 -  measurement 2 ) divided by the mean, (expressed as 
a percentage).
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Baseline Pre-infusion (p va lue  vs 
baseline)
Peak (p va lue vs 
pre -in fus ion )
1 hour after 
infusion
(p va lue vs 
pre -in fus ion )
Cardiac output 
(1/min)
hypoxia/NO/ 4.45 ± 0.27 5.64 ± 0.30 <0.01 5.14 ± 0 .2 8 <0.05 5.09 ± 0 .3 1 ns (*)
hypoxia/saline 4.70 ± 0.48 5.56 ± 0 .5 1 <0.05 5.47 ± 0 .5 1 ns 5.14 ± 0 .4 2 ns
normoxia/ NO/ n /a 4.43 ± 0 .2 1 n /a 4.15 ± 0 .2 7 ns 4.14 ± 0 .3 0 ns
Heart rate (bpm)
hypoxia/NO/ 66 ± 4 79 ± 3 <0.01 76 ± 3 ns 80 ± 3 ns
hypoxia/saline 56 ± 3 73 ± 2 <0.01 69 ± 5 ns 67 ± 4 ns
normoxia/ NO/ n /a 74 ± 5 n /a 63 ± 4 ns 59 ± 5 ns
VTI(lvot) (cm/s)
hypoxia/NO/ 23.3 ± 0 .5 23.8 ± 1.0 ns 22.5 ± 0 .8 ns (*) 22.8 ± 0 .9 ns
hypoxia/saline 22.4 ± 1 .3 23.4 ± 1 .3 ns 23.2 ± 1 .7 ns 22.3 ± 1.6 ns
normoxia/ NO/ n/a 20.7 ± 1.4 n /a 21.5 ± 2 .0 ns 22.5 ± 1.4 ns
Table 3-3: Cardiac output and its constituent components. * p = 0.07
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Pearson r = 0.87 
p < 0.001
(Measurement 1 + Measurement 2)12
35-1
30-
25-
20-
15-
Pea r son  r = 0 .9944
p < 0.001__________10-1
!*‘XTVyoj)*r“!y*'»,
Pearson r = 0.9909
p < 0.001_________
Ip  <0.001
p < 0.001
Figure 3-14: Correlation (left column) and Bland-Altman plots (right column) o f the 
intra-observer variability in the five physiological variables recorded (panels from  top: 
A = FBF,; B = VTI(lv0T), C = estim ated  PASP, D = PAT and E = IVRT).
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Feasibility (%) Mean reading (unjts) R2
Bland-Altman 
analysis: 
Bias (95% Cl)
Coefficient of 
Variation [%)
Pulmonarv arterial oressure 
TR 62 29.8 (mmHg) 0.98 0.8 (-2.1 to  3.8) 5.8
PAT 100 1 5 6 .3  (ms) 0.96 -2.5 (-13.2 to  8.2) 3.9
IVRT 9 6 9 3 .3  (ms) 0.77 1.4 (-20.6 to  23.3) 14.8
Cardiac outDut 
V T I( lv o t) 100 4 .9  (|/min) 0.99 0.1 (-0.8 to  0.9) 1.9
Svstemic vascular resistance 
FBF 100 2.3 (ml/lOOml/min) 0.76 -0.1 (-0.6 to  0.5) 12.5
Table 3-4: Summary tab le  o f the in tra-observer va riab ility  in the physiologica l measures recorded.
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3.3.10. Organ chamber bioassay
The vasodilator effect of NaNC>2 upon isolated rings o f rabbit pulmonary artery 
(PA) and abdominal aorta (AA) are displayed in Figure 3-15 (below).
The responses of both the PA and the AA to lOpM NaN02 were potentiated by a 
hypoxic environment (PA: 95% 0 2 8.3 ± 1.6% vs 1% 0 2 16.7 ± 1.2%, p<0.05; AA: 95%  
0 2 3.0 ± 1.1% vs 1% 0 2 45.0 ± 5.7%, p<0.05). However, whilst the vasodilator effect of 
NaN02 was more pronounced upon the PA than the AA in an oxygenated environment, 
this effect was reversed in hypoxia.
Pulmonary
artery
Abdominal
aorta
Figure 3-15: Aortic & Pulmonary arterial responses to lOpM NaN02. N=6. * p<0.05 
(paired t-test).
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3.4, Discussion
3.4.1. The effective utilisation of hypoxia in a physiological study
The hypoxia protocols were conducted in an environmental chamber that eliminated 
the difficulties o f achieving stable control o f hypoxia associated with the use o f a face- 
mask. There are three major problems with studies which utilize a face-mask delivered 
ventilation system. Firstly, subjects are immediately exposed to the maximal degree o f  
hypoxia being tested, which is associated with an acute and significant cardiovascular 
stress. For example, the investigators in this study reported pronounced tachycardia and 
tachypnoea upon entering the chamber before each set o f measurements. Secondly, any 
study performed will be too short to reliably assert that changes observed have not been 
influenced by the evolving effects o f hypoxia itself. Thirdly, subjects may find the 
wearing o f a face-mask claustrophobic147, compromising their breathing pattern and 
potentially altering blood pH via a respiratory alkalosis.
In this study one hour was required in order for the chamber to reach a Fi0 2  o f 12%, 
therefore subjects were exposed to a gradual decline in FiC>2 rather than a sudden drop. 
Consequently HR did not increase during this one hour period. In addition the subject was 
free to move around a large experimental space during each protocol. Partly as a result o f 
the detailed attention afforded to subject wellbeing everybody recruited completed their 
study, despite a total protocol time o f nearly five hours.
The results o f the hypoxia/saline protocol demonstrate that after the hypoxia- 
equilibration period a steady baseline had been achieved in virtually all physiological 
variables; a baseline from which the effects o f NaNC>2 could be assessed. The only 
measurement where this was not the case was the IVRT of the right ventricle. However,
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this variable is the least established o f the three echo surrogates markers used in this 
study.
3.4.2. Limitations of the physiological measures employed
Ideally this study would have measured pulmonary vascular resistance directly, for 
example using a Swan-Ganz thermodilution catheter. However, facilities for this were not 
available in the environmental chamber and its use in healthy volunteers outside of a 
hospital environment is ethically questionable. Instead three validated surrogate 
echocardiographic measurements o f pulmonary arterial pressure were used.
It should be acknowledged that without invasive measurements it is not possible to 
be certain that a change in pulmonary arterial pressure equates to a change in pulmonary 
vascular resistance. For instance, if  vascular resistance is constant but cardiac output falls 
pressure will also reduce. However, in our study the NCVassociated reduction in 
pulmonary arterial pressure was between 12-17%, which was approximately double the 
reduction in cardiac output observed. This suggests that a vasodilator effect o f NO2 ' upon 
pulmonary vascular resistance was present, although invasive studies are needed to 
confirm this finding.
Non-invasive assessment o f pulmonary arterial pressure using echocardiography 
has some limitations. An estimation o f PASP from the velocity o f TR remains the most 
widely accepted and reproducible marker, but it is limited by a prevalence o f regurgitation 
of only 30 to 70%132. In this study TR was detected in just over half o f subjects. However 
the other two markers used, PAT and the right ventricular IVRT, gave similar results with 
a detection rate approaching 100% and a robust coefficient o f variation. The sensitivity o f 
these two markers to demonstrate a difference in this protocol was reliant upon their use 
in the same subject, at a consistent location within the RV for each measurement to
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minimise variance. They are therefore strong research tools but may be o f less use in a 
clinical environment.
Venous strain gauge forearm occlusion plethysmography is a well established 
technique for measuring systemic arterial blood flow, but the assumption is made that 
changes observed in a single vascular bed can be generalised to the whole of the systemic 
vasculature. The test is also strongly influenced by changes in temperature, which alter 
the flow o f blood to the skin, and therefore assiduous control o f the experimental 
environment is needed, as was present in this study. Invasive monitoring o f arterial 
systemic pressure would have been useful, but facilities to perform this were not available 
in the environmental chamber and its use in healthy volunteers would again have been 
ethically questionable.
Lastly, the reduction in HR during the normoxia/N02 protocol may have resulted in 
an unsteady baseline o f FBF on which the effects o f NaNC>2 were assessed in normoxia. 
This could have been limited by incorporating a longer relaxation period for each subject 
before the start o f these protocols.
3.4.3, Limitations of the biochemical measures employed
Tri-iodide reagent OBC has been established through a number o f studies to be a 
sensitive and accurate technique to detect plasma [NO2’] and [HbNO]55,138,140,148. Indeed, 
in this thesis both plasma [NO2 '] and [HbNO] provided values sufficiently robust for 
successful statistical analysis to be employed. In particular, variability in the baseline 
values o f these two NO metabolites in the hypoxia/N02 protocol (i.e. mean ± SD: plasma 
[N 02‘] = 168.6 ± 40.9 and [HbNO] = 47.5 ± 23.1) indicated that adequate power was 
present to detect, respectively, a 30% & 25% difference between means with a sample 
size o f six.
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In contrast to above, the measurement o f both plasma and erythrocyte thiol-groups 
in this thesis provided disappointing results. This finding is consistent with previous 
reports criticising the ability o f tri-iodide reagent OBC to accurately quantify thiol-group 
concentrations76,11' 149. One o f the principle concerns expressed is that the labile nature of 
the S-NO bond results in sample degradation either during initial processing or by the 
addition o f sulphanilamide. The results o f this thesis are consistent with these concerns as 
the quantity o f liberated NO measured in baseline thiol-group samples were much lower 
than those previously reported measured using different analytical techniques52,15°.
Furthermore, the concentrations o f thiol-groups measured in this thesis were much 
lower than those o f plasma [NO2’] or [HbNO]. Therefore, the inherent “signal noise”, 
which forms part o f the raw output obtained when measuring NO metabolites using OBC, 
would have formed a larger proportion o f the total signal, see Figure 2-8 (page 6 6 ). This 
factor, known as an adverse “signal to noise ratio”, reduces the sensitivity o f the assay to 
detect a difference between low-concentration samples and has previously been reported 
by this laboratory96.
One alternative method used to measure thiol-group concentration is photolysis- 
based chemiluminescence, a process whereby light is used to cleave the S-NO bond 
instead o f a chemical reagent. Previous studies using this assay have shown significant 
differences in thiol-group concentrations during transit across a single vascular bed60. 
However, authors using this methodology tend to report a much greater basal 
concentrations o f thiol-groups than those found in the current study77.
In summary, the use o f tri-iodide reagent OBC in this thesis to measure blood NO 
metabolites provided a robust measure o f both plasma [NO2’] and [HbNO]. However, in 
keeping with previous reports in the literature, thiol-groups could not be measured with
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the same degree o f confidence and therefore their significance in this model could not be 
commented on further.
3.4.4. The effect of hypoxia upon blood NO metabolites
During the hypoxia-equilibration period [HbNO] increased. This is due to Hb 
possessing a greater number o f free haem-binding sites as Sa0 2  decreases55. It would also 
be expected that plasma [NO2'] would decrease in this situation if  simple reapportionment 
o f blood NO metabolites was occurring, (see section 1.4.4; page 18). However, plasma 
[NO2'] did not alter during the hypoxia-equilibration period. Indeed, a transient rise 
compared to “baseline” was present at “protocol time 30 min”. These findings taken 
together suggest an additional factor is controlling plasma [NO2 ] and [HbNO] levels 
during acute exposure to hypoxia. It is likely that a balance is present between the 
increased formation o f plasma [NO2’] and [HbNO] as a product o f endothelial NO 
production and the reapportionment o f NO metabolites into the erythrocyte as O2 levels 
falls.
Other groups have previously reported that plasma [NO2 '] does not alter after six 
hours o f exposure to Fi0 2  12%142. However, one study151 has shown that long term 
residents at high altitude (Tibetans, 4,200m) have a ten-fold greater plasma [NO2 ] than 
lowland dwellers (USA residents, 200m). The authors o f this study propose that this 
increased plasma [NO2’] is the mechanism by which Tibetans are adapted to life at high- 
altitude.
3.4.5. The enhanced vasodilator effects of NaNOz in hypoxia
A systemic, intravenous, infusion NaNC>2 resulted in a vasodilator effect in hypoxia 
which was not present when the same infusion regime was given in normoxia. 
Importantly, only a small rise in plasma [NO2’] occurred as a result o f the single low-dose
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infusion regime given. The approximate doubling in systemic plasma [NO2’] present in
this study is similar to the increase observed in man following maximal stimulation of the
endothelium by ACh87.
As would be expected, the vasodilator activity o f NaNC>2 resulted in an increase in
FBF (arteriodilation), a decrease in cardiac output (venodilation causing a decrease in
stroke volume) and no change in HR. Unexpectedly, however, an increase in peripheral
systolic blood pressure was also present. A possible explanation why systolic blood
pressure did not fall would be that there was peripheral pressure amplification present. In
healthy young subjects the peripheral blood pressure is greater than the central blood
pressure, due to its augmentation by the backward reflections o f systolic arterial pulse
waves traveling at a relatively slow velocity through a compliant vascular tree152. This
1effect is exaggerated by the administration o f a vasodilator , which further slows the 
reflected pulse wave. In this study, brachial sphygmomanometry may have recorded 
augmented peripheral pressure, when central pressure might have fallen or remained 
constant.
Despite the observation that NaNC>2 has an enhanced vasodilator effect in hypoxia, 
three features o f this study suggest that the mechanism by which this occurred is not 
consistent with the deoxy-Hb theory o f NO2* reduction.
Firstly the most compelling data is that the profiles o f plasma [NO2 ] following 
NaNC>2 infusion were similar in both hypoxia and normoxia. According to this theory 
NO2 ’ should enter the deoxygenated erythrocyte preferentially to generate vasodilatory 
NO and HbNO. It would therefore be expected that plasma [NO2 ] would achieve a lower 
maximum and have a shorter half-life when infused in hypoxia compared to normoxia. 
However, the similar profiles o f plasma [NO2"] reported in this thesis suggest that NO2" 
entry into the erythrocyte and absorption by surrounding tissue is unchanged in hypoxia
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compared to normoxia, despite the presence o f a vasodilator effect in the former 
environment.
Secondly the changes in [HbNO] across the hypoxia/NOj protocol were not 
temporally matched with the vasodilator effects o f NO2’ observed. Previously, increases 
in [HbNO] associated with concomitant physiological changes have been used by 
proponents o f the deoxy-Hb theory o f NO2 ' reduction as evidence for its validity88. 
However, this thesis demonstrates that [HbNO] is not an appropriate index o f NO2’ 
associated vasodilator activity. This finding does not negate the deoxy-Hb theory of NO2 ' 
reduction, as it is free NO rather than HbNO which is important for biological activity. 
However it does suggest a limited role o f Hb-mediated NO generation in the vasodilator 
effect o f NO2*.
Thirdly, the persistence o f a vasodilator effect o f NaN0 2  in the pulmonary vascular 
bed at a time when both [HbNO] and plasma [NO2"] had returned back to pre-infusion 
levels is again inconsistent with this theory.
Therefore, the results o f the present study suggest that alternative mechanisms are 
responsible for the bioactivity o f low-dose NaN0 2  in hypoxia.
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3.4.6. Potential mechanisms for the biological activity of NaNCh
Figure 3-16 (page 115) summarises two potential mechanisms responsible for the 
enhanced bioactivity o f NaNC>2 in hypoxia. It should also be acknowledged that a 
component o f NaNC>2 associated hypoxic-vasodilator activity is both NO-independent and
• • • S d .indomethacin-labile , though little is known regarding this potential route o f action.
3.4.6.I. Tissue-based reductase activity
One possible mechanism which recent in-vitro work has proposed is that NO2’ 
reduction at a tissue level is the major source o f bioactive NO resulting from its 
supplementation154, 155. Several tissue NO2’ reductases have been suggested, including 
myoglobin, XO, eNOS and aldehyde dehydrogenase93, 156, 157, all o f which exhibit 
enhanced NO2’ reducing capacity in hypoxia. This theory is supported by the observation 
that, as a small anion, NO2’ is capable o f rapidly equilibrating across the entire fluid 
volume o f the body43 (i.e. the intra-vascular, extra-vascular and intra-cellular spaces). 
Therefore, any NO2* entering the circulation will rapidly become available to enzymes 
within the vessel wall. In contrast, the same cannot be said for the transit o f NO2 ' across 
the erythrocyte membrane, which is slow especially at concentrations o f less than 400nM 
(data from this laboratory, manuscript currently in preparation).
Furthermore, in keeping with a tissue based mechanism of NO2 ’ reduction, the 
prolonged effect o f NaNC>2 observed in the pulmonary vasculature may be due to the 
lower O2 levels present in the pulmonary arteries compared to the systemic arterial 
circulation. Therefore, pulmonary tissue enzymes would have been primed by a greater 
degree o f hypoxia than those in the systemic arterial circulation; resulting in an enhanced 
and potentially prolonged vasodilator effect observed following administration o f the 
same dose o f NaNC>2 .
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Unfortunately this in-vivo observation was not repeated in the isolated vessel model. 
This model was designed following previous publications which demonstrate that at high 
doses o f NaNC>2 veins are more responsive than arteries89. In the present study, the 
vasodilator effect o f NaNC>2 , whilst being enhanced by hypoxia, was more pronounced in 
the AA rather than the PA. However a number o f differences between these two systems 
exist. Firstly, the in-vitro model is blood independent. Secondly, it is necessary to use a 
much larger dose o f NaNC>2 in an in-vitro isolated vessel model in order to see a 
vasodilator effect o f NaNC>2 than it is in-vivo. Also, capacitance rather than resistance 
vessels are used. These vessels are not directly responsible for the control o f vascular 
resistance146, and correspondingly they may behave in a different manner. Lastly the 
degree o f hypoxia present in the in-vitro model was much greater than that achieved in 
our subjects in the chamber.
3.4.6.2. An intermediate molecule
A second potential mechanism is that stable, intermediate, metabolites o f NO2’ in 
blood is responsible for its vascular activity. These include erythrocyte-associated NO2'- 
mediated ATP release158 and N2O3159. SNO groups have also been proposed as this 
intermediate160, and it has been shown that a transient increase in plasma [NO2 ] increases 
their population95. However, as previously explained, we were unable to detect a change 
in plasma or erythrocyte SNO levels in this study due to the limitations of the biochemical 
assay employed.
In summary the data provided in this thesis strongly suggests that a differential 
metabolism o f NO2’ at a tissue level is the key behind the enhanced vasodilator activity of 
NaN0 2  in hypoxia.
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Figure 3-16: Diagram of the potential mechanisms responsible for the metabolism of 
NaN02 in normoxia (left) and hypoxia (right). Note that N03 levels may be marginally 
lower in hypoxia compared to normoxia, however the change (nmol) would be outside of 
the detectable range of plasma N03 possible with OBC (mmol).
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3.5. Chapter summary
N i t r i t e  a n d  H y p o x i a
1. In man, NaN02 has an enhanced vasodilator effect upon both the 
systemic and pulmonary circulations when given in hypoxia 
compared to normoxia.
2. The pharmacokinetic profiles of NaN02 are the same whether it is 
given in hypoxia or normoxia.
3. The vasodilator action of NaN02 in hypoxia does not have a temporal 
associated with the concentration of [HbNO].
4. The vasodilator effect of NaN02 in the hypoxic pulmonary vasculature 
is independent of an elevated plasma [N02] level.
5. Points 2 ,3  & 4 are all supportive of an alternative mechanism of 
hypoxia-associated enhanced NaN02 activity than the deoxy-Hb 
theory of N02' reduction. Possible routes include tissue-based 
reduction of NO»‘ or the formation of an intermediate molecule.
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Chapter 4: Nitrite and Ischaemia
4.1. Introduction
4.1.1. A historical perspective of NOz as an anti-anginal agent
The earliest account o f the use o f NO2’ as an anti-anginal agent is in a Chinese 
medical manuscript from the 8 th Century AD161. This document details the ingestion of 
potassium NO3', which in itself possesses no vasodilator properties, as a treatment for 
angina. However, the author specifically requests that the recipient ‘hold the medicine 
under their tongue and swallow the saliva a phenomenon now known to facilitate oral- 
bacteria mediated reduction o f NO3* to NO2’, (see section 1.4.5; page 2 0 ).
More recently, publications from the 19th century demonstrate that NO2 ' had 
become a popular means of treating angina162 as its stable chemical structure allowed for 
cheap preparation and easy storage163. However, the effects were slow and unpredictable 
and so NO2’ fell out o f favour as faster-acting agents such as organic nitrates became 
available164.
Common to all o f these early accounts was the use o f high-doses o f NO2’, a 
treatment regime which can result in vascular collapse and syncope in the recipient165. 
However, as chapter 3 o f this thesis demonstrates, NaNC>2 is a preferential vasodilator in 
hypoxia. Therefore NaNC>2 could potentially be an anti-ischaemic agent at much lower 
doses than were used historically. This would be an important finding for two reasons. 
Firstly, it would prove that NaNC>2 is a targeted vasodilator. Secondly, and o f greater 
practical importance, the administration of NaNC>2 at these doses would be without the 
side effects o f systemic vasodilatation associated with the use o f organic nitrates166.
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4.1.2. Quantification of ischaemia by myocardial tissue Doppler 
imaging
The longitudinal fibres o f the myocardium are responsible for long-axis left-
• 1 f k l  aventricular function . They are predominantly located in the sub-endocardium and are 
therefore situated further away from the conduit epicardial coronary arteries than the rest 
o f the myocardium. In addition, the sub-endocardium is under an increased pressure load 
during systole when compared to the remainder of the myocardial wall, as it lies 
immediately adjacent to the non-compressible blood volume o f the intra-ventricular 
cavity. Both o f these factors serve to create a watershed area for ischaemia in the sub- 
endocardial region , with myocardial long axis function falling progressively from 5 
seconds after the onset o f ischaemia169.
Exertional myocardial ischaemia, resulting from an imbalance between myocardial 
blood supply and cardiac workload, will therefore cause a reduction in myocardial wall 
systolic velocities169. Furthermore, the measurement o f myocardial wall PSV using tissue 
Doppler echocardiography can be used to identify patients with significant coronary 
artery disease during DSE145.
In summary tissue Doppler imaging o f acute changes in systolic myocardial wall 
velocities (in particular PSV) obtained at the time o f DSE is a previously validated means 
by which cardiac function can be quantified and myocardial ischaemia identified.
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4.1.3. Aims of this chapter
The study in this chapter was designed to quantify regional myocardial function 
during a DSE in subjects with known inducible myocardial ischaemia. Subjects 
underwent two separate studies, each conducted double-blind. On one occasion a low- 
dose iv infusion o f NaN0 2  was administered, one shown in chapter 3 o f this thesis to be 
physiologically inert when infused in normoxia. On the other visit a matched 0.9% saline 
(placebo) infusion was given. Regional cardiac function at different HR was quantified 
during each study, using tissue Doppler imaging o f myocardial basal-wall PSV. Then, 
following unblinding of the study, PSV was compared between treatments and different 
myocardial basal-wall segments to see if  an anti-ischaemic effect o f NaN0 2  was evident.
4.1.4. Original Hypothesis
1. In subjects with known inducible cardiac ischaemia the administration of 
iv NaN0 2 * during dobutamine stress echocardiography will allow the 
heart to perform more work prior to the onset of angina than a matched 
placebo infusion given in the same environment.
*  delivered at a dose known not to vasodilate in normoxia
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4.2. Study design
A placebo-controlled double-blinded cross-over DSE study was performed to 
assess the effects o f NaNC>2 upon cardiac function in patients with established coronary 
ischaemia, as shown in Figure 4-1, (page 121). The recruitment criteria and pre-study 
requirements are detailed in section 2.2.2 (page 53).
All subjects underwent two separate DSE examinations, separated by at least two 
days (mean average time between studies = 1 0  days). The protocol for each visit was the 
same apart from the double-blind administration o f a different study infusion (i.e. an iv 
infusion o f either NaNC>2 or 0.9% saline). The dose o f NaNC>2 given was identical to that 
used in chapter 3, however it was administered at a slightly faster rate to complement the 
protocols performed in chapter 5. Randomisation was performed by the clinical trials 
division o f the pharmacy department o f the University Hospital o f Wales, Cardiff.
Prior to each DSE study subjects had an iv cannula placed into both ante-cubital 
fossae. The study infusion was given into the dominant arm whilst the non-dominant arm 
received the dobutamine infusion. The study infusion was started ten minutes before the 
dobutamine infusion protocol and continued for twenty minutes in total. This regime was 
chosen as it was anticipated that each DSE study would last for at least ten minutes, 
therefore resulting in subjects achieving peak plasma [N(V] levels at the same time as 
peak-dose dobutamine was being administered. Baseline images were obtained 
immediately prior to the beginning o f the study infusion. At this, and each subsequent 
DSE protocol stage, the myocardial longitudinal velocity profile was recorded in the 
basal-wall segments o f six different LV walls (BL, BS, BA, BI, BAS, BPost); a process 
detailed further in section 2.13 (page 71). During subsequent off-line analysis, with the 
interpreter still blinded to the infusion received, the PSV and its associated HR in each 
myocardial basal-wall segment was measured. The interpreter was then un-blinded.
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DSE 2
DSE 2
DSE 1
DSE 1
0.9% saline 
( 1 .5m l/m in for20  min)
NaN02 (1 Mmol/ml @ 
1.5m l/m in for 20 min)
Figure 4-1: Design of the double-blinded placebo-controlled DSE study performed in 
chapter 4.
4.2.1. Data analysis
Once un-blinded, the two original study data-sets (i.e. NaN02 and saline) were 
divided into different groups in a series o f separate analyses. The data was split in order 
that both ischaemic and control (non-ischaemic) myocardial walls could be identified; 
therefore resulting in four key groups o f basal-wall segments for comparison: 
ischaemia/saline, ischaemia/NaN02, control/saline, control/NaN02. Four separate 
analyses o f the overall data-set were undertaken: whole myocardial analysis, 
angiography-directed analysis, top and bottom halves analysis and upper and lower 
tertiles analysis. The latter three o f these analyses employed different techniques to 
allocate ischaemic and control myocardial walls. Figure 4-2 (page 122) is a summary 
diagram o f how the overall data-set was used to perform these different analyses.
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4 . Upper and low er  
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Figure 4-2: Summary flow diagram of the analyses applied to the overall data-set to
allow specific interpretation of both ischaemic and control regions of myocardium.
4.2.1.1. Whole myocardial analysis
The first analysis included data from all myocardial basal-wall segments, split 
only into two groups depending upon the study infusion received (i.e. NaNC>2 or saline). 
Here the response in both ischaemic and control myocardial walls was pooled within each 
group to see if  a gross effect of NaNC>2 on whole myocardial function was present.
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4.2.1.2. Angiography-directed analysis
Established criteria145 were used to focus analysis upon the myocardial basal-wall 
segments most likely to be subtended by the subject’s stenosed coronary artery or arteries; 
which had previously been ascertained by coronary angiography. The BA wall was 
measured where disease to the left anterior descending (LAD) coronary artery was 
present, the BI wall with right coronary artery (RCA) disease and the BPost wall with 
circumflex (Cx) coronary artery disease. A control basal-wall segment was also selected, 
from a region o f myocardium supplied by a non-stenosed coronary artery. Consequently 
only one ischaemic and one control myocardial basal-wall segment was identified from 
each subject.
4.2.1.3. Top and bottom halves analysis
The above analysis, whilst being highly specific to the identification o f ischaemic 
myocardial walls, ignored a large pool of data obtained from other potentially ischaemic 
basal-wall segments. A third analysis was therefore performed to stratify and assess all of 
the myocardial basal-wall segments in the overall data-set.
The first stage o f this analysis required additional examination of the saline data­
set. This data-set represented the results o f a standard DSE performed in each subject, i.e. 
one without an active study intervention. Therefore, in the saline data-set only, the 
percentage increase o f absolute PSV from baseline to peak-dose dobutamine was 
calculated for each basal-wall segment o f each subject. It has previously been reported 
that the average percentage increase, compared to baseline, in a healthy myocardial basal- 
wall segment at peak-dose dobutamine is about 100%. This is opposed to the average 
percentage increase in ischaemic myocardial walls being approximately 50-75%145. It 
therefore follows that, in a study population which contains ischaemic myocardial walls,
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the range o f percentage increases in myocardial basal-wall segment PSV between 
baseline and peak-dose dobutamine most likely represents a continuum. At one end of this 
scale will lie the basal-wall segments o f the most ischaemic myocardial walls (i.e. those 
with the lowest percentage increase in PSV) and at the other end of the scale the least 
ischaemic myocardial walls’ basal-wall segments (i.e. those with the greatest percentage 
increase in PSV).
Therefore, within each o f the six myocardial basal-wall segment categories (e.g. 
BS), subjects were ranked according to their percentage increase in absolute PSV between 
baseline and peak-dose dobutamine (in the saline study data-set). An example of this 
process can be seen in Table 4-4 (page 130). Following on from this ranking (within each 
basal-wall segment category) the data was split into those subjects’ myocardial walls 
which were in the top half o f responders (i.e. control walls) and those in the bottom half 
o f responders (i.e. ischaemic walls). This resulted in four different groups of data: 
ischaemia/'saline, ischaemia/NaN02, control/saline, control/NaN02. Importantly, this 
process o f data analysis ensured that the groups o f myocardial basal-wall segments 
labelled as ischaemic was not biased towards the inclusion o f a particular category of  
basal-wall segment.
4.2.1.4. Upper and lower fertile analysis
This analysis employed the same ranking o f subjects, within each o f the six 
myocardial basal-wall segment categories, as outlined above. However, this time 
subjects’ myocardial basal-wall segments were split into tertiles within each category of 
basal-wall segment. The lower fertile represented the ischaemic group and the upper 
tertile the control group. The middle tertile was not included in this analysis.
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4.3. Results
4.3.1. Demographic data and clinical characteristics
The summary demographics and clinical characteristics o f the subjects recruited to 
participate in chapter 4 are shown in Table 4-1 (below).
Variable
Number 10
Age (years) 56.2 ±4.2
Gender (male/female) 5/5
Weight (kg) 89.6 ±5.3
BMI 30.9 ± 1.3
Cardiac disease profile:
1VD 7/10
2 VD 3/10
Left ventricular ejection fraction (%) 55.6 ±2.0
Cardiovascular risk factors:
Hypercholesterolaemia 10/10
(total cholesterol (mmoi/o) 5.4 ±0.5
Diabetes mellitus 4/10
Hypertension 6/10
Family history of premature IHD 3/10
Smoker (current or within the last 3 months) 4/10
Medication:
Aspirin 10/10
Statin 10/10
Beta-blocker 7/10
Long acting nitrate 4/10
Calcium channel blocker 4/10
Clopidogrel 1/10
Nifedipine 1/10
Table 4-1: Demographics and clinical characteristics of the subjects who participated in 
chapter 4 . 1VD = single vessel coronary disease, 2VD = two vessel coronary disease. Left 
ventricular ejection fraction was measured using the biplane Simpson's method.
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4.3.2. Anatomical details of subject coronary vasculature 
Digital quantitative coronary angiography was used to assess the coronary anatomy 
o f each subject prior to recruitment. Summary details o f the coronary arteries responsible 
for the inducible myocardial ischaemia present in each subject are shown in Table 4-2 
(below).
D iam eter stenosis [%) Area stenosis (%) MLD (mm)
81.8 ± 4 .4 93.9 ± 1.9 0.52 ±0 .16
Table 4-2: Angiographic sum m ary data o f the index coronary a rte ry  stenoses. Thirteen 
lesions were present (ten subjects; seven w ith single vessel disease (1VD) and three w ith  
tw o  vessel disease (2VD)). Lesion breakdown by ind ividua l coronary artery: LAD = 5, 
Cx = 3 and RCA = 5. MLD (m in im al lum ina l diameter).
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4.3.3. Example individual data-set
Figure 4-3 (page 128) and Table 4-3 (page 129) show a typical data-set obtained 
from a subject who had a 95% stenosis o f the proximal LAD coronary artery. Data is 
presented as a series o f scatter-plot graphs with change in HR (AHR) on the x axis and 
change in PSV (APSV) on the y axis (each value is compared to the baseline reading 
taken from the same basal-wall segment). Six graphs are shown, each relating to a 
separate myocardial wall. Both NaNC>2 and saline studies are represented within each 
graph by a series o f points; each an x/y plot o f AHR and its corresponding APSV at a
different DSE protocol stage. The relationship between PSV and dobutamine-dose during
1
a DSE examination in healthy human subjects has previously been stated to be linear 
Therefore a linear regression analysis o f the points within individual DSE studies (i.e. 
NaNC>2 or saline) is also displayed on each graph. The gradients o f these twelve linear 
regression lines can be found in Table 4-3 (page 129).
The calculations performed in this subject to help identify whether a myocardial 
wall was ischaemic or control are also shown in Table 4-3 (page 129). Baseline and peak- 
dose dobutamine absolute PSV values from each basal-wall segment in the saline data-set 
are displayed, together with the percentage increase in PSV between these two time- 
points. The same analysis is performed in all subjects; the results are then pooled and 
grouped according to basal-wall segment category (e.g. BL). Within these groups subjects 
are ranked according to the percentage increase in PSV recorded, see Table 4-4 (page 
130) for an example o f this process performed in the BL wall. According to this ranking 
each myocardial basal-wall segment group is split into either halves or tertiles for 
identification o f the different ischaemia and control groups used in analyses 3 and 4 
respectively.
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Figure 4-3: An example data-set taken fro m  an ind iv idua l sub jec t Each o f the six graphs 
displayed is o f  a d iffe ren t m yocard ial w all category. The response o f APSV to AHR during  
both  o f  the DSE studies perform ed (i.e. N aN02 and saline) are p lo tte d  separately on each 
graph together w ith  the ir associated mean linear regression analysis lines.
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Saline study NaN02 study
Myocardial 
wall segment
Baseline 
PSV (cm/s)
Peak-dose 
dobutamine 
PSV (cm/s)
% Increase 
in PSV
Linear regression 
gradient
Linear
regression
gradient
BL 6.61 10.84 64 0.093 0.159
BS 6.09 10.03 65 0.069 0.052
BA 6.61 13.88 110 0.110 0.142
Bl 6.62 11.87 79 0.093 0.089
BAS 4.81 7.33 53 0.048 0.053
BPost 4.84 9.80 103 0.120 0.120
P P P P P P
Table 4-3: Analysis o f each basal-w all segm ent o f  the subject outlined in Figure 4-3 (page 128). The absolute baseline PSV and peak-dose 
dobutam ine PSV are displayed, toge the r w ith  percentage increase in absolute PSV which occurs between these tw o  time-points. This data  is 
used to  rank the responses o f  a ll subjects w ith in  each category o f  basal-w all segm ent and then to  iden tify  m yocardia l walls as e ither ischaemic 
o r contro l; see Table 4-4 (page 130). The twelve ind iv idua l linear regression analyses gradients measured in Figure 4-3 are also shown.
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Subject number Percentage increase in PSV from baseline to peak-dose dobutamine in the saline data-set
05 185
10 167
09 167
03 105
06 102
01 95
11 92
08 67
02 64
07 47
Table 4-4: The ranking o f subjects' individual basal-wall segm ents within the BL basal- 
wall segm ent category. Those basal-wall segm ents which lie in the upper and lower 
tertiles are shaded and the do tted  line delineates the boundary between the top half and 
the bottom  half of results. This sam e process was performed fo r all six basal-wall 
segm ent categories. Those basal-wall segm ents identified as belonging to a specific 
tertile/half within each category were then pooled fo r use in analyses 3 & 4. The subject 
presented previously in this section is highlighted (subject number = 02).
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4.3.4. Study haemodynamics
Table 4-5 (below) and Figure 4-4 (page 132) show the summary haemodynamic 
characteristics o f the two sets o f DSE studies performed. The majority o f DSE studies 
were stopped due to the onset o f typical anginal symptoms and patient request; apart from 
five studies where the full protocol was completed. No significant adverse events 
happened during any study. There were two cases o f transient bradycardia at peak dose- 
dobutamine, both occurring in the saline DSE study of subjects with 2VD. It is possible 
that these two events were due to an increase in vagal tone resulting from ischaemia- 
derived stimulation o f myocardial mechano-receptors.
DSE protocol 
stage
NaNOz
study N
Saline
study N p value
Baseline 66 ±2 10 73 ±4 10 ns
5 pg/kg/min 66 ±2 10 72 ± 5 10 ns
10 pg/kg/min 79 ±5 10 85 ±7 10 ns
20 pg/kg/min 105 ± 6 10 107 ± 7 10 ns
30 pg/kg/min 117 ± 5 9 120 ± 7 9 ns
40 pg/kg/min 119 ± 12 3 127 ± 2 2 n/a
+ 3 min 102 ± 6 10 101 ±7 10 ns
+15 min 76 ±2 10 80 ±4 10 ns
Table 4-5: The HR profile in each group o f DSE studies. N = number o f subjects who 
achieved this stage. Between-groups statistical analysis was perform ed within individual 
stages using an unpaired t-test.
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Figure 4-4: HR profile (top) and systolic/diastolic blood pressure profiles (bottom) in both 
sets o f DSE studies. Note that only tw o subjects (saline group) and three subjects (NaN02 
group) reached the highest level o f dobutamine infusion.
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4.3.5. The effect of NaNCh upon PSV in ischaemic and control 
myocardium
Data from 55 o f 60 potential (six walls in ten subjects) myocardial walls were of 
sufficient quality to analyse their basal-wall PSV throughout each DSE study. Four 
separate analyses o f the overall data-set were performed, as outlined previously in section 
4.2.1 (page 121). Three o f these analyses employed different criteria to separate 
myocardial basal-wall segments into either ischaemic or control groups, thus splitting the 
data into four groups for comparison (i.e. ischaemia/saline, ischaemia/NaN02, 
control/saline and control/NaNOi) .
Each analysis consists o f a scatter-plot graph o f the pooled data. The mean linear 
regression gradient, its associated 95% Cl and R2 value for each group are also shown. 
Two different sets o f variables are used for statistical comparison between groups. Firstly, 
the individual linear regression gradients measured in each myocardial wall (averaged 
within each grouping) are compared (see example data-set in Table 4-3; page 129). 
Secondly, the values o f APSV/AHR at peak-dose dobutamine measured in each 
myocardial basal-wall segment are also compared. A repeated-measures ANOVA with 
Newman-Keuls post-test was used to compare the difference in all cases unless only two 
groups o f data were present, when a unpaired t-test was used.
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4.3.5.I. Whole myocardial analysis
An x/y scatter-plot of the relationship between AHR and APSV in all basal-wall 
segments o f the saline and NaN02 data-sets is shown in Figure 4-5 (page 135). Table 4-6 
(page 136) summarises the outputs o f linear regression analyses o f these scatter-plots. 
Each o f the two groups analysed contained data from 55 basal-wall segments.
There was an approximate 10% difference in the mean linear regression gradient 
between the saline (0.091) and NaNC>2 (0.105) groups, but a large overlap was present 
between their respective 95% CL
Between-groups statistical analysis is shown in Figure 4-6 (page 136). Comparison 
o f the individual linear regression gradient data demonstrated no difference between the 
two groups (i.e. saline = 0.12 ± 0.01 vs NaN02 = 0.13 ± 0.01; p >0.05). In addition, no 
difference was present with analysis o f the APSV/AHR at peak-dose dobutamine data (i.e. 
saline = 7.3 ± 0 .6 cm/s/s vs NaNC>2 = 8 . 1  ± 0.5cm/s/s; p >0.05).
In summary, analysis o f this data-set provided no clear evidence of an influence of  
NaNC>2 upon whole myocardial function. However, linear regression analysis of the data 
did suggest that a difference between the NaNC>2 and the saline groups may be present.
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Figure 4-5: A scatter-plot graph of APSV and AHR in the 'whole myocardial analysis' data­
set. The mean linear regression lines of the two data-sets, together with their respective 
95% Cl, are also displayed. Each of the two groups plotted contains data from all of the 
55 walls contained in the overall data-set.
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Group Mean gradient (95% Cl) R2
NaN02 0.105(0 .096-0 .115 ) .61
Saline 0.091 (0 .081-0 .101) .55
Table 4-6: Linear regression analysis outputs fro m  the 'whole myocardial analysis' data­
set; shown in Figure 4-5 (page 135).
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Figure 4-6: Between-group comparison o f the 'whole myocardial analysis' data-set 
APSV/AHR a t peak-dose dobutamine data (left) and averaged individual wall linear 
regression gradient data (right). No significant results were present.
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4.3.S.2. Angiography-directed analysis
Scatter-plot graphical representations of the relationship between APSV and AHR 
in the ‘angiography-directed analysis' data-set are shown in Figure 4-7 (page 138); with 
the outputs from linear regression analyses o f these plots summarised in Table 4-7 (page 
139). Ten basal-wall segments were included in each o f the four groups analysed.
There was an approximate 25% difference between the mean linear regression 
gradients o f the ischaemia/NaN02 (0.119) and ischaemia/saline (0.092) groups; however 
their respective 95% Cl overlapped. The mean linear regression gradients in the control 
groups were o f values between those measured in the two ischaemia groups, 
((control/NaNC>2 -  0.103, control/saline = 0 .1 1 2 ).
Between-groups statistical comparisons o f this data-set are shown in Figure 4-8 
(page 139). No differences were present within the APSV/AHR at peak-dose dobutamine 
analysis (i.e. ischaemia/saline = 7.0 ± 1 .2 cm/s/s vs. ischaemia/NaN02 = 8 . 6  ± 1 .2 cm/s/s, 
control/saline = 9.9 ± 1.5cm/s/s and control/NaN02 — 7.8 ± l.Ocm/s/s; p >0.05 for each 
comparison). However, analysis o f the individual linear regression gradient data-set 
showed a difference between the ischaemia/saline (0 . 1 1  ± 0 .0 2 ) and the
ischaemia/NaN02 (0.15 ± 0 .0 2 ) groups (p<0.05). This was the only difference present 
with statistical analysis o f these four groups, in particular no differences were shown 
between the ischaemia/saline group and either the control/saline (0.14 ± 0.02) or the 
control/NaN02 (0.13 ± 0 .0 2 ) groups.
In summary, in this focused data-set o f myocardial basal-wall segments which had 
been selected by coronary angiography to be highly likely to exhibit features o f inducible 
ischaemia, evidence was present that low-dose NaNC>2 was acting as an anti-ischaemic 
agent.
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Figure 4-7: Scatter-plot graphs o f APSV and AHR in the 'angiography-directed analysis' 
data-set (top graph = ischaemic walls, bottom  graph = control walls. The response in 10 
different myocardial walls is analysed in each group plotted). Linear regression analyses 
(mean & 95% Cl) o f the combined data fo r  each group are also displayed.
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Group Mean gradient (95% Cl) R2
ischaemia/saline 0 .092 (0 .070-0 .114 ) .60
ischaem ia/NaN02 0 .119(0 .097-0 .141 ) .69
control/saline 0 .112(0 .087-0 .137 ) .67
contro l/N aN 02 0.103(0.080 -  0.125) .66
Table 4-7: Linear regression analysis outputs from  the 'angiography-directed analysis' 
data-set; shown in Figure 4-7 (page 138).
Figure 4-8: Between-group comparison o f the 'angiography-directed analysis' data-set. 
APSV/AHR a t peak-dose dobutamine data (left) and averaged individual wall linear 
regression gradient data (right). #  p<0.05. Only statistically significant comparisons are 
shown.
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4.3.S.3. Top and bottom halves analysis
X/y scatter-plot graphs of the relationship between APSV and AHR in the ‘top and 
bottom halves analysis’ data-set are shown in Figure 4-9 (page 141), and the linear 
regression analyses o f these plots are summarised in Table 4-8 (page 142). As the overall 
data-set contained 55 myocardial walls the split o f data for this analysis was not quite 
even: the ischaemia category contained 28 basal-wall segments and the control category 
27 basal-wall segments.
An approximate 25% difference was present in the mean linear regression gradients 
o f the ischaemia/NaN02 (0 .1 0 0 ) and ischaemia/saline (0.076) groups, with only a small 
overlap o f their respective 95% CL In addition, there was no appreciable difference 
between the mean linear regression gradients measured in the two control myocardial wall 
groups (icontrol/NaN02 = 0 .1 1 2 , control/saline = 0.114).
Between-groups statistical comparisons are shown in Figure 4-10 (page 142). A 
difference was present within the APSV/AHR at peak-dose dobutamine data-set between 
the ischaemia/saline group and the other three groups (i.e. ischaemia/saline = 4.9 ±
0 .6 cm/s/s vs. ischaemia/NaN02 = 8 . 0  ± 0 .8 cm/s/s, control/saline = 9.7 ± 0 .8 cm/s/s and 
control/NaNC>2 = 8.4 ± 0.7cm/s/s; p <0 . 0 1  for each comparison). No difference was 
present between each o f the three other groups in this comparison. A similar result was 
present with analysis o f the individual linear regression gradient data, with a difference 
demonstrated between the ischaemia/saline group and the other three groups (i.e. 
ischaemia/saline = 0 . 1 0  ± 0 . 0 1  vs. ischaemia/NaN02 = 0.13 ± 0 .0 1 , control/saline -  0.15 
± 0 . 0 1  and control/NaNO2 = 0.14 ± 0 .0 1 ; p <0.05 for each comparison).
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Figure 4-9: Scatter-plot graphs of the relationship between APSV and AHR in the 'top and 
bottom halves analysis' data-set. Top = ischaemic walls (28 basal-wall segments) and 
bottom  = control walls (27 basal-wall segments). Linear regression analyses (mean & 
95% Cl) of the combined data for each group are also displayed.
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Group Mean gradient (95% Cl) R2
Saline/ischaemia 0.076 (0.064 -  0.088) .55
NaNO^ischaemia 0.100(0 .085-0 .114) .56
Saline/control 0 .114(0 .101-0 .127) .69
NaNOz/control 0 .112(0 .100-0 .125) .68
Table 4-8: Linear regression analysis outputs from the 'top and bottom halves analysis' 
data-set; shown in Figure 4-9 (page 141).
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Figure 4-10: Between-group comparison of the 'top and bottom halves analysis' data-set. 
APSV/AHR at peak-dose dobutamine data (left) and averaged individual wall linear 
regression gradient data (right), ft p<0.05, * p<0.01. Only statistically significant 
comparisons are shown.
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4.3.S.4. Upper and lower tertiles analysis
The relationship between APSV and AHR in the ‘upper and lower tertiles analysis ’ 
data-set is shown graphically in Figure 4-11 (page 145), with the linear regression 
analysis outputs o f these plots summarised in Table 4-9 (page 146). 18 basal-wall 
segments are contained within each group, with the balance o f 19 basal-wall segments 
from the middle tertile not included in this analysis. Of the 18 basal-wall segments in the 
lower tertile (i.e. ischaemic group) only two were from a myocardial region that was not 
either directly subtended by a stenosed coronary artery, or adjacent to a subtended 
segment.
An approximate 40% difference was present in the mean linear regression gradients 
of the NaN02/ischaemia (0.100) and saline/ischaemia (0.063) groups, with no overlap of 
their respective 95% CL Furthermore, there was no appreciable difference between the 
mean linear regression gradients measured in the two control myocardial wall groups 
(NaNO2/control = 0.118, saline/control = 0.113).
Between-groups statistical comparisons are shown in Figure 4-12 (page 146). A 
similar result was seen with both the APSV/AHR at peak-dose dobutamine data and the 
individual linear regression gradient data. The APSV/AHR at peak-dose dobutamine data 
demonstrated a lower increase in PSV, adjusted for HR, in the ischaemia/saline group 
compared to the other three groups, (i.e. ischaemia/saline = 3.7 ± 0.6cm/s/s vs. 
ischaemia/NaNC>2 = 8 . 2  ± l.Ocm/s/s, control/saline = 10.5 ± 1 . 1  cm/s/s and control/ 
NaN02 -  8.4 ± 0.7cm/s/s; p <0.001 for each comparison). No difference was present 
between each o f the three other groups in this comparison.
Similarly, the individual linear regression gradient data demonstrated that the 
average gradient in the ischaemia/saline group was lower than the three other groups, (i.e.
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ischaemia/saline = 0.08 ± 0 . 0 1  vs. ischaemia/NaNC>2 = 0.13 ± 0 .0 2 , control/NaN02= 0.16 
± 0.02 and control/saline = 0.14 ± 0.01; p <0.01 for each comparison).
In summary, in the previous two sets of analyses where individual myocardial 
basal-wall segments were ranked according to their PSV response, a difference was 
clearly demonstrated between the ischaemia/saline group and the three other groups 
categorised within these data-sets. Furthermore, a difference could not be shown 
statistically between the ischaemia/NaN02 group and the two control groups. These 
combined results demonstrate that low-dose NaNC>2 is capable o f improving functional 
reserve in myocardial walls subtended by a stenosed coronary artery.
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Figure 4-11: Scatter-plot graphs of the relationship between APSV and AHR in the 'upper 
and lower tertiles analysis' data-set. Top graph = ischaemic walls and bottom graph = 
control walls (18 basal-wall segments in each group). A linear regression analysis (mean 
& 95% Cl) of the combined data for each group is also displayed.
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Group Mean gradient (95% Cl) R2
ischaemia/saline 0 .063(0 .050-0 .075) .53
ischaemia/NaN02 0 .100(0 .080-0 .119) .52
control/saline 0 .113(0 .095-0 .132) .64
control/NaN02 0 .118(0 .103-0 .133) .72
Table 4-9: Linear regression analysis outputs from the 'upper and lower tertiles analysis' 
data-set; shown in Figure 4-11 (page 145).
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Figure 4-12: Between-group comparison of the 'upper and lower tertiles analysis' data­
set. APSV/AHR at peak-dose dobutamine data (left) and individual wall linear regression 
gradient data (right). * p<0.01 . + p<0.001. Only statistically significant comparisons are 
shown.
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4.3.6. Retrospective analysis of the APSV vs AHR data 
Initial, visual, interpretation o f the relationship between APSV and AHR in the 
different analyses performed suggested that this relationship may not be linear, as has 
previously been stated to be the case in healthy controls167. Subsequent analysis o f the 
‘upper and lower tertiles analysis’ data-set, shown in Figure 4-13 (page 148) 
demonstrated that the relationship o f APSV to AHR also fit a non-linear regression 
analysis with a one-phase exponential-association-curve equation. Indeed, the R2 values 
for this fit were greater than those obtained with linear regression analysis in three of the 
four groups contained within this data-set (i.e. ischaemia/saline R2: linear regression =
0.53 vs non-linear regression = 0.60; ischaemia/NaN02 R2: linear regression = 0.52 vs 
non-linear regression = 0.65; control/saline R : linear regression = 0.64 vs non-linear 
regression = 0.59 and control/NaNC>2 R2: linear regression = 0.72 vs non-linear regression 
= 0.80).
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Figure 4-13: Scatter plot graphs of the 'upper and lower tertile analysis' data-set as 
previously shown in Figure 4-11 (page 145). Mean non-linear regression analyses with a 
one-phase exponential-association equation (with 95% Cl) of the combined data within 
each group are also displayed.
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4.3.7, Analysis of variance of the results
4.3.7.I. Variability between days
As baseline-corrected changes in PSV were used in the analysis o f  the response o f  
PSV to HR, an analysis o f  the difference between baseline PSV values in individual 
myocardial basal wall segments was performed; see Figure 4-14 (below). This 
demonstrated that no difference was present between studies in any o f  the six myocardial 
basal wall segments investigated.
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Figure 4-14: Baseline PSV of the six basal myocardial walls analysed during each DSE
study. No difference was present between visits in any of the basal wall segments, 
(repeated measures ANOVA with Newman-Keuls post-test).
Page | 149
C h a p t e r  4 N i t r i t e  a n d  I s c h a e m i a
4.3.7.2. Intra-observer variability
Thirty paired readings of PSV, chosen from all stages of either DSE study, were 
used to determine the intra-observer reproducibility of this variable. The results are shown 
in Figure 4-15 (below). The mean of the explored readings was 8.46cm/s. Linear 
regression analysis of the correlation between these two readings gave an R2 of 0.96. 
Bland-Altman analysis showed no significant paired difference, with a bias of 0.15cm/s 
(95% Cl -1.16 to 1.45). The coefficient of variation was 4.4%, (calculated using the 
method described in section 3.3.9, page 101).
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Figure 4-15: Intra-observer variability in PSV measurement. Correlation (left) and Bland- 
Altman plot (right) are shown.
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4.4. Discussion
The key finding o f this chapter is that in human subjects with inducible myocardial 
ischaemia, due to a flow limiting coronary artery stenosis, an infusion o f a low-dose of 
NaNCb is capable o f alleviating objective measures o f ischaemia when administered 
during quantitative tissue Doppler DSE. Furthermore the dose o f NaNC>2 used is one 
established in chapter 3 of this thesis to approximately double plasma [NO2 ] and be 
physiologically inert in normoxia.
4.4.1. Limitations of this study
The use o f a double-blinded placebo-controlled cross-over study in this chapter was 
one of the strongest possible study designs available to detect a treatment difference 
between NaNCh and placebo in subjects with inducible myocardial ischaemia. The 
number o f subjects recruited into this study was small, but appropriate to the original aims 
of this chapter, i.e. an initial exploratory investigation o f a biochemical hypothesis in a 
clinical model.
A potential criticism of this study is the limitation of myocardial imaging to the 
measurement o f a single variable: basal-wall PSV. From the tissue Doppler images 
obtained it would have been possible to analyse a number of different indices of 
myocardial function. PSV was chosen as it has previously been validated in a large multi­
centre study to be a sensitive means o f identifying ischaemic myocardium during DSE145. 
However, it is less specific to the identification o f individual ischaemic territories than 
other deformation parameters such as strain and strain rate imaging170. This is for two 
reasons.
Firstly, PSV is a composite measure of myocardial function in all three segments of 
the myocardial wall being measured (i.e. the apical, mid and basal wall segments). The 
heterogeneity o f coronary blood supply to different myocardial walls means that an
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individual coronary artery may perfuse a number o f different segments across a number 
of adjacent myocardial walls. For example, all six basal-wall PSV measurements may be 
reduced by a stenosis to a coronary artery which supplies the entire apical region. The 
tethering o f adjacent segments with different coronary blood supplies enhances the 
sensitivity o f basal-wall PSV to detect ischaemia but reduces the specificity it has to 
identify which coronary artery is subtending an ischaemic region of myocardium.
A second caveat to the interpretation o f PSV is that it is reduced, both at baseline 
and during stress, by the presence o f diseases which are cardiovascular risk factors (e.g. 
hypercholesterolaemia171 and DM172). Subjects who participated in this study had 
multiple cardiovascular risk factors (see Table 4-1; page 125). Therefore the response o f  
PSV to HR in each myocardial basal-wall segment will have been influenced by a 
composite o f both ischaemia-associated myocardial dysfunction and the underlying 
cardiovascular risk factor burden. However, whilst it should be acknowledged that in the 
early stages o f these diseases myocardial functional deterioration may be regional173, the 
subjects in this study all had long-standing, established, adverse cardiovascular risk factor 
profiles. Therefore, in this study, the deterioration in myocardial function that resulted 
from the associated co-morbidities present will have been predominantly global rather 
than segmental174,175. In addition, when identifying ischaemic myocardial walls, specific 
criteria were used to ensure that an equal number of basal-wall segments from within each 
basal-wall segment category were included. This process limited the bias towards the 
inclusion o f any particular basal-wall segment category in the ischaemia group.
It follows that the difference in myocardial function observed in this study between 
the ischaemia/saline groups and the control/saline groups is most likely attributable to 
myocardial ischaemia alone. Therefore, this second criticism does not detract from the 
overall result o f this chapter. It does, however, provide a potential explanation for the
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better fit that non-linear regression analysis with a one-phase exponential association 
curve equation had to the data presented compared to linear regression analysis, (i.e. a 
reduction in subjects’ myocardial functional reserve resulted in APSV reaching a plateau 
within the range o f AHR included in this analysis).
In summary, it was never within the scope o f this thesis to perform an exhaustive 
analysis o f the effect of NaNC>2 upon ischaemic myocardial tissue; in fact such an analysis 
could form the basis o f a whole different thesis. In particular, in this chapter it was not my 
intention to include all o f the many different methods by which myocardial ischaemia can 
be quantified. Indeed other, more specific, deformation-imaging markers could have been 
used (e.g. post-systolic strain index176, peak-systolic strain rate177 or strain imaging 
diastolic index178). Consequently, there are significant caveats to the interpretation of the 
results presented; specifically whether the segments identified as ischaemic were actually 
ischaemic. However, the overall design o f this study and its subsequent analysis 
incorporated several careful features to try and limit the influence o f these caveats. Lastly, 
it should be emphasized that each o f the four analyses performed were in agreement, with 
more than one o f them demonstrating a clear beneficial effect o f low-dose NaNC^ upon 
the function of ischaemic myocardium.
4.4.2. Targeted therapeutic delivery by NaNCh
NaNC>2 is a slow vasodilator in normoxia when compared to other more efficient 
NO-donors38 (e.g. GTN). As the historical context o f NaNC>2 therapeutics outlined in the 
introduction to this chapter demonstrates, this biological feature led in the past to large 
doses being prescribed (in order to achieve a quick response). This provided an erratic, 
profound and sustained systemic vasodilator effect in patients which was neither 
conducive to compliance nor effective pharmacotherapy. However, the results of this 
chapter demonstrate that administration o f low-dose NaNC>2 , at a level which does not
Page | 153
C h a p t e r  4 N i t r i t e  a n d  i s c h a e m i a
influence normoxic vasculature, can prevent exertional myocardial ischaemia in patients 
with stable angina. Thus NaNC>2 is a targeted vasodilator, capable o f providing an NO- 
type effect (though not necessarily acting exclusively via this mechanism of action84) to 
tissues in need without the systemic side effects associated with other, less discriminate, 
NO-donors.
Chronic low-dose NO2’ supplementation may therefore be an effective alternative 
treatment for angina. Whilst organic nitrates will remain the primary pharmacological 
means o f administering an NO-type effect in clinical practice there are two key benefits 
which NO2' therapy may have over these agents. Firstly, it may avoid tolerance since 
primates that received a continuous iv NO2" infusion over a 14 day period did not exhibit 
features of tachyphylaxis in their blood pressure responses to additional intermittent high-
00
dose NO2' bolus administration ; a problem intricately associated with the chronic use o f 
organic nitrates. Secondly, there is no mortality benefit to the long-term administration of 
organic nitrates post-MI179; indeed their use in this clinical setting may be harmful180. In 
contrast, there is a growing body o f literature from animal studies which proposes that 
chronic oral NO2’ supplementation protects against damage resulting from a subsequent
101 1 <>2 •
MI ’ , an idea expanded on m chapter 5. The proposal that long term NO2’
supplementation has a beneficial influence upon the cardiovascular system is also 
supported by the observations that a ‘healthy’ Mediterranean diet is one high in both NO2 ' 
and NO3' 183, as are certain Chinese medicines which pertain to be beneficial to the
1 fidcardiovascular system .
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4.5. Chapter summary
1. In human subjects with inducible myocardial ischaemia due to 
obstructive coronary artery disease a low-dose NaN02 infusion reduces 
objective markers of myocardial ischaemia measured during DSE.
2. The dose of NaN02 administered suggests that its mechanism of action is 
one of targeted therapeutic delivery to tissue in need only.
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Chapter 5: Nitrite and Ischaemia/Reperfusion Injury
5.1. Introduction
The stimulus o f remote ischaemic pre-conditioning (RJPC) protects tissue from 
injury during IR. Kharbanda used a regime o f RJPC whereby a cuff attached to the 
contralateral arm to that being studied was inflated to 200mmHg for five minutes, a 
process repeated three times with a five minutes gap between inflations. This procedure 
mitigated against the endothelial dysfunction produced immediately afterwards by twenty 
minutes o f forearm ischaemia and subsequent reperfusion122. The protective effects of 
IPC are therefore systemic. As outlined in section 1.6.4 (page 47), IPC acts through a 
series o f complex molecular cascades, o f which NO is a key component. Furthermore, the 
administrated o f either a low-dose o f sublingual GTN185 (25pg; dose used clinically to 
treat angina = 400pg166) or oral NO3’ supplementation186 both offered similar protection to 
that achieved by RJPC when applied to the same model as Kharbanda. In the study where 
oral NO3' was given an approximate two-fold increase in plasma [NO2 ] was observed.
This in-vivo data, together with a substantial body o f in-vitro and animal work (see 
section 1.6.5, page 49) strongly suggests that the administration o f a low-dose o f NaNC>2 
should offer protection against IR injury. However, this has not explicitly been shown in 
man. Also, it has not been shown whether the process of RJPC is associated with an 
alteration in plasma [NO2 ] levels.
More importantly, the in-vivo studies outlined above have been limited to exploring 
the pre-conditioning benefits o f NO2’. Of greater clinical relevance would be whether 
NaN0 2  is an effective post-conditioning agent. The animal study performed by Gonzalez
1 87suggests that this would be the case , but this result has yet to be translated into man. If 
NaN0 2  were capable o f post-conditioning then it could offer a valuable new means of
156
C h a p t e r  5 N i t r i t e  a n d  i R i n j u r y
limiting the damage o f an acute MI, if  administered at the time of reperfusion during 
primary percutaneous coronary intervention.
5.1.1. Aims of this chapter
The first study in this chapter was designed to assess whether plasma NO metabolite 
levels alter as a result of RIPC. The remaining series of studies were formulated to test 
whether NaN0 2  is a pre-conditioning or a post-conditioning agent. The same model of 
forearm IR injury was used as that employed by the studies outlined in the previous 
section. NaN0 2  was given either before (IPC model) or after (IPostC model) simulated 
IR. FMD measurement was used to assess endothelial function before and after forearm 
IR injury, the difference between these two values indicating the degree of endothelial 
damage which had occurred and thus whether any protection had been afforded by 
N aN 02.
5.1.2. Original Hypotheses
1. RIPC will be associated with an increase in plasma [NO2Tand/or 
RSNO levels.
2. Low-dose iv NaN02 will mitigate against IR injury in an in-vivo 
forearm model when given either as a pre-conditioning or a post­
conditioning agent.
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5.2. Study protocols
Each subject recruited in this chapter was asked to prepare for their study in the 
same manner as outlined in section 3.23 (page 79). Studies were performed in a 
temperature controlled room in the Wales Heart Research Institute. All forearm IR studies 
were powered as is appropriate for a similarly designed FMD crossover study188. For 
statistical analysis either a repeated measures ANOVA test with Newman-Keuls post test 
(for analysis o f more than two variables) or a paired t-test was used.
5.2.1. RIPC protocol
o
O nO
Stimulus
Blood
sample
RIPC
Figure 5-1: Diagram of the RIPC protocol; designed to assess the systemic plasma NO 
metabolite profile during the four hours following the stimulus of RIPC.
The plasma NO metabolite profile during the four hours following RIPC was 
assessed in six healthy volunteers; see Figure 5-1 (above). An iv cannula was placed in 
the dominant arm from which venous blood samples were taken. “Baseline ” blood was 
sampled, followed by three five minutes cycles o f contralateral upper arm cuff inflation to 
200mmHg, each separated by a five minute rest period. Blood sampling was repeated at 
“30 min ”, “60 min ”, “90 min ” and “240 min ”.
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5.2.2. Stage of damage protocol
-------------------------------------------------------------------------------------------------
40 minutes
FMD 1 FMD 2
\ ________________________________________________________________ y
Figure 5-2: Diagram of the stage of damage protocol.
To assess whether any transient damage to endothelial function occurred as a result 
o f a single FMD measurement the protocol outlined in Figure 5-2 (above) was performed. 
The purpose o f this study was to identify the most appropriate timing of NaNC>2 
administration when used as a pre-conditioning agent (i.e. before or after the first FMD 
reading). Two FMD measurements were performed with a forty minute rest period 
inbetween.
5.2.3. NaN02 pre-conditioning protocol
20 min 20 min 20 min
Infusion: 
NaN02 (lpmol/ml 
@ l-5ml/mijn} 
o r
0.9% saline 
(1.5ml/min)
FMD 1
Proximal cuff 
inflation 
(200mmHg)
Cuff release /  
reperfusion FMD 2
v__________________________________________________________________________y
Figure 5-3: Diagram of the NaN02 pre-conditioning protocol.
To investigate whether NaNC>2 is a pre-conditioning agent the protocol outlined in 
Figure 5-3 (above) was performed. The tissue being studied was exposed to an increased 
level o f plasma [NO2"] prior to IR injury. An iv cannula was placed in the contralateral 
arm to that being studied. An infusion o f either NaN0 2  or 0.9% saline was then given.
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The infusion dose was identical to that used in chapter 3, however it was given slightly 
faster to complement the NaN02 post-conditioning protocol (see section 5.2.4, below). 
Each individual returned on a separate occasion at least 72 hours later to repeat the study, 
this time receiving the alternative infusion to that given during the first visit. Subjects 
were blinded as to which infusion they received at each visit.
5.2.4. NaNCh post-conditioning protocol
FMD 1
Proxim al cu ff  
inflation  
(2O0mm Hg)
Infusion:
N aN 02 ( lp m o l/m l  
@  1 .5 m l/m in )  
or
0.9% saline 
(1.5ml/min)
Cuff re lease  /  
reperfusion FMD 2
Figure 5-4: Diagram o f the NaN02 post-conditioning protocol.
To investigate whether NaNC>2 is a post-conditioning agent the protocol outlined in 
Figure 5-4 (above) was performed. This study was identical in design to the NaN02 pre­
conditioning protocol, apart from the timing o f the study infusion being altered so that it 
was received exclusively during the ischaemic phase. Consequently the forearm tissue 
bed under investigation was only exposed to an increase in plasma [NO2 ] at the point of 
reperfusion.
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5.2.5. Analysis of pH/SaCh peri-ischaemia
On a separate day, in six of the participants whom had volunteered for an IR 
protocol, venous samples were taken for analysis of the pH and Sa0 2  during forearm IR. 
A cuff was placed around the upper arm and a venous cannula was sited in the ipsilateral 
antecubital fossa. A ‘baseline ’ blood sample was taken and the cuff inflated to 200mmHg. 
Immediately prior to cuff release at twenty minutes a second sample was taken ( ‘20 
minutes *). One minute into reperfusion a third sample was taken ('+1 minute ’) and a final 
sample was also taken after twenty minutes o f reperfusion ( ‘+20 minutes ’).
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5.3. Results
All data was analysed by a single individual who was blinded to the original 
infusion (NaNC>2 or 0.9% saline). All continuous data is presented as mean ± SEM.
5.3.1. RIPC protocol
5.3.1.1. Subject demographics
The summary demographics o f the healthy volunteers recruited to participate in the 
RIPC protocol are displayed in Table 5-1 (below).
D em ographic
N um ber 6
Age (years) 29.3 ± 2 .7
M ale /  Fem ale 5 / 1
W eight (kg) 78.5 ± 6.6
BMI 25.4 ± 1 .7
Table 5-1: RIPC p ro toco l sum m ary demographics.
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5.3.1.2. Plasma NO metabolite profile following RIPC
Table 5-2 (below) and Figure 5-5 (page 164) are a summary o f the results of this 
protocol. Plasma [NO2*] increased in response to RIPC, being greater than “baseline ” at 
all subsequent time points. The increase in plasma [N 02‘] at “30 min” compared to 
“baseline” was +134.8 ± 28.5 nmol/1, a rise o f a similar magnitude to that reported after 
the infusion o f N aN 0 2 given in chapter 3 (i.e. +205.5 ± 20.9 nmol/1, see page 89). Plasma 
[RSNO] levels were much lower than plasma [N 02‘] and did not change throughout the 
study.
Protocol
stage
Plasma [N02 ] 
(nmol/l)
P value 
(vs baseline)
Plasma [RSNO] 
(nmol/l)
P value 
(vs baseline)
Baseline 112.4 ± 10.5 n/a 11.1 ±1 .3 n/a
30 minutes 247.2 ± 26.3 <0.01 10.1 ± 2.9 ns
60 minutes 235.4 ± 22 .1 <0.01 10.4 ± 1.7 ns
90 minutes 203.7 ± 15.8 <0.05 18.7 ± 3 .5 ns
240 minutes 180.8 ± 29.4 <0.05 8.4 ±2 .1 ns
Table 5-2: The four hour plasm a NO m etabolite profile following RIPC.
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300-
200 -
100 -
Baseline 3 0 m in  6 0 m in  9 0 m in  240 min 
Protocol time (min)
2 5 i
oa
a
20 -
Baseline 30 m in 60 m in 90 m in 240 m in 
Protocol time (min)
Figure 5-5: The profile of systemic venous plasma [N02] (top) and [RSNO] (bottom) 
during the four hours following RIPC. * p<0.01, #  p<0.05.
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5.3.2. Stage of damage protocol
5.3.2.I. Subject demographics
The summary demographics o f the participants who performed the stage o f damage 
protocol are displayed in Table 5-3 (below).
Demographic
Number 9
Age (years) 2 7 . 7  ± 2 . 0
Male /  Female 5 / 4
Weight (kg) 7 1 . 9  ± 5 . 6
BMI 2 4 . 3  ± 1 .3
Table 5-3: Stage of damage protocol subject demographics.
i.
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5.3.2.2. FMD measurement variability
In order to ensure that the same stimulus was being delivered into a matched 
environment for both FMD measurements certain key variables were recorded; 
summarised in Table 5-4 (below).
A difference in skin temperature was present between the two FMD measurements. 
However, this change was not associated with a difference in any of the other key 
variables. In particular the baseline brachial arterial diameter and flow stimulus 
responsible for each FMD response was similar between each reading.
Variable FMD 1 FMD 2 P value
Room Temperature (°C) 23.5 ±0.3 23.8 ±0.5 ns
Skin Temperature (°C) 30.7 ±1.1 27.1 ±1.3 <0.05
Baseline arterial diameter (mm) 3.5 ±0.2 3.5 ±0.2 ns
Baseline arterial VTI (cm/s) 0.053 ± 0.005 0.050 ± 0.005 ns
Flow stimulus {%) 691 ±61 717 ±57 ns
Heart rate (/min) 6 6  ± 4 6 6  ± 4 ns
Blood pressure (mmHg) 123/72 ± 4/4 119/73 ± 5/4 ns
Table 5-4: Summary of the key stimulus and environment variables recorded at each 
FMD measurement Statistical comparisons performed by paired t-tes t
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5.3.2.3. Endothelial function
The peak FMD measurements taken during this protocol are shown in Figure 5-6 
(below). The second peak FMD was reduced by approx 30% as compared to the first 
FMD (FMD 1 = 7.1 ± 1.0% vs FMD 2 = 4.8 ± 0.8%; p<0.01). This difference may have 
been influenced by the small change in environmental conditions present between the two 
protocols (i.e. a reduction in skin temperature). However, for the purposes of this study it 
was assumed that a degree of damage to endothelial function was present over the forty 
minutes following the performance of a FMD reading. In the NaN02 pre-conditioning 
protocol it was therefore decided that the study infusion should be given prior to the first 
FMD measurement.
FMD 1 FMD 2
1 2 i
1—*
IQ­
Q S'
u. 6 _
X
CO 4-O
a. 2-
0-
B;;-
S> ^ .g
13
FMD 1 FMD 2
Figure 5-6: Peak FMD measured in the stage of damage protocol, mean data (left) and 
individual data (right). * p<0.01.
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5.3.3. NaNCh pre-conditioning protocol
5.3.3.1. Subject demographics
The demographic data o f the subjects who took part in the NaN02 pre-conditioning 
protocol is contained in Table 5-5 (below).
Demographic
Number 10
Age (years) 24.6 ± 1.4
Male /  Female 6 / 4
Weight (kg) 70.2 ±4.1
BMI 23.7 ± 0.9
Table 5-5: Subject demographics for the NaN02 pre-conditioning protocol.
S.3.3.2. FMD measurement variability
Table 5-6 (page 169) contains details of the environmental conditions and flow 
stimulus delivered during each FMD study. Comparison between the two FMD studies 
performed within each visit showed that no differences were present with any of these 
variables.
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Variable FMD 1
Control 
FMD 2 P value FMD 1
NaNOz 
FMD 2 P value
Room
Temperature (°C)
24.0
±0.4
25.0
±0.4 ns
24.6
±0.9
25.2
±0.9
ns
Skin
Temperature (°C)
29.8
±0.9
29.1
± 1 . 2 ns
29.0
±1.3
29.6
± 1 . 2 ns
Baseline arterial 
diameter (mm) 3.7 ±0.2 3.8 ±0.2 ns 3.8 ±0.2 3.8 ±0.2 ns
Baseline arterial 
VTI (cm/s)
0.051 ± 
0.003
0.051 ± 
0.004 ns
0.051 ± 
0.004
0.048 ± 
0.004 ns
Flow stimulus (%) 719 ± 65 728 ± 62 ns 761 ± 70 837 ± 60 ns
Heart rate (/min) 61 ± 2 58 ±1 ns 59 ±2 56 ±2 ns
Blood pressure 
(mmHg)
119/72
± 4 /3
116/72
± 4 /3 ns
116/68
± 3 /1
113/68
± 2 / 1 ns
Table 5-6: Summary of the key stimulus and environment variables within each visit of 
the NaN02 pre-conditioning protocol. Statistical comparisons are made between the two 
FMD measurements performed during each visit using a paired t-test.
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5.3.3.3. IR injury
Peak FMD was reduced by approximately 40% in the control group (FMD 1 = 6 . 8  ± 
0.7% vs FMD 2 = 3.9 ± 0.7%;p<0.01), confirming that the stimulus for forearm IR injury 
used in this study causes damage to endothelial function. This damage did not occur 
during the visit when NaNC>2 was infused (FMD 1 = 5.9 ± 0.7% vs FMD 2 = 5.2 ± 0.5%; 
p=ns). There was no difference between FMD 1 taken at each of the two visits. Figure 5-7 
(below) is a graphical display of this data.
ion
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I C ontro l ! ■  N a N 0 2
12-
1 0 -
1  8 -  Q
I  6-
X
9  A -  v  4- 
a.
2 -
^  '" v ..
fl
»
FMD 1 FMD 2
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12n
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Figure 5-7: Peak FMD results from the NaN02 pre-conditioning protocol. Mean data (top 
graph) and individual data (bottom graphs) is presented. * p<0.01.
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S.3.3.4. The haemodynamic response to the study infusion
In section 3.3.6 (page 94) it was demonstrated that the same dose of NaNC>2 as used 
in this chapter had no effect upon FBF when delivered intravenously in a normoxic 
environment. To confirm this finding brachial arterial diameter, HR and blood pressure 
were recorded at the start and end of the twenty minute study-infusion period in the 
NaNC>2 pre-conditioning protocol.; the results o f which are reported in Table 5-7 (below).
No change was observed with any o f these variables as a result o f the infusion of 
either 0.9% saline or NaNC>2 . This result reiterates the fact that the infusion regime of 
NaNC>2 used in the current study does not have an appreciable dilator effect upon 
normoxic vasculature.
Control NaNOz
Variable Start End P value Start End P value
Arterial 
diameter (mm) 3.8 ± 0.3 3.8 ±0.3 ns 3.9 ± 0.3 3.9 ± 0.3 ns
Heart rate 
(/min) 63 ±2 61 ± 2 ns 62 ±3
59 ±2 ns
Blood pressure 118/72 ± 118/72 ± ns 113/69 ± 114/69 ± ns
(mmHg) 3/4 6/4 2 / 2 3/1
Table 5-7: Arterial diameter, HR and peripheral blood pressure at the start and end of the 
twenty minute study-infusion period during both visits of the NaN0 2  pre-conditioning 
protocol. (n=7). Statistical comparisons are made by paired t-test.
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5.3.4. NaNCh post-conditioning protocol
5.3.4.I. Subject demographics
Table 5-8 (below) is a summary o f the demographic data o f the subjects who 
participated in the N aN 02 post-conditioning protocol.
Demographic
Number 9
Age (years) 26.1 ± 1.8
Male /  Female 5 /4
Weight (kg) 71.3 ±5.0
BMI 24.1 ± 1.3
Table 5-8: Summary demographics for participants in the NaN02 post-conditioning 
protocol.
S.3.4.2. FMD measurement variability
Table 5-9 (page 173) is a summary o f the variables measured during each FMD 
recording at each visit o f the N aN 02 post-conditioning protocol. All variables remained 
constant within each visit, apart from systolic blood pressure which fell by approximately 
6 % at both visits. Importantly, there was no difference in baseline arterial diameter or 
flow stimulus during each FMD measurement within each visit.
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Control NaN02
Variable FMD 1 FMD 2 P value FMD 1 FMD 2 P value
Room
Temperature (°C)
23.7 ±0.2
Not
recorded
n/a
23.8 ± 
0.2
Not
recorded
n/a
Skin
28.9 ± 1.0
Not n/a
28.2 ± Not
n/a
Temperature (°C) recorded 1.2 recorded
Baseline diameter 
(mm) 3.4 ±0.2 3.5 ±0.2 ns
3.4 ± 0.2 3.5 ±0.2 ns
Baseline VTI 0.046 ± 0.044 ±
ns
0.042 ± 0.039 ±
ns
(cm/s) 0.005 0.005 0.002 0.003
Flow stimulus (%) 764 ± 55 768 ± 41 ns 829 ± 59 868 ± 47 ns
Baseline heart 
rate (/min)
63 ± 2 61 ± 2 ns 61 ± 2 59 ± 2 ns
Baseline blood 121/74 ± 114/73 ± <0.05 * 118/75
112/74 ±
<0.05 *
pressure (mmHg) 3/3 5/3 ± 4 /3 4/2
Table 5-9: Summary of the key stimulus and environment variables within each visit of 
the NaN02 post-conditioning protocol. Comparisons are m ade between the two FMD 
measurements perform ed during each visit using paired t-test. * Difference in systolic BP 
only.
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5.3.4.3. IR injury
Similar to the NC1NO2 pre-conditioning protocol, the percentage FMD was reduced 
by approximately 40% as a result of IR exposure during the control visit (FMD 1 = 8 . 6  ± 
0.6% vs FMD 2 = 5.6 ± 1.0%; p <0.05). However, unlike with the previous study, the 
same difference was observed at the NaNC>2 visit (FMD 1 = 7.5 ± 0.5% vs FMD 2 = 4.4 ± 
0.5%; p<0.05). These results are displayed in Figure 5-8 (below).
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Figure 5-8: Peak FMD results for the NaN02 post-conditioning protocol. Mean data (top 
graph) and individual data (bottom graph) is shown. * p<0.05.
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5,3.5. Summary of the ischaemic conditioning effects of NaNOi
Figure 5-9 (below) is a summary graph of the two IR protocols performed in this 
chapter. The degree of endothelial dysfunction caused by the IR stimulus is displayed on 
the y axis (i.e. FMD 2 -  FMD 1). A similar amount of damage was produced in the two 
control groups and the IPostC/NaN02 group (i.e. IPC/saline = 2.9 ± 0.9%, IPostC/saline 
= 3.0 ± 0.9% and IPostC/NaN02 = 3.2 ± 0 .6 %; p>0.05 for all comparisons). However, the 
degree of damage present in all three of these groups was greater than that found in the 
IPC/NaN02 protocol (0.7 ± 0.5%; p<0.01 for all comparisons).
Taken together these results suggest that a low-dose iv infusion of NaNC>2 can act as
1 i o z :
an ischaemic pre-conditioning agent, as would be expected from the literature ’ 
However the same regime of NaNC>2 does not appear capable of acting as an ischaemic 
post-conditioning agent.
IPC study IPostC study
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Figure 5-9: Summary graph detailing the degree of endothelial dysfunction produced as a 
result of the two IR protocols performed in this chapter. * p<0.01.
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5.3.5.I. Analysis of pH /  SaCh peri-ischaemia
The peri-ischaemia profiles o f forearm venous blood pH and SaC>2 are reported in 
Table 5-10 (below). Venous SaC^ reduced as a result of twenty minutes exposure to 
ischaemia. At one minute into reperfusion it was increased compared to baseline, typical 
of the reduced O2 extraction per cardiac cycle which results from reactive hyperaemia146. 
After twenty minutes reperfusion venous SaC>2 had returned to a value not different to that 
recorded at baseline. Venous blood pH did not alter at any point during the protocol.
Protocol
stage Sa02
P value 
(vs baseline) pH
P value 
(vs baseline)
Baseline 71.5 ±7.2 n/a 7.34 ± 0.02 n/a
20 minutes 50.9 ± 5.8 <0.05 7.34 ± 0.02 ns
+1 minute 87.1 ±2.8 <0.05 7.34 ± 0.02 ns
+ 20 minute 65.0 ± 8.2 ns 7.37 ± 0.03 ns
Table 5-10: Venous pH and Sa02 of the ischaemic forearm during the IR protocol.
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5.3.6. Subsequent analysis: Does NaNCh vasodilate during early 
reperfusion?
Motivated by the previous results in this chapter further analysis was performed to 
investigate whether the regime of NaNC>2 given exhibited any vasodilator activity 
immediately upon entry into a recently ischaemic vascular bed. The brachial arterial 
diameter, recorded every three seconds during the first five minutes of the reperfusion 
phase of the NaN02 post-conditioning protocol, was analysed. If the effects of NaNC>2 
were being potentiated by the ischaemic vascular bed (e.g. via conversion to NO) then it 
would be expected that the brachial arterial diameter would be greater in the early 
reperfusion phase during the active (NaN02) visit compared to the control (0.9% saline) 
visit. Figure 5-10 (below) details the three variables of arterial diameter measured from 
the profile obtained.
Reperfusion Time
Cuff release
Figure 5-10: Brachial arterial diameter profile during the first five minutes of the 
reperfusion phase. Three different parameters were measured: 1. Peak increase in 
diameter. 2. Increase in diameter at five minutes. 3. Area under curve of the increase in 
arterial diameter over the initial five minutes. The first two values are expressed as a 
percentage increase in size relative to the baseline diameter reading taken immediately 
before the twenty minute ischaemic period.
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5.3.6.I. Results
Figure 5-11 and Table 5-11 (both on page 179) demonstrate that no difference was 
present in the arterial diameter profile recorded during the reperfusion phase o f each visit 
of the NaNC>2 post-conditioning protocol. This data suggests that NaNC>2 was not being 
converted to NO in this model; evidence that may explain why NaN0 2  was not an 
effective post-conditioning agent when used in this chapter.
It is possible that the brachial artery was maximally dilated as a result of the large 
flow stimulus created by the preceding twenty minutes o f arm ischaemia. However, 
although this argument may compromise the validity o f the peak diameter measurement it 
should be noted that no difference was present between the other two parameters 
measured. Furthermore, comparison between the FMD 1 peak increases in arterial 
diameter in the two branches of the NaN0 2  pre-conditioning study showed a similar result 
(control = 6 . 8  ± 0.7% vs NaNC>2 = 5.9 ± 0.7%; p=ns). This final comparison is between 
five minutes o f forearm ischaemia with or without an infusion of NaNC>2 immediately 
preceding.
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Figure 5-11: Profile of the brachial arterial diameter during the first five minutes of 
reperfusion in the NaN02 post-conditioning protocol.
Variable Control NaNOz P value
1. % A peak 20.7 ±1.4 21.9 ±1.6 ns
2. % A 5min 13.4 ±1.0 12.8 ±1.5 ns
3. 5min AUC (mm.s) 93.7 ±5.0 92.1 ±5.2 ns
Table 5-11: Summary measurements of the arterial diameter profile in the early 
reperfusion phase of the NaN02 post-conditioning protocol. Statistical comparisons are 
made using paired t-test.
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5.3.7. Variability of measures employed
Thirty paired readings, chosen at random, o f the four key measures employed in this 
chapter were used to determine their intra-observer reproducibility. The results of these 
analyses are reported in Table 5-12 (below) and Figure 5-12 (page 181). The coefficient 
of variation was calculated using the method described in section 3.3.9 (page 101).
Mean value 
explored
Bland-Altman Coefficient
Measure r2 analysis: 
Bias (95% Cl)
of Variation 
{%)
Baseline diameter 
(mm) 3.81 0.98
-0 . 0 0 1  
(-0.17 to 0.17)
1 . 6
Baseline flow VTI 0.050 0.89 -0 . 0 0 0 2 7.5(cm/s) (-0 . 0 1 1  to 0 .0 1 0 )
Flow stimulus (%) 710 0.82
-24 
(-224 to 178) 1 0 . 0
FMD (%) 5.61 0 . 8 6 -0 . 1 1  (-2.02 to 1.79) 1 2 . 2
Table 5-12: Summary of the intra-observer variability of the four key indices reported in 
chapter 5.
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Figure 5-12: Correlation and Bland-Altman intra-observer analyses o f the four key indices 
reported in chapter 5. Panels: A -  basal diam eter; B -  basal flow, C - f lo w  stimulus, D -  
FMD.
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5.4.1. Plasma [NO2 ] increases in response to RIPC
The stimulus o f RIPC caused venous plasma [NO2 ] to increase over a four hour 
time period. An increase in venous plasma [NO2 ] has previously been proposed to be a 
marker o f enhanced eNOS activity87. The potential implications o f this finding are two­
fold: firstly as an insight into the process o f IPC and secondly as a simple test of 
endothelial functional reserve.
The profile o f plasma [NO2’] after RIPC appears similar in temporal nature to the 
early window o f tissue protection from IR injury which this stimulus also affords185. 
However, in itself this is a simple observation of an association and not a proof of 
mechanism. It is therefore not possible to state from the data in this chapter that an 
increase in plasma [NO2’] is an essential part o f the IPC process. Indeed, the more likely 
conclusion is that an increase in plasma [NO2’] is a shadow of an increase in NO 
production, which as previously stated in section 1 .6 .4  (page 4 7 ), is known to be an 
important component o f the IPC cascade.
Venous plasma [NO2'] has been reported by Rassaf to increase acutely (i.e. within
1 80
3 0  seconds) after cuff deflation during an FMD measurement . This study also noted a 
close relationship between the profile o f brachial arterial diameter and plasma [NO2 ] 
during FMD measurement. This similarity extended across patient groups, with the 
brachial arterial diameter and plasma [NO2 ] response to FMD measurement being 
blunted in subjects with multiple cardiac risk factors. The authors proposed that the 
profile o f plasma [NO2'] produced during FMD measurement is a marker of eNOS 
activity and endothelial function. However, although a correlation is clearly present in this 
study it is not certain that the difference in plasma [NO2’] across patients groups is 
directly caused by a decrease in eNOS activity. It is also possible that the change in
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plasma [NO2 ] observed is due to a reapportionment o f NO metabolites as the blood 
oxygenation state alters; a principle explained in section 1.4 .4  (page 18). Specifically, 
immediately upon cuff deflation the forearm experiences a hyperaemic state. This will 
result in a decrease in O2 extraction per cardiac cycle and an increase in venous Sa02146, 
as demonstrated in this chapter. Correspondingly, plasma [NO2'] levels will increase in 
proportion to the degree o f reactive hyperaemia present. It therefore follows that a subject 
with an attenuated FMD response will experience less forearm hyperaemia and 
correspondingly a blunted increase in plasma [NO2 ] levels. These acute changes in 
plasma [NO2'] are therefore independent o f eNOS production o f NO.
The present study is o f a different design to that o f Rassaf in several important ways. 
Firstly, a five minute reperfusion period is present prior to the first plasma [NO2'] 
measure. Secondly, a longer time period is profiled following cuff deflation, one remote 
from the effects o f reactive hyperaemia. Consequently the increase in plasma [NO2'] 
observed is more in keeping with enhanced eNOS-associated NO-production, as the shear 
stress o f RIPC was the only stimulus placed upon plasma [NO2 ] levels in this fasted 
model. However, in order to confirm that the source o f raised plasma [NO2 ] is eNOS 
derived this study would have to be repeated in the presence o f L-NMMA.
The RIPC protocol is therefore a potential ‘endothelial stress te s t’; a means of 
assessing endothelial function which could require substantially less technical expertise 
than FMD measurement. Furthermore, although it has previously been proposed that an 
isolated measure o f venous plasma [NO2’] reflects an adverse cardiovascular risk 
profile190, it is uncertain as to whether a raised189 or lowered191 level is abnormal. This 
conflicting data in the literature probably reflects the measurement o f plasma [NO2 ] in 
both compensated and decompensated disease states. However, this problem could be
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avoided if  instead o f looking at the absolute level o f plasma [NO2’], the delta increase 
after a fixed physiological stimulation is analysed.
5.4.2. Limitations of the forearm model of IR injury
Tight control o f forearm physiology was achieved within each visit in the two 
protocols in this chapter where transient forearm IR injury was created. In particular, both 
the baseline arterial diameter and percentage flow stimulus were similar for each FMD 
reading. It was also shown that the infusion regime o f NaNC>2 administered had no effect 
upon systemic haemodynamics or brachial arterial diameter. Taken together, these 
observations confirm that the only stimulus responsible for any difference present 
between the two FMD measures performed at each visit was the intervening IR period.
Surprisingly, in the stage o f  damage protocol a decrease in FMD was noted simply 
upon its repetition forty minutes after being initially performed. One previous study has 
reported that FMD does not alter when repeated in the same subject after intervals of 30,
1 Q?60 and 120 minutes . It is uncertain why the data reported in this chapter is different to 
this study. It is possible that the difference presently observed was related to different 
environmental conditions (i.e. skin temperature) between the two FMD measures 
performed in that specific protocol.
However, it is important to state that the results o f the stage o f damage protocol do 
not interfere with the original aims o f this chapter. In particular a reproducible model of 
ER injury was created and systemic iv NaN (> 2  was administered into this model at a stage 
before any injury had occurred; in order to assess whether a pre-conditioning effect could 
be produced. Also, even if  performing a single FMD measurement caused a degree of 
endothelial dysfunction (stage o f damage protocol: FMD 1 minus FMD 2 = approx. 2%), 
additional damage was produced in the IR control protocols (FMD 1 minus FMD 2 =
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approx. 3%). This latter value was not affected by the addition o f NaNC>2 as a post­
conditioning agent.
5.4.3. NaN02 is a pre-conditioning but not a post-conditioning agent
In this chapter iv NaNC>2 delivered at a low-dose, one which approximately doubles 
plasma [NCV] to a level similar to that achieved with RIPC, had a pre-conditioning effect 
upon ischaemic tissue. However, the same regime of NaNC>2 when delivered as a post­
conditioning agent did not confer a similar benefit. This result is different to that 
previously reported by Gonzalez187, who showed that NaNC^ could act as a post­
conditioning agent in a canine model o f acute MI. However, it is a result in keeping with 
those reported in chapter 3 o f this thesis. In particular this finding confirms that 
favourable environmental conditions are required for bioactivity of low-dose N (V  to be 
observed (i.e. hypoxia or ischaemia).
Gonzalez reported that NaNC>2, given systemically during the final five minutes of a 
sixty minute coronary artery ligation protocol, reduced myocardial IR injury. A high-dose 
o f NaNC>2 was used; one associated with a thirty-fold increase o f plasma [NO2 ] to 
6pmol/l. It is therefore possible that the dose o f NaN02 used in the current study was too 
low. However, this is unlikely for two reasons. Firstly, it has previously been reported that 
doses o f NaNC>2 similar to those used in this chapter are effective pre-conditioning
•I
agents ; and secondly it is known that a timely administered post-conditioning stimulus 
confers a similar degree o f tissue protection to that observed after an IPC stimulus106.
An alternative explanation for the success o f NaNC>2 as a post-conditioning agent in 
the Gonzalez model could be that systemically administered NaN02 was absorbed, before 
the reperfusion phase, from within the left ventricular cavity into the ischaemic portion of 
myocardium. An increased level o f myocardial tissue NO2" would have therefore been 
present peri-ischaemia. Consequently, this tissue-located NO2’ would have been exposed
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to an ischaemic environment; thus favouring its bioconversion to NO. It follows that 
NaN0 2  was not tested as a pure post-conditioning agent in the Gonzalez study. 
Contrastingly, the model o f IR injury used in this thesis was able to avoid this problem 
and assess NaN0 2  as a pure post-conditioning agent.
In summary, in order for NaN0 2  to produce an ischaemic-conditioning effect it most 
likely first requires reduction to NO125. This is in contrast to the hypoxic-vasodilator 
effects o f NaNC>2 which are still present (though reduced) in the presence o f the NO 
scavenger CPTIO84. Reduction o f NO2' to NO is favoured in ischaemic tissue193, and if  
NaN0 2  is present within tissue at this time then a beneficial effect can be observed (i.e. a 
pre-conditioning effect). However, upon reperfusion the favourable substrates for NO2’ 
reduction associated with an ischaemic environment will rapidly reduce. It follows that 
conversion will not be favoured at that time and NaN0 2  will not be effective as a post­
conditioning agent. This theory is supported by a recent study which demonstrates the 
critical role o f the tissue-based enzyme myoglobin in NCV-associated protection from IR 
injury124. Figure 5-13 (page 187) is a summary diagram of this potential mechanism of 
action.
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Figure 5-13: The potential mechanism behind the presence of a pre-conditioning but lack 
of a post-conditioning effect of NaN02. When given prior to an ischaemic insult N02 has 
time to equilibrate with the surrounding tissue, from where it is reduced to NO by the 
favourable environment of ischaemia. This increase in NO in turn promotes the ischaemic 
conditioning cascade. However, when NaN02 administration is delayed until the 
reperfusion phase the associated hyperaemia present discourages its transit to the 
surrounding tissue. In addition, the recovery of the ischaemic environment reduces the 
substrate available to reduce N02' to NO. As a result of these two hostile factors a 
beneficial effect of NaN02 administration is not observed in the post-conditioning setting.
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5.4.4. A clinical appreciation of the results 
Both the model o f forearm IR injury used in this chapter and the animal model of 
myocardial IR injury used by Gonzalez110 have design limitations which restrict the 
interpretation o f their results. Each is inferior to a well conducted randomised controlled 
trial performed in patients. However, it is important not to discount the potential insights 
which can be gained from these studies. In particular, the results o f this chapter raise 
concerns regarding the efficiency o f NaNC>2 as a post-conditioning agent. This 
observation is pertinent as a large scale clinical trial is currently underway, designed to 
investigate the post-conditioning role o f NaN0 2  in acute myocardial infarction194.
A proportion o f patients undergoing acute primary PCI to treat a MI will have 
reperfused their coronary vasculature at the time of initial imaging. This is a result of 
early antiplatelet treatment195 and the endogenously production of the lytic agent tPA196. 
Furthermore the effect o f a post-conditioning stimulus is lost if  it is not administered 
within 10 min o f reperfusion114. Whilst these caveats are applicable to any post­
conditioning agent they assume a greater importance when considering NaN0 2 , as this 
agent appears to require an initial ischaemic environment to exhibit an effect, possible via 
bioconversion to NO.
Therefore, it can be predicted that NaN0 2  should be a clinically effective IPC agent. 
However, its translation into an ischaemic post-conditioning agent is less certain. Several 
other promising ischaemic-conditioning agents investigated in the past have failed to
1 07translate sound laboratory findings into a measurable clinical benefit . These previous 
disappointing results are due to a number o f reasons. Firstly, the process o f post­
conditioning is only capable o f limiting infarct size when the occlusion time has been less 
than 45 minutes198. Secondly, only large MI provide enough tissue at risk to demonstrate 
a convincing mortality/morbidity benefit with the use o f post-conditioning agents199.
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Therefore surrogate end-points are often reported (e.g. AUC o f a 48-hour plasma 
creatinine kinase profile200) in order to observe a statistically significant benefit; but 
obfuscating the advantages gained by performing a RCT in patients. Thirdly, the process 
of ischaemic-conditioning becomes less effective with increasing age201 or in diseased 
states such as DM or heart failure202. Unfortunately, patients who fulfil these criteria are 
at an increased risk o f a MI and are therefore well represented in clinical trials. Lastly, 
conventional pharmacological treatment of a MI (e.g. morphine, aspirin and GTN) may 
itself inadvertently trigger a conditioning response197. It follows that any available benefit 
to patients in the form o f ischaemic-conditioning may already be conferred through best 
current medical practice.
In summary the data presented in this thesis would suggest that, despite the previous 
publication o f promising laboratory studies, low-dose NaNC>2 may not be an effective 
post-conditioning agent when utilized in a clinically relevant model (e.g. peri-MI).
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1. Plasma [N02’J increases over a four-hour period following RIPC, 
probably as a result of enhanced eNOS activity.
2. A low-dose iv infusion of NaN02 protects against forearm IR injury when 
administered as a pre-conditioning but not a post-conditioning agent.
3. The exposure of an ischaemic vascular bed to a modest increase in 
plasma [N02‘] at the point of reperfusion does not result in conduit 
vessel vasodilatation.
Page | 190
C h a p t e r  6 P i l o t  s t u d y
Chapter 6: Pilot study
6.1. NO2' associated myocardial protection in CABG patients
Chapter 5 o f this thesis demonstrated that NaNC>2 is an IPC agent. Patients 
undergoing on-pump coronary artery bypass grafting (CABG) would be ideal recipients 
o f such a protective mechanism, as this surgical procedure is associated with a significant 
reperfusion injury to myocardial tissue203. This insult occurs as a result o f cardioplegia 
associated cardiac arrest; a process whereby the heart is stopped by perfusion o f a 
cardioplegia solution (e.g. St. Thomas’s solution) and the patient’s circulation is switched 
to an external cardio-pulmonary bypass machine (i.e. on-pump)204. This is a necessary 
stage o f the operation as it enables the surgeon to create anastomoses between the 
diseased coronary arteries and the bypass grafts. Pre-treatment of cardiac tissue with 
NaNC>2 (i.e. by supplementation o f the cardioplegia solution) could potentially reduce the 
degree o f myocardial injury that occurs during on-pump CABG surgery.
6.1.1. Study design
To investigate this potential therapeutic use of NaNC>2 a pilot study to ascertain 
plasma [NO2’] levels peri-CABG surgery was undertaken in six patients undergoing on- 
pump CABG surgery for the treatment o f significant coronary arterial atherosclerotic 
disease at the University Hospital o f Wales. All patients received a cardioplegia solution 
consisting o f a 4:1 mix o f blood:crystalloid-cardioplegia; a treatment known to be 
superior to the use o f crystalloid-cardioplegia alone205. The crystalloid-cardioplegia 
solution used was a diluted mixture (i.e. 30ml in 500ml o f 0.9% saline) o f sterile 
concentrate fo r  cardioplegia (also known as St. Thomas’s solution), from Martindale 
pharmaceuticals, Essex, UK. Two samples were obtained from each subject: one of
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arterial blood and the other o f the blood/crystalloid cardioplegia solution. Both were taken 
simultaneously, immediately prior to the administration o f cardioplegia to the heart.
6.1.2. Results
The individual levels o f plasma [NO2 ] measured in each subject are shown in 
Table 6-1 (below). The results o f this pilot study were surprising, as they demonstrated 
that the addition o f dilute sterile concentrate fo r cardioplegia to whole blood increased 
plasma [NO2’] in the resulting mixture (i.e. untreated blood = 180.7 ± 50.2nmol/l vs. 
blood/crystalloid cardioplegia = 338.3 ± 75.3nmol/l; p <0.05, paired t-test). This increase 
(approximately +160nmol/l) occurred despite the concentration of [NO2 ] in dilute sterile 
concentrate fo r  cardioplegia being only 56nmol/l; suggesting that simple NO2’ donation 
from crystalloid-cardioplegia was not the mechanism responsible for the observed 
difference.
Patient
number
Untreated blood 
(nmol/l)
Blood + crystalloid- 
cardioplegia (nmol/l)
1. 113 151
2. 182 309
3. 129 540
4. 321 540
5. 325 378
6. 14 112
Table 6-1: The individual levels of plasma [N02'] present in the two samples taken from 
each of the six subjects analysed in this pilot study.
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6.2. Additional laboratory based pilot work 
To investigate the results o f the previous pilot study further an additional 
laboratory-based pilot study was performed. The aim o f this experiment was to create in- 
vitro the same two samples obtained in the patient pilot study and analyse their plasma 
[NO2’] and total-erythrocyte [NOx] levels. Total-erythrocyte [NOx] was measured as it is 
a marker o f all NO metabolites present within the erythrocyte140 (i.e. erythrocyte- 
associated NO2’ and Hb-bound NO). This was chosen over the measurement o f  
erythrocyte [NO2’] because the latter was insensitive to detecting changes following 
NaN0 2  infusion in chapter 3 o f this thesis. Venous blood samples from ten healthy 
individuals were mixed 4:1 with the same dilute sterile concentrate fo r  cardioplegia 
solution as used in the previous section. Plasma [NO2 ] and total-erythrocyte [NOx] of 
both the venous blood and the laboratory-prepared blood/cardioplegia solution were 
measured.
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6.2.1. Results
The results of this experiment are shown in Figure 6-1, (below). This data 
replicated the findings of the first study, demonstrating that plasma [NO2 ] increases with 
the addition of a crystalloid-cardioplegia solution (untreated blood = 79.3 ± 17.7nmol/l 
vs. blood/crystalloid cardioplegia = 123.2 ± 14.9nmol/l; p <0.05, paired t-test). In 
addition, total-erythrocyte [NOx] was lower in the blood/cardioplegia sample than the 
untreated blood sample (untreated blood = 134.8 ± 17.9nmol/l vs blood/crystalloid 
cardioplegia = 105.2 ± 13.4nmol/l; p <0.05, paired t-test).
plasma [N02 ] total-erythrocyte [NOx]
H i  Untreated blood Hi Blood/cardioplegia mix
Figure 6-1: The relationship of plasma [N02] and total-erythrocyte [NOx] in the 
laboratory pilot study. N=10. # p<0.05.
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6.3. Discussion
The pilot data presented in this chapter demonstrates that the addition o f  
crystalloid-cardioplegia to whole blood results in a partial redistribution of NO 
metabolites from within the erythrocyte into plasma.
6.3.1. The redistribution of NO metabolites
One possible explanation behind the redistribution o f NO2' observed in this pilot 
study, from the intra- to the extra-erythrocyte compartment, could lie in the composition 
of the dilute sterile concentrate for cardioplegia solution. This preparation contains a 
high concentration o f anions, in particular Cl* ions (see Table 6-2, page 196). The normal 
plasma level o f [Cl*] is approximately 70mmol/l and the normal intra-erythrocyte 
concentration approximately 100mmol/l . Therefore, the addition of approximately 
60mmol/l o f Cl* to the system (i.e. blood mixed 4:1 with dilute sterile concentrate for  
cardioplegia (total concentration CT = 305mM)) will disrupt this equilibrium and 
osmosis will prompt the redistribution of Cl* ions from plasma to inside the erythrocyte. 
Transit o f Cl* ions across the erythrocyte membrane will occur via AE1 with the 
concomitant exchange o f both HCO3* and NO2’ into plasma, (see section 1.4.1 .2 .1 , page 
1 1 ). This exchange will result in an increase in plasma [NO2"] levels in the 
blood/cardioplegia solution.
In addition, cardioplegia also contains the local anaesthetic agent procaine 
hydrochloride. This is a sodium channel inhibitor166, but it also stimulates the release of 
K+ from within the erythrocyte207. It is possible that this release o f cations by the 
erythrocyte is associated with a concomitant loss of anions; perhaps intra-erythrocytic 
NO2*. The precise mechanism of the observed NO2’ release from erythrocytes 
demonstrated in this chapter is unknown, but certainly warrants further investigation.
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Content Concentration in diluted solution (30ml neat solution in 500ml 0.9% saline)
MgCI2 130 mmol/l
KCI 45 mmol/l
Table 6-2: Composition of the 'sterile concentration for cardioplegia' diluted solution. In 
addition this product also contains: procaine hydrochloride, disodium edetate, sodium 
hydroxide and water.
6.3.2. The beneficial effects of blood/crystalloid cardioplegia
In summary, the beneficial effects observed in CABG patients treated with a 
blood/crystalloid cardioplegia solution may be due to an increase in the level o f plasma 
[NO2"] present in the blood/crystalloid-cardioplegia solution compared to arterial blood or 
crystalloid-cardioplegia alone. This effective NO2’ supplementation o f the cardioplegia 
solution would result in an increase in myocardial tissue [NO2 ] levels immediately prior 
to the onset of ischaemia; a process which could potentially act as an IPC stimulus. 
Whether further supplementation of NO2' levels above those achieved by this process 
would confer an additional benefit to patients is unknown. Recent literature would 
suggest that this was possible. It has been shown that RIPC, administered after 
anaesthesia and in addition to blood/crystalloid cardioplegia, has a beneficial effect upon 
patients in terms o f their serum troponin-t AUC profile in the first 72 hours after 
surgery208. Chapter 5 o f this thesis demonstrated that the process o f RIPC is associated 
with an increase in plasma [NO2 ] levels. Interestingly, the increase in plasma [NO2 ] 
observed in patients in this pilot study with the addition o f cardioplegia solution to blood 
(i.e. +160nmol/l) is similar in magnitude to that recorded after RIPC in chapter 5 (i.e. 
+135nmol/l) and following low-dose iv NaN0 2  infusion in chapter 3 (i.e. +200nmol/l).
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Chapter 7: General Discussion and Future Directions
The BHF Clinical Research Training Fellowship which formed the foundation of 
this thesis was conceived to investigate the effect of NO2’ supplementation in man in 
different environments; created by either deliberate modification in healthy subjects (i.e. 
hypoxia or simulated forearm ischaemia) or the presence of underlying pathology (i.e. 
inducible myocardial ischaemia). The work was motivated by experimental literature 
suggesting that NO2* has enhanced biological activity in altered environments which 
promote its reduction to NO (i.e. hypoxia or ischaemia)80,82,83. The overall focus of this 
thesis was therefore to translate the results o f these promising laboratory and early human 
studies into models o f greater physiological and clinical relevance.
This thesis had two aims. The first was to examine whether the theory o f deoxy-Hb 
mediated NO2’ reduction was consistent with analysis of the biochemical and 
physiological changes which occur following iv NaNC>2 infusion in both hypoxia and 
normoxia to healthy human subjects. The second was to ascertain whether NaNC>2 is 
capable o f targeted therapeutic delivery in human pathological models o f inducible 
ischaemia and IR injury.
To achieve these goals a low-dose o f NaNC>2 was used throughout this thesis. This 
dose was chosen on the back of pilot studies performed by other groups at much higher 
doses; with the driving rationale being that a minimally effective dose should be aimed 
for. In chapter 3 of this thesis this dose is shown to only increase plasma [NO2 ] 
approximately two-fold. It is interesting to note that this degree o f increase in plasma 
[NO2'] is similar in magnitude to that observed after maximal stimulation of the 
endothelium by ACh . A low-dose infusion regime was important for two scientific 
reasons. Firstly, previous studies in man of NO2 ' supplementation have almost exclusively
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employed much higher doses o f NaNCV, resulting in a ten-fold or greater increase in
Q A  0 *1  Q Q
plasma [NO2 ] ’ ’ . Such high doses were chosen so that convincing physiological
changes could be demonstrated in normoxia. However, as a result subtle biochemical 
changes with important mechanistic insights have been missed; as outlined in Chapter 3. 
Secondly, in order to demonstrate that NaNCb is capable of targeted therapeutic delivery 
it was important to administer a dose o f NaNC>2 that did not display vasodilator activity in 
normoxic tissue. Therefore, any observed effects were a result of environmental 
modification (i.e. hypoxia or ischaemia) enhancing the bioactivity of NaNC>2 .
7.1. The key findings of this thesis 
In summary the key findings o f this thesis are:
• A low-dose infusion of NaNCb has an enhanced vasodilator effect upon the 
systemic and pulmonary circulations in man when given in hypoxia compared to 
normoxia. In addition, the mechanism of this finding is more in keeping with 
enhanced tissue-based NO2’ bioactivity (via tissue reductase enzymes, e.g. XO) 
than deoxy-Hb mediated reduction o f NO2" to NO. This mechanism is supported by 
the observations that (i) deoxy-Hb levels do not correlate with the pattern of 
induced vasodilation observed and (ii) a prolonged vasodilator effect was present in 
the pulmonary vasculature even after plasma [NO2*] levels had returned back to 
baseline.
• The same low-dose o f NaN0 2  is capable of reducing exertion-induced myocardial 
ischaemia in patients with known stable angina. This beneficial effect occurs 
despite no vasodilator activity being present in normoxic tissue; suggesting that 
low-dose NaNC>2 delivers a targeted therapeutic effect.
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•  Low-dose NaNC>2 is an IPC but not an IPostC agent when given in a forearm model 
of IR injury. These results imply that the presence o f NO2 ' in blood at reperfusion 
alone is not sufficient for an ischaemic conditioning effect to be observed. This 
discrepancy is due to the need for an augmented level o f NO2’ to be present within 
tissue prior to the onset o f ischaemia. Consequently, the altered environmental 
conditions which follow potentially allow bioconversion o f NO2 ' to NO, which in 
turn will initiate the molecular cascades o f pre-conditioning.
Two individual themes contained within these key findings warrant further 
discussion. Firstly the importance o f tissue NO2 ’ levels when considering the biochemical 
and physiological effects o f NO2' supplementation and secondly the potential role of 
NaN0 2  as a therapeutic agent in different pathological situations.
7.2. The pharmacokinetics of NaNCh - the forgotten element 
One o f the principle results o f this thesis is the important role that NO2’ has outside 
of the intravascular compartment (i.e. the intracellular or interstitial spaces). Chapter 3 
demonstrated that, following an iv infusion o f NaNC>2 , a similar profile o f plasma [NO2’] 
was present in both normoxia and hypoxia but only the latter environment was associated 
with a measurable vasodilator effect. Furthermore, vasodilation persisted in the hypoxic 
pulmonary circulation at a time when plasma [NO2"] levels had returned to a level similar 
to baseline. Chapter 5 also showed that in order for low-dose NaN0 2  to exhibit an 
ischaemic conditioning effect it needs to be delivered prior to the onset o f IR injury; again 
stressing the importance o f tissue [NO2 ’] levels. These observations are supported by a 
study which shows that NO2* rapidly equilibrates across all fluid spaces of the body 
within 5 minutes o f its infusion43, with the exception of transit into the erythrocyte which 
is slower42.
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Previous publications have reported gradients o f plasma [NO2'] across a single 
vascular bed from artery to vein, either at rest74 or following NaNC>2 infusion80. These 
gradients, combined with physiological changes also present in these models, have been 
used as evidence in support o f the deoxy-Hb mediated NO2’ reduction theory o f enhanced 
NO2 ' activity in hypoxia. However, consumption o f NO2’ is only one o f three potential 
routes by which plasma [NO2 ] can be removed from the intravascular space. These three 
potential routes are:
1. Redistribution o f NO2' within the vasculature to other, inert, products (e.g. HbNO or 
NO3'), with no overall change in total NO metabolite levels.
2. Redistribution o f NO2’ by diffusion to the intracellular and interstitial spaces.
3. Conversion o f NO2" to NO, or another compound within the vasculature, resulting in 
a measurable NO-type effect.
This thesis illustrates the importance o f the second route o f NO2’ loss from the intra­
vascular compartment. Specifically, during both hypoxia and normoxia tissue uptake of 
infused NO2' is likely to be the same (hence the similar profiles of plasma [NO2"] in both 
hypoxia and normoxia shown in chapter 3). However, hypoxic tissue will utilise this NO2" 
differently. Therefore, the results o f this thesis do not detract from the observation that 
NO2’ is a vasodilator whose effects are potentiated by hypoxia; however they do raise 
concerns that this process is not due to deoxy-Hb mediated reduction of NO2' to NO. It is 
therefore likely that, when one considers the bioactivity o f NO2’, tissue [NO2'] levels are 
more important than plasma [NO2’] levels. This point is illustrated by comparison of the 
results o f this thesis to two human studies where oral NO3' has been used as a means to 
increase plasma [NO2’] levels.
Dietary supplementation with NO3 ' for three days reduced diastolic blood pressure 
by 3.7 mmHg40, with a comparable increase in plasma [NO2"] levels to that achieved in
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this thesis. In addition, a second study reported a similar reduction in both systolic and 
diastolic blood pressure three hours after a thirty minute period of oral ingestion of foods 
rich in NO3"186. Here, again, a comparable plasma [NO2 ] level was reached to that 
reported in this thesis. In both o f these studies a large (mmol) dose o f NO3' was given 
which was gradually absorbed from the recipient’s stomach. This led to a sustained 
elevation o f plasma [NO2’] levels over a longer period than that used in this thesis. 
Consequently a large proportion o f NCV would have been absorbed into the surrounding 
tissue in these studies, probably achieving sufficient tissue NO2’ levels to exert a 
vasodilator effect despite the normoxic environment. This explanation is supported by a 
different in-vivo study where an intra-arterial NaN0 2  infusion was given; here no 
vasodilator effect o f NaNC>2 was present in normoxia at doses greater than those used in 
this thesis89.
In summary, the measurement o f plasma [NO2'] alone is not a true marker of total 
body [NOT] as it disregards the presence o f NO2* in the body’s other fluid compartments. 
In addition, the observation that changes in plasma [NO2'] levels do not always concur 
with physiological changes suggests that extravascular NO2’ is an important source o f 
N 0 2' associated bioactivity. Importantly, this conclusion does not detract from the 
prospect that administration o f NaN0 2  to patients, to boost their tissue levels o f NO2", will 
be o f benefit in situation where the tissue-environment has been modified by either 
hypoxia or ischaemia.
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7.3. The clinical implications of NaNCh
This thesis has demonstrated that low-dose NaNC>2 is capable o f exerting a 
therapeutic effect in human models of: hypoxia, hypoxic pulmonary vasoconstriction, 
myocardial ischaemia and forearm IR injury. However an appreciation of the 
biochemistry o f NaNC>2 activity is essential if  its use as a therapeutic agent is to be 
matched with those pathologies where it is most likely to be of benefit.
7.3.1. Pulmonary hypertension
In light o f the prolonged effect on the pulmonary circulation shown in chapter 3, 
NaNC>2 may be particularly effective in the treatment o f pulmonary hypertension. One 
limitation to this could be that the aetiology o f pulmonary hypertension is often structural, 
rather than functional, and therefore some patients may not respond to the selective 
pulmonary vasodilator effect o f NaN0 2 . However, current therapies for pulmonary 
hypertension include vasodilators (such as nifedipine) which are known to help only a 
minority o f patients209. Nonetheless, it is standard practice to test whether patients 
respond to vasodilators2 1 0  and future studies would allow NaN0 2  to find its position 
alongside established therapies. Interestingly, the enhanced vasoconstriction specific to 
high altitude pulmonary oedema might also respond very well to NaNCb-
7.3.2. The modulation of ischaemic environments
It appears essential that NaNCh be present within tissue before the onset o f an 
ischaemic event for the maximum beneficial effect to be achieved. This makes NaNC>2 
more suited to use as a prophylactic agent for the treatment o f stable ischaemic symptoms 
(i.e. stable angina) or the prevention o f damage due to a predictable acute ischaemic event 
(i.e. as an IPC stimulus before elective surgery). However, the slow onset of action of 
NaNC>2 means that other NO-donor agents (e.g. organic nitrates) have a distinct
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therapeutic advantage when administered for the relief o f symptoms which are already 
present.
Little work has been performed on the in-vivo effects o f organic nitrates in hypoxia. 
One study has shown that their vasodilator effects are prolonged211. This would suggest 
that NaN0 2  could merely be the vehicle by which NO is provided to tissue and that any 
NO-donor drug would be equally effective. However, it must be recognized that in many 
of the pathologies where an increase in regional NO concentration would be desirable 
(such as MI, stroke or solid organ transplantation), the highly effective nature of even a 
low-dose o f organic nitrate could cause variability in blood pressure that would be 
undesirable. Consequently, the regime for the acute administration o f NaN0 2  suggested 
by this thesis could offer the therapeutic benefits o f local vasoactivity delivered to 
hypoxic tissue without systemic vascular collapse. In addition, the venoselective nature of 
NO2 ’ makes it especially suited to the treatment o f acute heart failure89; as the use o f iv 
organic nitrates in this setting, to reduce cardiac preload, is often limited by disabling 
systemic arterial vasodilation .
Lastly, it should be acknowledged that despite suggestions in the past that NO2' is a 
potential carcinogen212, more recent literature has not upheld this concern213. Also, 
previous studies have demonstrated that doses in excess o f those used in this thesis 
resulted in only a minor increase in met-Hb levels, which were not clinically significant90.
7.3.3. Dietary supplementation of NO2 '
Several studies have been published during the course of this thesis on the subject 
of dietary NO2’ therapy. Supplementation o f NO2', delivered via oral NO3', has been 
shown in man to reduce diastolic blood pressure40, protect against endothelial dysfunction
• • 1 9 A  • 1 QA
resulting from forearm IR injury , have an antiplatelet effect and reduce the O2 cost of 
exercise in healthy individuals214. In addition oral NO2' reduces myocardial IR injury in
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mice181. It should also be noted that the total NO2’ donation which results from oral NO2" 
administration is the same, though spread over a longer time period, than with iv NaNC>2 
use215.
Taking the above results together with the findings o f this thesis one can conclude 
that low-dose NaNC>2 is most suited to use as a long term oral supplementation agent. 
This mode o f therapeutic delivery capitalises on the relatively inert nature of NO2" in 
normoxia; augmenting the body’s pool of NO2’ as a potential reserve of NO-type effect, 
to be tapped into in the appropriate tissue compartment during times of need.
On a cautionary note long term augmentation o f the eNOS-NO axis with 1-arginine 
has been shown not to be beneficial, and perhaps harmful, to patients with peripheral 
vascular disease21 6 and post MI patients217. These results are complemented by studies 
detailed in section 4.4.2 (page 153) which show a similar lack o f beneficial effect 
observed in post MI patients given long term NO supplementation via organic nitrates 
therapy179, 180. However, there are important differences between these two drugs and 
low-dose NaN0 2 . Firstly, the effects o f 1-arginine will have been partly endothelial 
function dependent; a capacity which deteriorates with age and chronic disease218. 
Secondly, long term NO donation will result in an increase in a number o f different NO 
metabolites, including the potentially damaging molecule ONOO' (see section 1.4.1.3.2; 
page 14). By contrast, chronic NO donation should not be a feature o f oral NO2’ therapy 
and neither should its effect be dependent upon intact endothelial function. Instead low- 
dose NaN0 2  only provides an NO-type effect in times o f need. Therefore what 
historically has been considered to be the weakest feature o f NO2* pharmacology could in 
fact be its greatest asset.
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Publications related to this thesis
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dilates both peripheral and central vessels in hypoxia — a potential new therapy for  
ischaemia. Heart 2008;94(S2):A45-6.
• Ingram TE, Pinder AG, Milsom AB, Rogers SC, Thomas DE, James PE. Blood 
vessel specific vasoactivity to nitrite under normoxic and hypoxic conditions. The 35th 
meeting o f the International Society o f Oxygen Transport to Tissue. August 26-30. 
2007. Uppsala, Sweden.
• Ingram TE, Pinder AG, Pittaway E, Fraser AG, James PE. Nitrite-associated hypoxic 
vasodilatation in man: The pulmonary circulation is more susceptible to the 
vasodilator effects o f nitrite than the systemic circulation. Nitric oxide 
2008;19(S1);S38.
• Pinder AG, Ingram TE, Bailey DM, Fraser AG, James PE. Low dose systemic nitrite 
infusion to healthy human subjects in a hypoxic environmental chamber. Nitric Oxide 
2008;19(S1);S55.
Peer reviewed publications
• Ingram TE, Pinder AG, Milsom AB, Rogers SC, Thomas DE, James PE. Blood 
vessel specific vasoactivity to nitrite under normoxic and hypoxic conditions. 
Advances in Experimental Medicine & Biology 2009;645: 21-5.
• Ingram TE, Pinder AG, Bailey DM, Fraser AG, James PE. Low-dose sodium nitrite 
vasodilates hypoxic human pulmonary vasculature by a means which is not dependent 
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2010; 298:H331-9.
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Textbook chapters
• Pinder AG, Rogers SC, Khalatbari A, Ingram TE, James PE. The measurement of  
nitric oxide and its metabolites in biological samples by ozone-based 
chemiluminescence. In: Redox-Medicated Signal Transduction, Humana press, 2008.
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